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Abstract
Abstract
The objective of these studies was to investigate interactions between 
melatonin and the cytochrome P450 system.
CYP1A2 was identified as the cytochrome P450 enzyme responsible for the 
6-hydroxylation of melatonin, its principal route of metabolism, in rat liver.
Interaction studies were undertaken, in both rat and human liver, to establish 
if melatonin metabolism, through 6-hydroxylation and suphation, is influenced by 
frequently co-administered drugs. Fluvoxamine and 5-methoxypsoralen strongly 
inhibited the 6-hydroxylation of melatonin in rat liver, with the effect of 5- 
methoxypsoralen being even more pronounced in human liver. Diazepam, 
tamoxifen, paracetamol and 17oc-ethinyloestradiol failed to modulate the 6- 
hydroxylation of melatonin in both rat and human liver. 17a-Ethinyloestradiol, 
however, significantly decreased the sulphate conjugation of 6-hydroxymelatonin in 
human liver.
Pre-treatment of rats with caffeine significantly increased the nocturnal peak 
of endogenous 6-sulphatoxymelatonin in the urine, but not the total 24-hour 
production. Caffeine pre-treated animals excreted significantly more 6- 
sulphatoxymelatonin in the urine between 8 to 12 hours following melatonin 
administration. A significant correlation (R=0.8108) was observed between the 
nocturnal peak of endogenous 6-sulphatoxymelatonin in the urine and CYP1A2 
activity, in both control and caffeine-treated animals. A similar correlation was found 
between the amount of 6-sulphatoxymelatonin excreted in the urine following 
melatonin administration and CYP1A2 activity. Thus, both nocturnal endogenous 
and exogenous 6-sulphatoxymelatonin could be used for assessing CYP1A2 activity 
in humans.
Daily 24 h rhythms were observed in CYP1A1, CYP2B1 and CYP2E1 
activity. In contrast, no rhythms were evident in CYP1A2, CYP2A1/2, CYP2C11, 
CYP3A and testosterone 16a- and 16(3-hydroxylase activities, in CYP2D1 and 
CYP4A1 expression, as well as in the glutathione S- transferase, UDP-glucuronide 
transferase and epoxide hydrolase. Lesions of the suprachiasmatic nuclei led to the 
disappearance of the 24-h rhythms in CYP1A1 and CYP2E1 activity indicating that 
the SCN circadian clock may play a role in the rhythmic expression of these 
enzymes.
Abbreviations
Abbreviations
ACD 7-Alkoxycoumarin O-dealkylase
aMT6s 6-Sulphatoxymelatonin
ANOVA Analysis o f variance
APAP Acetaminophen
ASPS Advanced sleep phase syndrome
ATP Adenosine triphosphate
AUC Area under the curve
BNF p-Naphthoflavone
cDNA Complementary DNA
CDNB 1 -Chloro-2,4,-dinitrobenzene
Cmax Maximum concentration
CT Circadian time
CYP Cytochrome P450
CV coefficient of variation
DCNB 3,4-Dichloronitrobenzene
DGDW Double glass distilled water
DDC Diethyldithiocarbamate
DMSO Dimethyl sulphoxide
DNA Deoxyribonucleic acid
DSPS Delayed sleep phase syndrome
EBU Experimental biology unit
EDTA Ethylenediaminetetraacetic acid
EROD Ethoxyresorufin 0-deethylase
GET Geniculohypothalamic tract
GSH Glutathione
GST Glutathione S-tranferase
H2O2 Hydrogen peroxide
HIOMT Hydroxyindol-O-methyltransferase
HOC1 Hypochlorous acid
Abbreviations
HPLC High pressure liquid chromatography
IgG Immunoglobulin
ILC Intermediolateral column
i.p. Intraperitoneal
KC1 Potassium chloride
LD Light-dark
MROD Methoxyresorufin O-demethylase
NaCl Sodium chloride
Na2C 0 3 Sodium carbonate
NADH Nicotinamide adenine dinucleotide
NADP P-Nicotinamide adenine dinucleotide phosphate
NADPH Reduced nicotinamide adenine dinucleotide phosphate
N aH C 03 Sodium bicarbonate
NaOH Sodium hydroxide
NAPQI yV-Acetyl-p-benzoquinone imine
NAT N-acetyltransferase
NSB Non-specific binding tubes
o 2 Oxygen
•o 2 Singlet oxygen
•OH Hydroxyl radical
3-OH-APAP 3-Hydroxy-acetaminophen
PAH Polycyclic aromatic hydrocarbon(s)
PAPS Adenosine 3 ’-phosphate 5 ’-phosphosulphate
PB Phenobarbitone
PROD Pentoxyresorufin O-depentylase
PVN Paraventricular nucleus
RHT Retinohypothalamic tract
RIA Radioimmunoassay
RNA Ribonucleic acid
ROI Region of interest
Abbreviations
Rs Spearman Rank Correlation coefficient
SAH S-Adenosylhomocysteine
SAM S-Adenosylmethionine
SCG Superior cervical gaglia
SCN Suprachiasmatic nuclei
SD Standard deviation
SDS Sodium dodecylsulfate
SDS-PAGE Sodium dodecylsulfate polyacrylamide
S9 Post-mitochondrial supernatant fraction
SEM Standard error of the mean
SSRI Selective serotonin reuptake inhibitor
TBS Tris-buffered saline
TBS-T Tris-buffered saline Tween
TCA Trichloroacetic acid
TCDD 2,3,7,8-Tetrachlorodibenzo-p-dioxin
TEMED N, N,N’,N ’-Tetramethy lethy lenediamine
Tris-HCl Tris(hydroxymethyl)aminomethane-HCl
TMX Tamoxifen
UKHTB United Kingdom Human Tissue Bank
UV Ultraviolet
UVA Ultraviolet A
ZT Zeitgeber time
Acknowledgements v
Acknowledgements
I am grateful to several people for helping, in one way or other, with the writing of 
this thesis. I would like to express my gratitude to all of them, realizing that those 
whom I owe the most I cannot thank enough, and that the things for which I am most 
grateful, I cannot put into words.
I am very happy to have the opportunity to express my deep gratitude to my 
supervisors, Professor Costas loannides and Professor Debra Skene, for their 
encouragement, guidance and support during my entire PhD study. It would be hard 
to overstate how much I benefited from their deep insight. I can’t thank them 
adequately for all the effort they made to understand me and to bring out the best in 
me. I thank them for valuable suggestions and comments on the manuscript. This 
thesis could not have been written without their invaluable help.
I am most grateful to Professor Jo Arendt who financially supported my PhD 
project with her company Stockgrand Ltd. I would like to thank the following: Judie 
English and Benita Middleton and Kavita Thapan in the Chronobiology Lab for 
teaching me the techniques and supplying me with all the reagents; Michelle 
Coulson, who helped me enormously with the testosterone assay.
I wish to especially thank Peter Kentish for being available whenever I had 
problems, for helping me in every aspect in the lab but mostly for being such a good 
friend. I will always be indebted to him for his warmth, sensitivity and for his 
friendship.
I want to thank my parents, and my sisters Christina and Sevi for their love, 
patience and support.
Finally, I would like to dedicate this thesis to Costa Fragouli, who deserves an award 
for his patience and understanding during the final year of writing this thesis.
Contents vi
Contents
Abstract................................................................................................................................. ...........................  i
Abbreviations.................................................................................................................................................... ii
Acknowledgements.......................................................................................................................................... v
Contents............................................................... .............................................................................................. vi
Lists of Figures................................................................................................................................................  xii
List of Tables.................................................................................................................................................... xvi
CHAPTER 1: General Introduction
1.1 Melatonin and circadian rhythms.................................................................................... 1
1.1.1 The pineal gland and the production of melatonin.................................... ......................  1
1.L1.1 Biosynthesis o f melatonin.....................................................................................................  1
1.1.1.2 Regulation o f melatonin production...................................................................................  3
1.1.1.3 Secretion o f melatonin........................................................................................................... 4
1.1.2 Melatonin metabolism........................................................................................................... 5
1.1.2.1 Exogenous Melatonin: Pharmacokinetics.......................................................................... 7
1.1.3 Physiological role of melatonin...........................................................................................  8
1.1.3.1 Melatonin as a chronobiotic................................................................................................. 8
1.1.3.2 Melatonin as an antioxidant................................................................................................. 9
1.1.3.3 Melatonin as an oncostatic agent........................................................................................ 10
1.1.4 Clinical Applications of Melatonin.....................................................................................  11
1.1.4.1 Jet-lag......................................................................................................................................  11
1.1.4.2 Sleep disorders.......................................................................................................................  11
1.1.4.3 Cancer.....................................................................................................................................  13
1.1.4.4 Human aging and age-related diseases.............................................................................  13
1.1.5 The circadian generating system.........................................................................................  14
1.1.5.1 Entrainment............................................................................................................................  14
1.1.5.2 The suprachiasmatic nuclei..................................................................................................  15
1.1.5.3 Peripheral clocks.................................................................................................................... 16
1.2 Cytochrome P450 enzyme system.................................................................................... 16
1.2.1 Properties of mammalian cytochrome P450 enzymes......................................................  17
1.2.2 The nomenclature of cytochromes P450............................................................................  17
1.2.3 Drug-metabolising cytochrome P450 subfamilies...........................................................  19
1.2.3.1 CYP 1 family............................................................................................................................. 19
1.2.3.2 CYP2 fam ily............................................................................................................................. 19
1.2.3.2.1 CYP2A subfamily....................................................................................................................  20
1.2.3.2.2 CYP2B subfamily.................................................................................................................... 21
1.2.3.2.3 CYP2C subfamily.................................................................................................................... 21
Contents vii
1.2.3.2.4 CYP2D subfamily....................................................................................................................  22
1.2.3.2.5 CYP2E subfamily....................................................................................................................  22
1.2.3.3 CYP3fam ily.......................................................................    23
1.2.4 Genetic polymorphisms and implications in drug metabolism.......................................  23
1.2.4.1 The CYP2C19 (S-mephenytoin hydroxylase) polymorphism ..........................................  24
1.2.4.2 The CYP2D6 (debrisoquine hydroxylase) polymorphism ................................................ 24
1.2.5 Cytochrome P450-mediated drug interactions..................................................................  25
1.2.5.1 Enzyme Inhibition.................................................................................................................. 25
1.2.5.2 Enzyme Induction.................................................................................................................... 26
1.2.6 Role o f cytochromes P450 in melatonin metabolism......................................................  26
1.2.7 Daily rhythms in hepatic drug-metabolising enzymes..................................................... 27
1.3 Objectives and Hypotheses...............................................................................................  30
CHAPTER 2: Materials and Methods
2.1 Materials................................................................................................................................. 31
2.2 M ethods...................................................................................................................................  33
2.2.1 Rodent husbandry................................................................................................................... 33
2.2.2 Preparation of rat subcellular hepatic fractions.................................................................  34
2.2.3 Preparation of human post-mitochondrial fractions (S9)................................................  34
2.2.4 Protein determination............................................................................................................  35
2.2.4.1 Reagents...................................................................................................................................  35
2.2A.2 Procedure.................................................................................................................................  35
2.2.5 Determination of 6-sulphatoxymelatonin by radioimmunoassay...................................  36
2.2.5.1 The principle o f radioimmunoassay....................................................................................  36
2.2.5.2 Reagents.......................................................................................................................... ' ......  37
2.2.5.3 aMT6s assay procedure.........................................................................................................  39
2.2.6 Determination of cytochrome P450 enzyme activities.....................................................  39
2.2.6.1 Ethoxyresorufin O-deethylase............................................................................................... 39
2.2.6.2 Methoxyresorufin O-demethylase........................................................................................  39
2.2.6.3 Pentoxyresorufin O-dealkylase............................................................................................. 40
2.2.6.4 Testosterone hydroxylase assay............................................................................................  40
2.2.6.4.1 High Pressure Liquid Chromatography (H PLC).............................................................  41
2.2.6.4.2 Preparation o f HPLC Standards.........................................................................................  41
2.2.6.43 HPLC Solvents........................................................................................................................  42
2.2.6A.4 Chromatographic Conditions...............................................................................................  42
2.2.6A.5 Preparation o f the Substrate.................................................................................................  43
2.2.6A.6 Extraction o f Testosterone and Metabolites....................................................................... 44
Contents viii
2.2.6.4.6.1 Calculation o f the Extraction Efficiency..............................................................................  44
2.2.6A.6.2 Calculation o f Enzyme Activity.............................................................................................  45
2.2.6A.7 Separation o f testosterone metabolites................................................................................ 45
2.2.6.5 p-Nitrophenol hydroxylase...................................................................................................  47
2.2.7 Expression o f cytochrome P450 apoprotein levels: Western blotting.............................  48
2.2.7.1 Principle o f the immunodetection system ...........................................................................  48
2.2.7.2 SDS-PAGE (polyacrylamide gel electrophoresis)............................................................  49
2.2.7.3 Preparation o f microsomal samples and gel sample loading........................................... 50
2.2.7.4 Immunodetection and visualisation....................................................................................  51
2.2.8 Determination of conjugation enzymes............................................................................... 53
2.2.8.1 Glutathione S-transferase.....................................................................................................  53
2.2.8.1.1 Using DCNB as substrate...................    53
2.2.8.1.2 Using CDNB as substrate......................................................................................................  54
2.2.8.2 UDP Glucuronosyl transferase...........................................................................................  54
2.2.8.3 Epoxide hydrolase — .......................................................................................................   56
2.2.9 Procedure of SCN lesioning.................................................................................................  57
2.3 Data Analysis.......................................................................................................................... 58
CHAPTER 3: Melatonin 6-hydroxylation by cytochrome P450 enzymes
3.1 Introduction........................................................................................................................... 59
3.2 Objectives..............................................................................................................................  61
3.3 Materials and M ethods...............................................................................................   61
3.3.1 Methods............................................................................................   61
3.3.1.1 Incubation system ...................................................................................................................  61
3.3.1.2 Sulphate conjugate determination........................................................................................ 62
3.3.2 Preliminary studies.................................................................................................................  63
3.3.2.1 NADPH and O2 requirement fo r  the 6-hydroxylation o f melatonin...............................  63
5.3.2.2 Time-linearity o f 6-sulphatoxymelatonin generation........................................................  63
3.3.2.3 Protein-linearity o f 6-sulphatoxymelatonin generation...................................................  63
3.3.3 Cytochrome P450 induction studies....................................................................................  63
3.3.3.1 /3-Naphthoflavone induction......................................... .......................................................  64
3.3.3.2 Phenobarbitone induction..................................................................................................... 64
3.3.4 Cytochrome P450 inhibition studies...................................................................................  65
3.3.5 Statistical Analysis.................................................................................................................  67
3.4 Results..................................................................................................................................... 68
Contents ix
3.4.1 Optimisation of incubation conditions................................................................................. 68
3.4.2 Cytochrome P450-mediated melatonin 6-hydroxylation..................................................  71
3.4.3 Effect o f cytochrome P450 inducers..................................................................................... 71
3.4.4 Effect of selective cytochrome P450 inhibitors and substrates........................................ 73
3.5 Discussion.......................................... ...................................................................................  79
CHAPTER 4: Inhibition of melatonin 6-hydroxylase
4.1 Introduction..........................................................................................................................  87
4.1.1 Rationale for the selection of drugs..................................................................................... 87
4.2 Objectives............................................................................................................................... 92
4.3 Materials and M ethods.......................................................................................................  92
4.3.1 Liver samples.......................................................................................................................... 92
4.3.1.1 Rat liver.................................................................................................................................... 92
4.3.1.2 Human liver.............................................................................................................................  93
4.3.2 Experimental procedure........................................................................................................  93
4.3.2.1 Optimisation o f the incubation systems.............................................................................. 94
4.3.2.2 6-Sulphatoxymelatonin radioimmunoassay (RIA)............................................................  94
4.3.3 Statistical analysis..................................................................................................................  94
4.4 Results....................................................................................................................................  95
4.4.1 Optimisation of human liver incubation............................................................................  95
4.4.2 Effect of solvents on the 6-hydroxylation of melatonin..................................................  98
4.4.3 Effect of drugs on the 6-hydroxylation of melatonin.....................................................  99
4.4.3.1 Effect o f fluvoxamine............................................................................................................. 99
4.43.2  Effect o f 5-methoxypsoralen.................................................................................................  100
4.4 .33 Effect o f diazepam ....................................................................................................................  104
4.43 .4  Effect o f tamoxifen.................................................................................................................  107
4.43 .5  Effect o f acetaminophen.................... ...................................................................................  110
4 .43 .6  Effect o f 17oc-ethinyloestradiol...........................................................................................  112
4.4.4 Drug interactions with melatonin: A comparison between rat and human liver  114
4.5 Discussion..............................................................................................................................  120
4.5.1 Conclusions............................................................................................................................  125
Contents x
CHAPTER 5: Effect of caffeine on urinary 6-sulphatoxymelatonin excretion
5.1 Introduction...........................................................................................................................  126
5.2 O bjectives.............................................................................................................................. 127
5.3 Materials and M ethods......................................................................................................  127
5.3.1 Animals...................................................................................................................................  127
5.3.2 Study design...........................................................................................................................  128
5.3.2.1 Endogenous melatonin.......................................................................................................... 128
5.5.2.2 Exogenous melatonin............................................................................................................  128
53.2 .3  Determination o f CYP 1A2 activity. . ...................................................................................  129
53 .2 .4  Determination o f urinary 6-sulphatoxymelatonin............................................................  129
5.3.3 Statistical Analysis................................................................................................................. 129
5.4 Results....................................................................................................................................  130
5.4.1 Effect of caffeine treatment on hepatic CYP 1A2 activity..............................................  130
5.4.2 Effect of caffeine treatment on endogenous melatonin metabolism............................... 131
5.4.3 Effect of caffeine treatment on exogenous melatonin metabolism................................  136
5.5 Discussion............................................................................................................................... 139
CHAPTER 6: Daily rhythms in rat hepatic drug metabolising enzymes
6.1 Introduction............................................................................................................................ 144
6.1.1 The suprachiasmatic nuclei -  the endogenous circadian clock....................................... 144
6.1.2 Circadian Rhythm Entrainment - Photic entrainment......................................................  144
6.1.3 Peripheral Clocks - Liver...................    145
6.1.4 Daily rhythms in hepatic drug-metabolising enzymes.....................................................  145
6.2 Objectives...............................................................................................................................  147
6.3 Materials and M ethods........................................................................................................  148
6.3.1 Animals.................................................   148
6.3.2 Study design............................................................................................................................. 148
63.2.1 Daily rhythms in P450 and conjugation enzymes in the rat liver..................................  148
63.2.2 Effect o f SCN and PVN lesions on light/dark rhythm o f enzyme activities................... 149
6.3.3 Tissue preparation................................................................................................................... 149
6.3.4 Analytical methods................................................................................................................. 149
6.3.5 Statistical analysis...................................................................................................................  151
Contents xi
6.4 Results.....................................................................................................................................  151
6.4.1 Daily rhythms in cytochrome P450 expression................................................................  .151
6.4.2 Expression o f daily rhythm in conjugation enzymes........................................................ 164
6.4.3 Effect o f SCN and PVN lesions on daily rhythms............................................................  167
6.5 Discussion............................................................   172
6.5.1 Daily rhythms in xenobiotic-metabolising enzyme in rat liver..................................  172
6.5.2 Role of suprachiasmatic nuclei in the rhythmic pattern of cytochrome P450.............. 173
6.5.3 Role o f paraventricular nucleus in the rhythmic patterns of cytochrome P450............ 174
6.5.4 Significance of daily rhythms in P450 activity.................................................................. 174
CHAPTER 7: General Discussion
7.1 Introduction............................................................................................................................  177
7.2 Chapter 3: Melatonin 6-hydroxylation by cytochrome P450 enzym es..................  177
7.3 Chapter 4: Inhibition of melatonin 6-hydroxylase..................................................... 179
7.4 Chapter 5: Effect of caffeine on urinary 6-sulphatoxymelatonin excretion  183
7.5 Chapter 6: Daily rhythms in rat hepatic drug metabolising enzym es................  186
REFERENCES...............................................................   190
APPENDICES
APPENDIX I Copy of Ethics Committee Approval 
APPENDIX II Publication
List of Tables xvi
List of Tables
CHAPTER 1
Table 1.1 Cytochrome P450 families and subfamilies in rats and humans........................................  18
Table 1.2 Characteristics of xenobiotic-metabolising rat hepatic CYP enzymes..............................  20
Table 1.3 Summary of studies investigating daily rhythms in hepatic drug-metabolising
enzym es.....................................................................................................................................  29
CHAPTER 2
Table 2.1 Preparation of 6-sulphatoxymelatonin standards..................................................................  38
Table 2.2 The solvent gradient used to separate testosterone and its metabolites.............................  43
Table 2.3 Chromatographic retention times for testosterone and its metabolites..............................  47
CHAPTER 3
Table 3.1 Treatment with cytochrome P450 inducers...........................................................................  65
Table 3.2 Cytochrome P450 substrate/inhibitors employed.................................................................  67
Table 3.3 Requirement of O2 for the 6-hydroxylation of melatonin....................................................  71
CHAPTER 4
Table 4.1 Information about the donor of the liver tissue......................................................................  93
CHAPTER 5
Table 5.1 Cosinor analysis of endogenous urinary 6-sulphatoxymelatonin rhythms......................  135
Table 5.2 Effect o f caffeine-treatment on urinary excretion of endogenous 6-
sulphatoxymelatonin in rats....................................................................................................  135
CHAPTER 6
Table 6.1 Single cosinor analysis o f ethoxyresorufin O-deethylase, pentoxyresorufin O-
depentylase and p-nitrophenol hydroxylase activities......................................................... 152
Table 6.2 Cytochrome P450 enzyme activities during 12:12 h light:dark conditions....................... 153
Table 6.3 Minimum and maximum of cytochrome P450 enzyme activities........................................  154
Table 6.4 Testosterone metabolites during 12:12 h light:dark conditions..........................................  162
Table 6.5 Minimum and maximum activity of testosterone metabolites............................................. 163
Table 6.6 Phase II enzyme activities during 12:12 h light:dark conditions........................................  164
Table 6.7 Minimum and maximum of phase II enzyme activities.......................................................  164
CHAPTER ONE
GENERAL INTRODUCTION
Chapter 1: General Introduction 1
1.1 Melatonin and circadian rhythms
1.1.1 The pineal gland and the production of melatonin
Melatonin (A^-acetyl-5-methoxytryptamine) was first isolated from bovine pineal 
tissue and chemically characterised by the dermatologist Aaron Lemer (Lemer et al, 
1958; Lemer et al, 1959). In most species, the pineal gland and more specifically the 
pinealocytes are the primary sites of melatonin synthesis. Melatonin has also been 
reported to be synthesised in the retina (Zawilska and Nowak, 1992), the 
gastrointestinal tract (Lee and Pang, 1992; Bubenik, 2002), blood platelets (Champier 
et a l, 1997), skin (Slominski et a l, 2002) and bone marrow (Cardinali et al., 2003). 
It is generally believed that the production of melatonin in these tissues has a local 
function and does not contribute to circulating melatonin to a great extent.
1.1.1.1 Biosynthesis o f melatonin
The biosynthetic pathway, as well as the enzymes involved, has been elucidated by 
Axelrod and coworkers (Axelrod, 1974;. see review Klein, et al, 1991). The 
biosynthetic pathway of melatonin is presented in Figure 1.1. The first step involves 
the uptake of tryptophan from the circulation into the pinealocytes. Tryptophan is 
converted into 5-hydroxytryptophan by the mitochodrial enzyme tryptophan 
hydroxylase. Tryptophan hydroxylase increases about two-fold during darkness. The 
cytoplasmic enzyme aromatic acid decarboxylase subsequently catalyses the 
decarboxylation of 5-hydroxytryptophan to serotonin. The next step is crucial for the 
regulation of melatonin synthesis. It involves the acétylation of serotonin to N- 
acetylserotonin. The concentrations of serotonin in the pineal gland are very high, 
exhibiting a circadian rhythm with lowest levels during darkness. This drop in 
serotonin levels during darkness is mainly the result of increased metabolism of
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serotonin to Af-acetylserotonin. This reaction is catalysed by the enzyme 
arylalkylamine N-acetyltransferase (AA-NAT), which uses acetyl co-enzyme A as 
cofactor. N-acetyltransferase shows a remarkable circadian rhythmicity with a 20-200 
fold increase at night. This enzyme is rate limiting in the synthesis of melatonin. 
(Klein et ah, 1991). N-acetylserotonin is converted to melatonin by the cytosolic 
enzyme hydroxyindole-O-methyltransferase (HIOMT), using the methyl donor S- 
adenosyl methionine.
■ CHj—CH —NH% 
COOH
• N«
H
Tryptophan hydroxylase
HO.
COOH
H
Decarboxylase
HO,
AcetylCoA H
N-acetyltransferase
(NAT)CoA
•SAM
CH3O
Tryptophan
5-Hydroxytryptophan
Serotonin
(5-Hydroxytryptamine)
c h 2 -C h 2 _ n h  _ c - c h 3 
0
N-acetylserotonin
Hydroxyindol-O-methyltransferase
(HIOMT)
CH2 -C H 2 -N H  _  C -C H 3 
& Melatonin 
(N-acetyl-5-methoxytryptamine)
Figure 1.1 Biosynthetic pathway o f melatonin in the pineal gland. Tryptophan is taken up from the 
blood and converted into serotonin in two steps. The rate-limiting conversion of serotonin to N- 
acetylserotonin is the primary target for regulation of melatonin production. Melatonin is then released 
into the circulation. *SAM = S-adenosylmethionine, SAH = S-adenosylhomocysteine. Taken from  
Arendt, (1995).
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1.1.1.2 Regulation o f melatonin production
The melatonin rhythm is generated by the endogenous clock located in the 
suprachiasmatic nuclei (SCN) of the hypothalamus. The photoperiodic environment, 
i.e. the 24 h light-dark cycle, is the main zeitgeber (synchroniser) regulating the 
rhythm in melatonin production. The melatonin rhythm is entrained to the prevailing 
light-dark cycle. The photic information is transmitted to the central pacemaker in the 
SCN, primarily via the retinohypothalamic tract (RHT). During the day, light inhibits 
the synthesis of melatonin. The regulation of AA-NAT, which catalyses the 
transformation of serotonin to iV-acetylserotonin, the direct precursor of melatonin is 
controlled by the light-dark cycle. The neural pathway from the SCN to the pineal 
gland passes via the paraventricular nucleus (PVN) through the upper part of the 
cervical spinal cord, where synaptic connections are made with preganglionic cell 
bodies of the superior cervical ganglia (SCG) of the sympathetic chains (Moller and 
Bacres, 2002). Then neural cells in the SCG send projections to the pineal gland. The 
main neurotransmitter regulating the synthesis of melatonin is norepinephrine, which 
is released at night, in response to stimulatory signals from the SCN. Norepinephrine 
acts on both a- and p-adrenergic receptors to induce the activity of AA-NAT and 
drive the synthesis of melatonin (Figure 1.2). The cells of the SCN oscillate with 
period lengths close to the 24 h, these are synchronised by the light-dark signals 
perceived by the eyes and transmitted by the retinohypothalamic tract (RHT).
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ciâïi|ï„Melatonin Rhythm
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SEASONAL RHYTHMS Slccp-Wskc, immune function, etc.
Figure 1.2 The regulation of melatonin secretion. Photic information is conveyed to the 
suprachiasmatic nuclei (SCN), primarily through the retinohypothalamic tract (RHT). Light 
synchronises the activity of the circadian oscillator to exactly 24 hours. Neuronal efferent pathways 
from the SCN directly distribute circadian information to different brain areas, including the pineal 
gland that generates the melatonin rhythm. The neural route for environmental lighting control of 
melatonin secretion, after relay in the paraventricular nuclei (PVN), includes the intermediolateral 
column of the thoracic chord grey (ILC) and the superior cervical ganglion (SCG). The melatonin 
rhythm is used by the SCN to distribute its rhythmic information. Melatonin can feed back at the level 
of the SCN, as well as the retina itself. Taken from Cardinali and Pevet, (1998).
1.1.13 Secretion o f melatonin
With the onset of darkness, concentrations of melatonin in the pineal gland increase 
and the hormone is passively diffused into the cerebrospinal fluid and the circulation. 
After release into the circulation, melatonin gains access to various fluids, tissues and 
cellular compartments such as saliva, urine, amniotic fluid and milk. Since the pineal 
does not store melatonin, the plasma melatonin profile reflects the pineal activity 
(Reiter, 1991). hi humans, the secretion of melatonin starts around 21:00 h, peaks in 
the middle of the night between 02:00 h and 04:00 h and gradually declines thereafter 
(offset occurring 09:00 h). The plasma profile of melatonin displays a large inter­
subject variability, but is very reproducible from day to day in the same subject and
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represents one of the most robust circadian rhythms (Arendt and Skene, 2005), 
representing the ‘biological night’ (Figure 1.3). It provides a good evaluation of the 
melatonin secretion, when there is no renal or hepatic abnormality. The nocturnal 
production of melatonin is independent of the circadian cycle of the locomotor 
activity. In all species, whether diurnal or nocturnal, melatonin is secreted during the 
dark period of the light-dark cycle.
80 duration
70 '
acrophase (c; iculated peak time)
40 *
mid-range crossing30 ■
20 *
25% rise/fall 
onset/offset10 •
iso» 1700 1900 2100 2300 loo 300 500 700 900 iioo 1300 i5oo i7oo c lock  tim e h 
7iv m  im  urn 15m m i m i 21m i.m m  m  m  too ow
‘biological night’
Figure 1.3 Diagram of plasma melatonin profile. The features of this profile and that of salivary 
melatonin and urinary 6-sulphatoxymelatonin used to characterise the timing of the circadian clock are 
indicated. Melatonin treatment timing is often based on ‘circadian time’ (CT) where by convention CT 
14 is melatonin onset. 6-Sulphatoxymelatonin acrophase is approximately 2 h after the plasma 
melatonin acrophase. Taken from Arendt and Skene, (2005).
1.1.2 Melatonin metabolism
Melatonin is metabolised primarily in the liver and, to a lesser degree in the kidney 
(Kopin et a l, 1961) and brain (Hirata et al, 1974). The principal metabolic pathway 
in both humans and rodents, is 6-hydroxylation (Kopin et al., 1960). The
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hydroxylated product is excreted in the urine primarily as sulphate and, to a lesser 
extent, as a glucuronide conjugate. Early studies have established that, in both 
rodents and humans, the sulphate conjugate, 6-sulphatoxymelatonin (aMT6s), is the 
predominant metabolite (Kopin et al., 1960; Kveder and Mclsaac, 1961). The 
metabolic pathways of melatonin are shown in Figure 1.4.
Melatonin
CH,©
BrainLiver
c h 3o
HO
ch3o
c h 3o
nh2
o=s=o
N-y-acetyl-S-methox^’
kynurenamine6-Sulphatoxymelatonin
HO,
N-Acetylserotonin
N OH
H O
Cyclic 2-hydroxymelatonin
Figure 1.4 The metabolic pathways of melatonin in liver and brain.
Chapter 1 : General Introduction 7
Urine aMT6s excretion closely parallels the plasma melatonin profile (Arendt et al, 
1985). About 1% of melatonin remains unchanged in the urine. Other minor 
metabolite of melatonin has been identified, namely a cyclic isomer of 2- 
hydroxymelatonin (Vakkuri et a l, 1987). In addition to the 6-hydroxylation, 
exogenous melatonin is also demethylated to A-acetylserotonin (Leone and Silman, 
1984), which is then conjugated in a similar way to endogenous melatonin (Leone and 
Silman, 1984). In the brain, small amounts of melatonin are metabolised to two 
kynurenamines (Hirata et al, 1974). All these metabolic pathways are illustrated at 
Figure 1.4.
Patients with liver cirrhosis show a decreased melatonin clearance, with subsequent 
delayed rise of plasma melatonin peak and increased daytime levels (Iguchi et al, 
1982). Moreover, patients with chronic renal failure also show increased daytime 
plasma melatonin and 6-sulphatoxymelatonin levels and dampened melatonin 
circadian rhythmicity (Ludemann et al, 2001).
1.1.2.1 Exogenous Melatonin: Pharmacokinetics
Melatonin is usually administered orally at doses of 0.5-5 mg, which results in 
pharmacological levels in plasma (Deacon and Arendt, 1995). However, an oral dose 
of about 0.3 mg of melatonin administered before habitual bedtime results in plasma 
melatonin levels similar to physiological night-time levels (Zhdanova et a l, 1996). 
Following an oral dose of 80 mg melatonin, plasma melatonin concentration increased 
30 to 180 minutes later with an absorption half-life of 0.4 hours and an elimination 
half-life of 0.8 hours (Waldhauser et al, 1984). Large interindividual variations that 
can reach a 25-fold difference among subjects have been observed for oral melatonin
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absorption (Waldhauser et al, 1984; Aldhous et al, 1985). Plasma melatonin 
concentrations and melatonin half-lives depend on the dose and the type of oral 
preparation used (Guardiola-Lemaitre, 1997).
1.1.3 Physiological role of melatonin
The duration of melatonin secretion reflects the ‘biological night’ (Figure 1.3) and it 
appears that its primary function is to act as a time signal for the organization of daily 
and annual rhythms (Arendt, 2003). In humans, based on correlative observations, 
there is evidence that melatonin can entrain some circadian rhythms, especially of 
core body temperature and sleep-wake rhythms (Arendt, 2003). Other physiological 
functions may depend on the melatonin signal for their circadian organization, such as 
immune function, antioxidant defence, and glucose regulation (Claustral et a l, 2005).
1.1.3.1 Melatonin as a chronobiotic
Organisms are synchronised when they work in harmony with the environmental 
synchronisers such as the light-dark cycle, the sleep-wake cycle, and meal schedules. 
An important property of melatonin is its ability to resynchronise free-running 
circadian rhythms in rodents (Armstrong, 1989). Melatonin via melatonin receptors 
(MT1 and MT2) acts at the SCN to modulate its activity and phase-shift circadian 
rhythms (Dubocovich et a l, 2003). Properly timed melatonin administration shifts 
circadian rhythms and facilitates re-entrainment to the light-dark cycle (Arendt and 
Skene, 2005). The direction in which melatonin phase shifts the circadian system 
depends on the time of administration. This is described in a phase response curve 
(Lewy et al, 1998). The entrainment of free-running circadian rhythms in totally
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blind people is strong evidence of its “chronobiotic” effect in humans (Lockley et ah, 
2000; Sack et al., 2000; Hack et al., 2003).
1.1.3.2 Melatonin as an antioxidant
The oxidation of macromolecules by free radicals and reactive oxygen species, when 
the damage is not repaired, is involved in a variety of diseases (Reiter, 1995). 
Melatonin has been found to be a highly effective scavenger of free radicals and 
general antioxidant (Tan et al., 1993). It has also been found to reduce oxidative 
damage in various models where free radicals have been involved in the aetiology of a 
particular condition (Reiter et al., 2000; Reiter et al., 2001; Reiter et al., 2002; Tan et 
al., 2002). Melatonin directly neutralises a number of toxic oxygen- and nitrogen- 
based reactants, including the hydroxyl radical («OH), hydrogen peroxide (H2O2), and 
singlet oxygen CO2) (Tan et al., 2002; Allegra et al., 2003). Additionally, melatonin 
has indirect antioxidant actions. These include the stimulation of synthesis of another 
important intracellular antioxidant, glutathione (GSH) (Urata et al., 1999) and the 
promotion of its enzymatic recycling in cells to ensure that it remains in its reduced 
form (Reiter et al., 2000). Furthermore, melatonin preserves the functional integrity 
of other antioxidant enzymes, such as superoxide dismutase and catalase. Melatonin 
may also decrease free radical generation in mitochondria by enhancing oxidative 
phosphorylation, in that way lowering electron leakage and increasing ATP 
generation (Acuna-Castroviejo et al., 2001).
Clinically, oxidative stress has been proposed as the cause for tissue damage in many 
pathophysiological disorders such as hypoxia, inflammation, and tissue ischaemia 
(Reiter et al., 1994; Coyle and Puttfarcken, 1993). Clearly, melatonin appears to offer
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protection in a wide variety of diseases in which free radical damage has been 
implicated (Reiter, 1995; Reiter et al, 2002). More specifically, it appears to lower 
the oxidative damage in ischaemia (in the brain, heart, gut, liver, lung, urinary 
bladder), during toxic drug exposure, bacterial toxin exposure, in schistosomiasis, in 
heavy metal toxicity, in Alzheimer’s (Pappolla et ah, 2000), and in Parkinson disease 
(Antolin et al., 2002). Finally, free radicals and oxidative stress have also been 
implicated in the normal aging process (Reiter, 1995; Fielding and Meydani, 1997), 
and has been speculated that exogenous melatonin may play a protective role.
Although the above studies show an antioxidative action of exogenous melatonin, 
whether endogenous melatonin is secreted in sufficient quantities to have this effect in 
normal physiological conditions is still debatable (Arendt, 1996).
1.1.3.3 Melatonin as an oncostatic agent
A  considerable amount of evidence has been accumulated documenting the efficacy 
of melatonin in reducing tumour growth. Most of the data have been derived from 
studies in experimental animals (Sauer et a l, 2001; Flask et al, 2002) but also from 
trials in humans with a wide variety of different cancers (Lissoni et al, 2002). The 
concentrations of melatonin that reduce cancer cell proliferation, tumour growth and 
the incidence of métastasés range from physiological to pharmacological. The well- 
established antitumour mechanisms of melatonin include its antiproliferative actions, 
immunostimulatory effects on host anticancer defences and antioxidant activity. 
There is also evidence that the efficacy of pharmacological melatonin in limiting 
tumour cell proliferation depends on the time of its administration during the 24 h
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day, with the administration of melatonin late in the light period of the light-dark 
cycle to be more effective (Sauer et ah, 2001).
1.1.4 Clinical Applications of Melatonin
1.1.4.1 Jet-lag
Jet-lag is a pattern of symptoms generally seen after travelling across several time 
zones. Symptoms include disturbed sleep, increased sleep latency, tiredness during 
the day, depressed mood and reduced performance. The occurrence and severity of 
these symptoms seem to be dependent on the number of time zones crossed and the 
direction of the flight. In general, eastwards flights result in more severe jet-lag than 
westwards flights. Several studies have assessed the synchronising properties of 
melatonin aiming to hasten réadaptation in jet-lag (Arendt et a i, 1986; Arendt et al., 
1997; Petrie et ah, 1989; Petrie et ah, 1993; Suhner et al., 1998). In doses of 5-8 mg, 
melatonin has been administered double blind, placebo, controlled studies. Melatonin 
appears to improve the quality, and duration of sleep, to reduce night awakenings, and 
to improve daily alertness and performance efficiency compared with placebo. 
Collectively, in controlled and uncontrolled field studies, a 50% reduction in the 
subjective assessment of jet-lag symptoms has been observed. Currently there is 
enough evidence to suggest that melatonin is effective in the alleviation of jet-lag 
(Arendt and Skene, 2005).
1.1.4.2 Sleep disorders
Some sleep disorders are clearly related to misaligned circadian phase like delayed 
and advanced sleep phase syndromes (DSPS and ASPS). Individuals with DSPS 
experience difficulty in initiating sleep until as late as 04:00 h but can easily maintain 
normal sleep duration, while ASPS patients have difficulty to stay awake in the
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evening and to sleep after about 03:00 h. Appropriately timed melatonin and light are 
both effective in treating DSPS (Dahlitz et a l, 1991). These DSPS individuals are 
treated by scheduling their awakening so as to occur gradually earlier and earlier 
every day until they reach the desired time. The treatment involves going outdoors 
immediately after awakening for about 30 minutes and taking 0.5 mg of melatonin 
about 8 h after wake time. Individuals with ASPS are treated with exposure for 1 to 2 
hours to 10,000 lux light treatment in the evening, which should be completed at least 
1 hour before desired bedtime. Intake of melatonin is usually suggested at each 
awakening (Lewy et a l, 1985).
Melatonin has also been proposed for the treatment of sleep disorders that are not 
circadian rhythm related, with focus on insomnia in the elderly. With aging, sleep 
patterns tend to be disrupted, with night-time awakening and daytime sleepiness. It is 
known that the amplitude of melatonin is reduced with age (Touitou et a l, 1981; van 
Coevorden et a l, 1991, review Skene and Swaab, 2003).
There is some evidence that melatonin may effectively treat sleep disturbances in the 
elderly. Melatonin administration decreases the time to sleep onset, while not 
affecting the sleep architecture (Reid et a l, 1996; Gilbert et a l, 1999). Thus, 
melatonin treatment may be beneficial for some elderly suffering from insomnia. 
Moreover, several studies have reported that melatonin has a synchronising effect on 
the sleep-wake cycle when it is taken at bedtime and improves sleep in blind subjects 
(Arendt et al, 1988; Tzischinnsky et al, 1992; Arendt et a l, 1997; Sack et al, 2000; 
Hack et al, 2003).
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1.1.4.3 Cancer
Early studies demonstrated that the amplitude of the nocturnal peak in either urinary 
or plasma melatonin, as well as the 24 h urinary excretion was decreased in patients 
with primary breast cancer (Bartsch et al, 1981; Tamarkin et al., 1982). A decreased 
synthesis of melatonin seems to be responsible for the parallel depression of nocturnal 
serum melatonin and its main metabolite aMT6s in patients with breast cancer 
(Bartsch et a l, 1991). However, the lower amplitude of the nocturnal melatonin peak 
in postmenopausal women may be due to the age-associated decline in melatonin 
production (Skene et al., 1990).
Clinical trials have demonstrated that melatonin treatment of patients with various 
types of cancer may extend survival time in some metastatic patients, reduces tumour 
progression, decreases the severity of chemotherapy induced myelodyplastic 
syndrome, and improves the immunosuppressive effects of other cytotoxic drugs 
(Panzer and Viljoen, 1997). A phase II study suggested that melatonin (20mg/day) 
may amplify the therapeutic efficacy of tamoxifen in women with metastatic breast 
cancer patients and induce objective tumour regressions in metastatic breast cancer 
patients who do not respond to previous therapy with tamoxifen alone (Lissoni et al., 
1995). The mechanisms involved in the inhibition of hormone-dependent mammary 
cancer proliferation by melatonin are still unclear.
1.1.4A Human aging and age-related diseases
Several theories have related melatonin to aging but its role is still unclear (Reiter, 
1995). Studies showing that administration of melatonin in drinking water at night
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increased the life span of mice, led to claims that melatonin prolongs survival due to 
its immunoenhancing properties (Maestroni et al, 1988; Pierpaoli et a l, 1991; 
Pierpaoli and Regelson, 1994). Since aging is characterized by deterioration of many 
circadian rhythms that play an important role in physiology like sleep-wake cycle, 
core body temperature, alertness, and secretion of many hormones, it has been 
hypothesised that melatonin, by restoring these circadian rhythms, is capable of 
delaying the process of aging (Armstrong and Redman, 1991). In addition, it is 
believed that melatonin may protect against age-related diseases especially 
neurodegenerative nature like Alzheimer’s and Parkinson’s, as a rescuer of its 
antioxidant properties (Srinivasan, 2002; Gupta et a l, 2003).
2.7.5 The circadian generating system
The circadian generating system has three components: (i) a pacemaker, (ii) an input 
pathway(s) for entrainment of the pacemaker and (iii) an output pathway(s) for the 
expression of the overt rhythms. This is well illustrated by the mammalian melatonin 
rhythm generating and entraining system. There are three input pathways to the SCN, 
which are the glutamatergic retinohypothalamic tract (RHT) from the retina, the 
neuropeptide Y geniculohypothalamic tract (GHT) from the intergeniculate leaflet and 
the serotonergic input from the raphe nuclei (van Esseveldt et a l, 2000).
Ll.5.1 Entrainment
In a normal environment, circadian rhythms are synchronised to a period of 24 h by 
external rhythmic time cues known as zeitgebers. Circadian rhythms are entrained 
(synchronised) to the 24 h day primarily by 24 h light-dark cycle. Time cues other 
than the light-dark cycle, which may be involved in entrainment, include behavioural
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imposition such as forced activity and rest, social and nutritional (rhythmic feeding 
pattern) cues, temperature variations, knowledge of the clock time, and melatonin. 
However, the light-dark cycle is the major synchronizer of the circadian timing 
system (review Mistlberger and Skene, 2004).
In continuous darkness and in the absence of other time cues, mammalian circadian 
rhythms free run i.e. with a period longer or shorter than 24 h. When the light-dark 
cycle is artificially advanced or delayed, the circadian system slowly adapts to the 
new phase position. The time taken to adapt depends on the size of the phase shift 
and the zeitgeber strength. During the process of adaptation, endogenous rhythms are 
out of phase with the external environment (external desynchronisation). This occurs 
regularly in shift workers and in jet-lagged travellers and is considered to be 
responsible for many health and performance problems (Mistlberger and Skene, 
2004). Blindness, old age, and psychiatric disorders are also associated with disturbed 
circadian rhythms.
1.1.5.2 The suprachiasmatic nuclei
Suprachiasmatic nuclei (SCN), a paired structure, situated in the anterior of the 
hypothalamus, just above the optic chiasm, are the site of a master circadian clock that 
directly or indirectly regulates most of the body’s circadian rhythms. SCN lesions 
result in complete arrhythmicity of all behavioural and physiological processes, such 
as locomotor activity, feeding, hormonal release, temperature, indicating its primary 
role in the generation of circadian rhythmicity (Stephan and Zucher, 1972; Moore and 
Eichler, 1972; Abe et ah, 1979).
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1.1.5.3 Peripheral clocks
Recently evidence has accumulated to show that most peripheral tissues including the 
liver, kidney, heart and eye also contain oscillators independent of the SCN 
(Balsalobre et al., 1998; Balsalobre et al., 2000). There is considerable evidence that 
the liver expresses a number of circadian patterns of various drug enzyme activities 
(Barbason and Van Cantfort, 1976; Birt and Hines, 1982; Bruguerolle, 1998; 
Furukawa et al., 1999; Akhtar et al., 2002), but recently it has been demonstrated that 
the liver has also its own biological clock capable of generating its own daily rhythms 
besides its regulation via the SCN (Yamazaki et al., 2000). There is also recent 
evidence that food can entrain the liver clock independently of the SCN (Stokkan et 
al, 2001).
1.2 Cytochrome P450 enzyme system
The purpose of exogenous melatonin metabolism in body is to render it more water- 
soluble, and thus more readily excretable in the urine or bile. Drug metabolism 
involves the insertion or unmasking of functional groups on the parent molecule (e.g. 
through oxidation), catalysed by the cytochrome P450 enzymes, and the product is 
subsequently conjugated with endogenous substrates such as sulphate and glucuronic 
acid, and excreted.
Cytochrome P450 enzymes are primarily located on the membrane of the endoplasmic 
reticulum. The name derives from the spectral absorbance maximum produced at or 
near 450 nm when carbon monoxide, binds to the reduced enzyme (Nelson et a i,
1993). The highest concentration of cytochrome P450 enzymes is found in the liver 
followed by the small intestine, and in lower concentrations in other tissues such as
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kidneys, lung and brain (Krishna and Klotz, 1994). The hepatic cytochrome P450 
system is involved in the biosynthesis and degradation of endogenous compounds 
such as steroid hormones, cholesterol and fatty acids (Coon et al., 1992). In addition, 
cytochrome P450 enzymes play a major role in drug metabolism by converting drugs 
from a hydrophobic state to a more excretable hydrophilic form (Wrighton and 
Stevens, 1992).
1.2.1 Properties of mammalian cytochrome P450 enzymes
The cytochrome P450 (CYP) enzymes catalyse the NADPH- and oxygen-dependent 
oxidative transformation of a large number of diverse chemical compounds. In 
general, a specific CYP enzyme will catalyse the metabolism of a limited number of 
chemical structures such as steroids and fatty acids, while other CYP enzymes have 
broad substrate specificity. CYP enzymes are distributed in almost every organ of the 
human body, although the type of CYP enzyme in a tissue can be specific. The 
expression of many CYP enzymes is regulated by transcription factors, which become 
activated during exposure to various chemicals.
1.2.2 The nomenclature of cytochromes P450
In 1987, Nebert et al. recommended a classification system, which has been 
subsequently updated, and is currently widely used. This nomenclature groups 
enzymes and genes into families and subfamilies with the prefix CYP used to 
designate cytochrome P450 in all species (except mouse gene, where Cyp is used).
Families are designated by an Arabic number (e.g., CYP1), with all members of a 
particular family having more than 40% identity in amino acid sequence. A
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subfamily consists of enzymes in which the amino acid sequence is more than 55% 
identical. These are designated by a capital letter. The CYP2 family, for example, 
has several subfamilies including CYP2C, CYP2D and CYP2E. Finally, an Arabic 
numeral is used to represent the individual enzyme (e.g., CYP2E1).
Table 1.1 Cytochrome P450 families and subfamilies in rats and humans.
Family_______________Subfamily__________Rat Enzymes___________ Human Enzymes
CYP1 A 1A1 1A1
1A2 1A2
B 1B1 1B1
CYP2 A 2A1 2A6
2A2 2A7
2A3 2A13
B 2B1 2B6
2B2 
2B3 
2B12 
2B21
C 2C6 2C8
2C7 2C9
2C11 2C10
2C12 2C18
2C13 2C19
2C23 
2C24
D 2D1 2D6
2D2 2D7P
2D3 2D8P
2D4 
2D5 
2D18
E 2E1 2E1
CYP3 A 3A1 3A4
3A2 3A5
3A9 3A7
3A18 3A43
3A23
Adapted from http://dmelson.utmem.edu/P450.stats.all.2005.htm
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7.2.3 Drug-metabolising cytochrome P450 subfamilies
In rats and humans, enzymes of the CYP1, CYP2, and CYP3 families are responsible 
for the vast majority of drug metabolism and account for at least 70% of the total 
P450 content in human liver (Shimada et al., 1994).
1.2.3.1 CYP1 family
This family is comprised of two subfamilies, CYP1A and CYP1B. The CYP1A 
subfamily contains two proteins whereas CYP1B contains a single protein. CYP1A1 
is rarely expressed in human liver (Wrighton et a l, 1986) and it appears to be 
predominantly expressed in extrahepatic tissues (Guengerich, 1989). There is good 
evidence that in extrahepatic tissues CYP1A1 can be induced by cigarette smoke and 
polycyclic aromatic hydrocarbons (Guengerich, 1989; Quattrochi and Tukey, 1989). 
CYP1A2 has been shown to be present in the liver of untreated animals, and is 
induced by polycyclic aromatic hydrocarbons and isosaffole (Sesardic et al.„ 1990). 
In humans, the hepatic CYP1A2 concentration varies about 25-fold (Wrighton et ah, 
1986; Quattrochi and Tukey, 1989). Human CYP1A2 is also inducible by smoking 
and by the ingestion of charcoal-grilled foods (Sesardic et ah, 1988). CYP1B1 
appears to be the principal enzyme that catalysed the 4-hydroxylation of 17(3- 
oestradiol (Hayes et al., 1996). The chemical probes, the inducers and the inhibitors of 
rat CYP1A enzymes are summarised at Table 1.2.
7.23.2 CYP2 family
CYP2 is the largest cytochrome P450 family, consisting of a number of subfamilies 
that show different substrate specificity and are under different regulatory control.
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The chemical probes, the inducers and the inhibitors of rat CYP2 family enzymes are 
summarised at Table 1.2.
Table 1.2 Characteristics of xenobiotic-metabolising rat hepatic CYP enzymes.
CYP Chemical probes (reaction catalysed) Inducers Inhibitors
1A1 Ethoxyresorufin O-deethylase 3-Naphthoflavone a-Naphthoflavone
1A2 Methoxyresorufin O-demethylase 3-Naphthoflavone Furafylline
2A1/2 Testosterone 7oc-hydroxylase 3-methylcholanthrene Allylisopropyl acetamide
2B1/2 Pentoxyresorufin O-depentylase Phenobarbitone Orphenadrine
2C11 Testosterone 2a- & 16a-hydroxylases Phenobarbitone Sulphaphenazole
2D1 Debrisoquine 4-hydroxylase Non-inducible Quinidine
2E1 p-Nitrophenol hydroxylase Ethanol, Isoniazid, 
Acetone
Diethyldithiocarbamate
3A1/2 Testosterone 2(3-& 63-hydroxylases Phenobarbitone Ketoconazole
1.2.3.2.1 CYP2A subfamily
This subfamily consists of three members in humans, CYP2A6, CYP2A7 and 
CYP2A13, which comprises about 1% of the total hepatic cytochrome P450 content 
(Shimada et al., 1994). Rat CYP2A enzymes exhibit different substrate specificity 
with the human orthologues. In the rat, three members exist, CYP2A1, CYP2A2 and 
CYP2A3. Rat CYP2A1 catalyses the 7oc-hydroxylation of steroids, whereas human 
CYP2A6 hydroxylates coumarin but not steroids (Pearce et al, 1992). Rat CYP2A2 
is structurally similar to CYP2A1 and hydroxylates testosterone at the 15-position 
(Aoyama et a l, 1990). Rat CYP2A3, is not expressed in the liver, but in the lung 
(Kimura et a l, 1989) and olfactory mucosa (Liu et al, 1996). Human CYP2A6 
enzyme appears not to be inducible but a high interindividual variation has been 
observed (Pelkonen and Raunio, 1995). Human CYP2A6 may participate in 
procarcinogen activation but has a relatively minor role in drug biotransformation and
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accounts for only 4% of total human hepatic cytochromes P450 (Shimada et al.,
1994).
1.23.2.2 CYP2B subfamily
This subfamily consists of one member CYP2B6 in humans and comprises of less 
than 2% of total hepatic P450 content. In rat, two enzymes exist, namely CYP2B1 and 
CYP2B2 and display similar substrate specificity, with CYP2B1 exhibiting higher 
catalytic activity. A feature of this subfamily is that it is highly inducible by 
phenobarbitone. The chemical probe employed in the monitoring of this subfamily is 
the O-depentylation of pentoxyresorufin (Burke et al., 1985). Large interindividual 
variations have been observed in the expression of human CYP2B6 (Code et al., 
1997; Ekins et al., 1998; Roy et a l, 1999). CYP2B6 plays a limited role in drug 
metabolism but contributes to the metabolism of S-mephenytoin, S-mephobarbital, 
cyclophosphamide, and propofol (Court et al., 2001).
1.23,23 CYP2C subfamily
This is a large subfamily that in humans consists of CYP2C8, CYP2C9, CYP2C18 
and CYP2C19 and accounts for about 20 % of the total hepatic cytochrome P450 
content (Shimada et al., 1994). In rat liver, this subfamily is moderately induced by 
phenobarbitone and dexamethasone, but in human liver it is induced by rifampicin 
(Zhou et al, 1990). CYP2C9 and CYP2C19 are 91% homologous (Jung et al., 1998), 
and most of CYP2C9 substrates are also metabolised by CYP2C19 at some degree. 
Human CYP2C9 is primarily responsible for the metabolism of tolbutamide, S- 
warfarin, phenytoin, losartan, ibuprofen, flubiprofen, diclofenac, indomethacin, and 
celecoxib. Human CYP2C8 plays a minor role in the metabolism of drugs. The
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activity of CYP2C8 is inhibited by the flavone quercetin. Sulphaphenazole and other 
sulphonamides have been identified as CYP2C9 inhibitors (Back et al., 1988; Mancy 
et al., 1996). CYP2C9 is induced by barbiturates, carbamazepine, and rifampin 
(Miners and Birkett, 1998).
L2.3.2.4 CYP2D subfamily
In humans, there is only one member in this subfamily, CYP2D6, which represents on 
average of 1.5 % of total hepatic cytochrome P450 content (Shimada et al., 1994). 
Human CYP2D6 is responsible for the metabolism of a variety of 
psychopharmacological and cardiovascular drugs like, desipramine, nortriptyline, 
codeine, tramadol, and metoprolol. The chemical probes, the inducers and the 
inhibitors of rat CYP2D enzymes are summarised at Table 1.2.
1.2.3.2.5 CYP2E subfamily
This subfamily, in both rats and humans consists of one enzyme, CYP2E1 and 
accounts for an average 6.6 % of total hepatic cytochrome P450 content (Shimada et 
al., 1994). This enzyme plays an important role in the activation of small molecular 
weight compounds such as short-chain alcohols and organic solvents such as ether 
and chloroform. Chlorzoxazone is metabolised by CYP2E1 (Peter et al., 1990) and 
CYP2E1 plays an important role in oxidation of paracetamol (Manyike et al., 2000), 
and general anaesthetics (Hong and Yang, 1985). An important characteristic of 
CYP2E1 is its propensity to generate reactive oxygen species that may interact with 
DNA to induce mutations (Ekstrom et al, 1986). Human CYP2E1 is inhibited by 
diethyldithiocarbamate, the main metabolite of disulfiram (Guengerich et al., 1991; 
Brady et al, 1991) and is induced by chronic ethanol intake and by isoniazid (Bonis et
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aL, 1993). CYP2E1 is elevated in chronic alcoholics who hence are more vulnerable 
to paracetamol hepatotoxicity. The chemical probes, inducers and inhibitors of rat 
CYP2E1 are summarised at Table 1.2.
1.2.3.3 CYP3 family
The human CYP3A subfamily consists of CYP3A4, CYP3A5, and CYP3A7 (Gellner 
et al., 2001; Westlind et al., 2001; Domanski et a l, 2001). CYP3A enzymes are the 
most abundant in the liver and in the small intestine, accounting for about 30% of 
total hepatic cytochrome P450 content (Shimada et al., 1994). Most therapeutic 
agents are metabolised at part by this subfamily in humans. The major enzyme is the 
CYP3A4 in adults and is expressed in liver and the small intestine. CYP3A5 is 
polymorphically expressed in approximately 20% of the population, while CYP3A7 is 
present only in foetal liver (Gruet et al., 1996). The activity of this subfamily exhibits 
a wide individual variability in humans. In humans, the activity of CYP3A is induced 
by drugs such as rifampicin, dexamethasone, and anticonvulsants (Pelkonen et al.,
1998). The chemical probes, the inducers and the inhibitors of rat CYP3A enzymes 
are summarised at Table 1.2.
1.2.4 Genetic polymorphisms and implications in drug metabolism
Genetic polymorphisms have been identified for a number of cytochrome P450 
enzymes. Polymorphisms are detected by observing the differences between 
individuals or population in the function of the enzyme (phenotype) or in the gene of 
the enzyme (genotype). Polymorphisms of CYP drug-metabolising enzymes divide 
a population into two phenotypes, poor and extensive metabolisers (Ma et al, 2004). 
Poor or slow metabolisers have the homozygous autosomal recessive allele (usually
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mutant alleles), whereas extensive or rapid metabolisers possess the heterozygous or 
homozygous dominant allele. The cytochrome P450 enzymes for which phenotypic 
and genotypic have been described include CYP1A1, CYP1A2, CYP2A6, CYP2C9, 
CYP2C19, CYP2D6 and CYP2E1. The best characterised CYP polymorphisms are 
those for S-mephenytoin hydroxylase (CYP2C19) and for debrisoquine 4-hydroxylase 
(CYP2D6). The implications in drug metabolism depend on the extent to which the 
affected pathway contributes to the overall elimination of the drug.
1.2.4.1 The CYP2C19 (S-mephenytoin hydroxylase) polymorphism
CYP2C19 that is primarily responsible for the metabolism of the anticonvulsant drug 
S-mephenytoin has been identified as genetic polymorphic, and individuals are 
characterised as either poor or extensive metabolisers. The poor metabolisers 
phenotype occurs in 2-5% of Caucasian population and 18-23% of Asian population 
(Kupfer and Preisig, 1984; Nakamura et al., 1985).
1.2.4.2 The CYP2D6 (debrisoquine hydroxylase) polymorphism
The most known polymorphic enzyme is CYP2D6 or debrisoquine hydroxylase. The 
gene, CYP2D6, is located on chromosome 22 and mutation of this gene can result in 
reduced or low affinity forms of the enzyme. The poor metabolisers phenotype 
occurs in 7-10% of Caucasian population and in about 1% of Asian population 
(Zanger et al., 2004). Besides the poor and the extensive metabolisers, another group 
has been identified, the ultra rapid metabolisers. This group is associated with 
CYP2D6 of extremely high activity (Chang and Kam, 1999). The clinical 
consequences of CYP2D6 polymorphism is that there is a 2 - 5 times difference 
between the poor and the extensive metabolisers in their ability to metabolise
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CYP2D6 substrates. Poor metabolisers experience more side effects than the 
extensive metabolisers since they need less dose of the drug. Furthermore, the third 
group of the ultra rapid metabolisers will not reach the therapeutic serum 
concentration of the drug if given at a dose given to normal extensive metabolisers.
1.2.5 Cytochrome P450-mediated drug interactions
Drug interactions involving the cytochrome P450 enzymes generally result from one 
of two processes, enzyme inhibition or enzyme induction.
1.2.5.1 Enzyme Inhibition
The majority of clinically important drug interactions involve inhibition of the drug 
metabolising enzymes. A drug may inhibit a CYP enzyme whether or not it is one of 
its substrates. If both drugs are substrates of the same CYP enzyme, the metabolism 
of one or both drugs may be delayed. The most selective CYP inhibitors generally are 
mechanism-based inhibitors. These are substrates for the target CYP and are 
converted to reactive species that covalently bind to the CYP enzyme leading to its 
inactivation. This type of inhibition is irreversible and is also known as suicide 
inhibition (Guengerich, 1990; Murray, 1992). In general, the inhibitor will decreases 
the metabolism of the drug and generally leads to increased pharmacological effect or 
toxicity. The process of the inhibition generally begins with the first dose of the 
inhibitor, and onset of inhibition correlates with the half-life of the drug involved 
(Dossing et al, 1983).
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L2.5.2 Enzyme Induction
Drug interactions due to enzyme induction are less common than inhibition-based 
drug interaction, as induction necessitates repeated exposure to huge dose of the drug, 
but are similarly severe and clinically important. Induction of CYP enzymes can 
result from exposure to environmental pollutants as well as drugs. The most common 
mechanism is the transcriptional activation leading to increased synthesis of CYP 
enzyme proteins (Lin and Lu, 1998). The metabolism of the affected drug is 
increased, leading to decreased intensity and shorter duration of drug effects. It is 
difficult to predict the time course of enzyme induction because several factors 
including the half-life of the drug and enzyme turnover influence the time course of 
induction (Dossing et al., 1983).
1.2.6 Role of cytochromes P450 in melatonin metabolism
Human studies have revealed that acute administration of fluvoxamine increased the 
night-time production of melatonin (Skene et a l, 1994). Endogenous plasma 
melatonin was increased without a similar increase in its urinary metabolite, 6- 
sulphatoxymelatonin, suggesting that fluvoxamine could inhibit the metabolism of 
endogenous melatonin. This was later confirmed in studies where administration of 
fluvoxamine led to increased serum concentrations of exogenous melatonin (von Bahr 
et a l, 2000; Hartter et al, 2001). Fluvoxamine is an established potent inhibitor of 
the CYP1A2 enzyme (Brosen et al, 1993), but is also a moderate inhibitor of the 
CYP2C19 and, to a lesser extent, of the CYP3A4 enzymes (Venkatakrishnan et al., 
1999). Furthermore, in animal studies, administration of 5-methoxypsoralen, an 
inhibitor of CYP1A2, increased the levels of endogenous plasma melatonin, possibly 
by impairing its metabolism (Mauviard et al., 1995). Additionally, treatment of male
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rats with the environmental toxicant 2,3,7,8-tetrachlorobenzo-p-dioxin (TCDD), one 
of the most potent inducers of the CYP1A subfamily, decreased the levels of serum 
melatonin by stimulating its metabolism (Pohjanvirta et al., 1996). Finally, in a study 
conducted with human cytochrome P450 proteins expressed in (3-lymphoblastoid cell 
lines, CYP1A1 and CYP1A2 enzymes were the most efficient in metabolising 
melatonin (Yeleswaram et a l, 1999). It should be pointed out that in this study, 
however, the disappearance of melatonin was monitored and not the formation of 6- 
hydroxymelatonin.
1.2.7Daily rhythms in hepatic drug-metabolising enzymes
Early studies by Radzialowski and Bousquet (1967; 1968) demonstrated that the 
activity of the enzymes that metabolise aminopyrine, p-nitroanisole, and hexobarbital 
in male and female rat livers show a light-dark rhythm, with maximum activity 
occurring at 02:00 h and minimum activity at 14:00 h. These light-dark rhythms 
disappeared following adrenalectomy, suggesting the involvement of the endocrine 
system in the regulation of the light-dark rhythm in drug metabolism. Nair and 
Casper (1969) showed that in the liver of female rats, the activity of the enzymes 
metabolising hexobarbital, imipramine, p-nitroanisole and aminopyrine, also 
exhibited light-dark rhythms. The maximum activity of all these enzymes occurred 
during the dark period and the minimum activity during the light period. The rhythm 
was reversed when the light-dark cycle was artificially reversed, indicating that light 
may act as a synchroniser of these rhythms. Lake et al (1976) demonstrated that the 
metabolism of two cytochrome P450 substrates, aniline and biphenyl, exhibited a 
light-dark rhythm in the hamster. The maximum activity occurred at the onset of the 
light period and the minimum activity at the onset of the dark period.
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The rat hepatic 7-alkoxycoumarin O-dealkylase activities, which reflect a wide-range 
of cytochrome P450 activities but not individual CYP enzymes, were investigated 
(Fukurawa et al., 1999). The maximum activities occurred during the dark period and 
the minimum activities during the light period. These researchers demonstrated that 
fasting had no effect on the light-dark rhythms in the 7-alkoxycoumarin Odealkylase 
activities when compared with ad libitum feeding under a 13:11 h light-dark cycle 
(Fukurawa et al., 1999). They also investigated whether there were sex differences in 
these activities under a 13:11 h light-dark cycle. It was observed that in female rats 
the 7-alkoxycoumarin Odealkylase activities failed to show daily rhythms and this 
was attributed to the lack of rhythmic secretion of growth hormone that occurs in 
male rats (Fukurawa et ah, 1999). The role of adrenal hormones and the SCN was 
also evaluated in the regulation of these rhythms. Lesions of the SCN abolished the 
rhythmic variation in these activities (Fukurawa et al., 1999), indicating that the SCN, 
the site of the principal generator of circadian rhythms, may play a crucial role in the 
regulation of the cytochrome P450 activities through neural or hormonal pathways.
Collectively, all the above studies provide strong evidence that light-dark rhythms 
exist in some cytochrome P450 drug-metabolising enzymes. However, these studies 
do not provide adequate information on which specific cytochromes P450 show light- 
dark rhythms and how these rhythms are regulated (e.g. via SCN, feeding, etc). The 
findings from all these studies are summarised in Table 1.3.
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Table 1.3 Summary of studies investigating daily rhythms in hepatic drug-
metabolising enzymes.
Enzyme Species
/Sex
L:D cycle 
(lights on)
Sampling 
Interval/  
Samples
Maximum  
Activity 
clock time/ZT
Minimum
Activity
clock
time/ZT
References
p-Nitroanisole N- 
demethylase
Rat /M 15.5:8.5 h 
(06.30-22.00 h)
4 h / 6 02.00 h / 19.5 14.00 h / 7.5 Radzialowski 
& Bousquet, 
1967
p-Nitroanisole N- 
demethylase
Rat /M 13.5:10.5 h 
(06.30-20.00 h)
4 h / 6 02.00 h / 19.5 14.00 h / 7.5 Radzialowski 
& Bousquet, 
1968
p-Nitroanisole N- 
demethylase
R a t / F 14:10 h 
(6.30-20.30 h)
15 h / 2 02.00 h / 7.5 10.00 h / 3.5 Jori et a l,  
1971
Aminopyrine N- 
demethylase
Rat /M 13.5:10.5 h 
(06.30-20.00 h)
4 h / 6 02.00 h / 19.5 14.00 h / 7.5 Radzialowski 
& Bousquet, 
1968
Aminopyrine N- 
demethylase
R a t / F 14:10 h 
(6.30-20.30 h)
15 h/24 h/6 02.00 h / 7.5 10.00 h / 3.5 Jori et a l,  
1971
Radzialowski
Hexobarbital
hydroxylase
Rat /M 13.5:10.5 h 
(06.30-20.00 h)
4 h / 6 02.00 h / 19.5 14.00 h / 7.5 & Bousquet, 
1968
Hexobarbital
hydroxylase*
Rat /M 12:12 h 
(06.00-18.00 h)
4-8-4 h / 4 16.00 h / 10 08.00 h / 2 Nair & Casper, 
1969
Hexobarbital
hydroxylase
R a t / F 14:10 h 
(6.30-20.30 h)
15 h / 2 02.00 h / 7.5 10.00 h / 3.5 Jori et a l,  
1971
Imipramine N- 
demethylase
Rat/ F 14:10 h 
(6.30-20.30 h)
15 h / 2 02.00 h / 7.5 10.00 h / 3.5 Jori et a l,  
1971
7-Methoxycoumarin
O-dealkylase
Rat /M 13:11 h 
(06.00-19.00 h)
4 h / 6 01.00 h / 19 09.00 h / 7 Furukawa et 
al,  1999
7-Propoxycoumarin
O-dealkylase
Rat /M 13:11 h 
(06.00-19.00 h)
4 h / 6 05.00 h / 23 17.00 h / 11 Furukawa et 
al,  1999
Glutathione S- 
transferase**
Rat /M 12:12 h 
(08.0-20.00 h)
4 h / 6 20.00 h / 12 24.00 h / 16 Tunon et a l,  
1992
Glutathione S- 
transferase
Rat /M 12:12 h 
(07.00-19.00 h)
4 h / 6 13.00 h / 6 21.00 h / 14 Inoue et a l,  
1999
* Received intraperitoneal injection of phenobarbitone 150 mg/kg at 4 times of the 24-h day. 
**24-h fasting before each time point of sacrifice of animals.
In a single study conducted in humans the light-dark rhythm in CYP3A4 activity was 
investigated using the ratio of urinary 6P-hydroxycortisol to cortisol excretion in the 
urine as a diagnostic probe (Ohno et al, 2000). In this study ten male subjects got up 
at 07:00 h and went to bed at 23:00 h (16:8 h LD cycle), received identical meals and
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drinks, and their urine was collected every four hours for three consecutive 24 h 
periods. The urinary ratio of 6(3-hydroxycortisol to cortisol was minimum in the 
morning (09:00-13:00 h) and maximum in the evening (17:00-21:00 h), which may 
reflect a light-dark rhythm in CYP3A4 activity in healthy males.
Studies investigating the existence of light-dark rhythms in glutathione S-transferase 
in rat liver found that maximum activity occurred during the dark period with 
minimum in the light period (Tunon et al., 1992). In contrast, the mouse liver 
glutathione S-transferase activity towards 1 -chloro-2,4-dinitrobenzene (CDNB) was 
maximum during the light period and minimum during the dark period (Inoue et al,
1999). These contradictory findings could be explained by the fact that different 
species were used but also more importantly by the fact that in the study of Tunon et 
al, the animals were subjected to 24 h fasting prior to each time point of sacrifice.
1.3 Objectives and Hypotheses
The main objectives of the current project were to:
(a) Identify the specific cytochrome P450 enzyme(s) involved in the hepatic 6- 
hydroxylation of exogenous melatonin in rat;
(b) Evaluate possible pharmacokinetic interactions between melatonin and other 
therapeutic agents with which it may be co-administered; studies will be 
performed in both rat and human liver;
(c) Assess the effect of caffeine treatment on the rate of metabolism of endogenous 
and exogenous melatonin; and
(d) Investigate whether 24 h daily rhythms in individual hepatic cytochrome P450 and 
conjugation enzymes exist, and investigate the underlying mechanism(s).
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The main hypotheses of the current project were:
(a) The hepatic 6-hydroxylation of exogenous melatonin is mediated by 
cytochrome P450 enzymes.
(b) (i) Therapeutic agents metabolized by CYP1A2 and co-administered with 
exogenous melatonin will inhibit its 6-hydroxylation.
(ii) Therapeutic agents not metabolized by CYP1A2 and co-administered with 
exogenous melatonin will not inhibit its 6-hydroxylation.
(c) Caffeine pre-treatment will increase the rate of metabolism of both 
endogenous and exogenous melatonin.
(d) (i) Individual hepatic cytochrome P450 and conjugation enzymes will exhibit 
24 h daily rhythms.
(ii) The 24 h daily rhythms will be abolished by SCN and PVN lesions.
CHAPTER TWO
MATERIALS AND METHODS
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2.1 Materials
Chemicals and reagents were purchased from the following sources:
Amersham Biosciences, Pollards Wood, Nightingales Lane, Bucks, Ltd., UK.
ECL kit for cytochrome P450, Western blot immunodetection and ECL mini 
camera, horseradish peroxidase, ECL Western blotting detection reagents, ECL 
Hybond™-C nitrocellulose membrane and 4- 14C-testosterone.
BDH Chemicals, Poole, Dorset, Ltd., UK.
Hydrochloric acid, sodium hydroxide, copper sulphate, potassium sodium tartrate, 
sodium hydrogen carbonate, 4-nitrocatechol, ethanol, and methanol.
BD Biosciences, Crowley, Oxford, Ltd., UK.
The antibodies to rat CYP2B1/2, rat CYP2E1, and rat CYP3A.
Fisher Scientific International Company, Ltd., Loughborough, UK.
Dimethylsulphoxide, glycine, and perchloric acid (70%).
Hopkins and Williams, Essex, Ltd., UK. 
p-Nitrophenol.
Melford Laboratories Ltd., Ipswich, Sulfolk, UK.
NADP (nicotinamide adenine dinucleotide phosphate) and NADPH (reduced 
nicotinamide adenine dinucleotide phosphate.
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Peterborough Hospital Human Research Tissue Bank, UK Human Tissue Bank 
(UKHTB), Leicester, UK
Human liver tissue (31g).
Promega Ltd., Southampton, UK.
Acrylamide, bis-acrylamide.
Sigma -Aldrich Company Ltd., Poole, Dorset, UK.
5-Methoxypsoralen, tamoxifen citrate, caffeine, coumarin, orphenadrine, 
tolbutamide, sulphaphenazole, debrisoquine, resorufin, ethoxy-, pentoxy-, and 
methoxyresorufin, tris-buffer, EDTA, bovine serum albumin, mercaptoethanol, 
glucose-6-phosphate dehydrogenase, pyronin Y, Folin-Ciocalteau phenol reagent, 
adenosine 3'-phosphate 5'-phosphosulphate, phenobarbitone, a-naphthoflavone, p- 
naphthoflavone, testosterone, 6a-, 6P-, 15a-, 7a-, 16a-, 16p-, lip -, 2a- and 2p- 
hydroxytestosterone, androstenedione, peroxidase-linked donkey anti-sheep IgG, 
peroxidase-linked donkey anti-rabbit IgG.
Stockgrand Ltd., School of Biomedical and Life Sciences, Guildford, UK.
Sheep anti-aMT6s (6-sulphatoxymelatonin) antiserum.
Ultrafme Ltd., Manchester, UK.
Furafylline, (S)-(+)mephenytoin, ketoconazole, and quinidine.
CYP1A antibodies were raised in sheep by A.D. Rodriguess (Rodrigues et al., 
1987). The antibodies recognised both members, CYP1A1 CYP1A2, of the CYP1A
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subfamily. And did not cross-react with proteins from other families. The antibodies 
to CYP2A, CYP2C11 and CYP2D1 were generous gifts from Dr Y.Funae (Osaka 
University Medical School, Japan) and U. Zanger (Dr Margarete Fisher-Bosch- 
Institut fur Kliniche Pharmacologie, Stuttgart, Germany), respectively. The antibody 
to CYP4A1, raised in sheep was a generous gift from Dr G. Gibson (University of 
Surrey, UK).
2.2 Methods
2.2.2 Rodent husbandry
Male Wistar albino rats (200 - 250 g) were bred in-house in the Experimental 
Biology Unit (EBU) University of Surrey (Guildford, Surrey, UK) in a controlled 
housing unit. The unit was controlled to produce a 12-hour light dark cycle (LD; 
lights on at 06.00 h) with a constant temperature 20 ± 1 °C and humidity of 50%. 
For the majority of the studies, rats were housed in plastic based cages with metal 
mesh lids, with a minimum of two rats per cage and maximum of four rats per cage. 
The cages were lined with sawdust and equipped with a drinking bottle and a food 
inlet. The food was a standard expanded rat and mouse diet in the form of diet 
pellets, purchased from Bantin and Kingman (B&K Universal Ltd., Hull). For 
individual urine collections, rats were transferred to metabolic cages. These cages 
housed one rat per cage. The cage was made from metal with a funnel shape base, 
below which a urine collection vessel is connected and a container for the collecting 
of faeces. A drinking bottle and food inlet were connected to each cage.
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2.2.2 Preparation of rat subcellular hepatic fractions
Male Wistar albino rats were sacrificed by cervical dislocation. Throughout the 
procedure, tissue fractions were kept cold (0 - 4°C) by using cooled homogenising 
medium and centrifuge rotors, and by keeping tissue homogenisers and centrifuge 
tubes on ice. The livers were immediately removed and placed in plastic beakers 
containing 1.15% (w/v) KC1. The livers were weighed, and were scissor minced. 
After homogenisation using a Potter-Elvejham homogeniser, the total volume was 
adjusted to a 25% w/v (1 g of liver in 4 ml) using 1.15% (w/v) KC1. The 
homogenate was centrifuged at 10,000 x g, at a temperature of 4°C, for 20 minutes 
to remove cell debris, nuclei, mitochondria and lysosomes. Post-mitochondrial 
supernatant (S9) was carefully removed avoiding the pellet and upper lipid layer, 
and was stored at -20°C until required. The microsomal fraction was prepared by 
further centrifugation of the post-mitochondrial supernatant. Known volumes of 
post-mitochondrial supernatant samples were thawed and transferred into 
appropriate sized pre-cooled ultracentrifuge tubes, and centrifuged at 200,000 x g for 
45 minutes at 4°C. After centrifugation the cytosol was either kept for phase H 
assays or discarded. The pellet was resuspended to the original volume using 1.15% 
w/v KC1.
2.2.3 Preparation of human post-mitochondrial fractions (S9)
Use of human liver tissue was approved by the University of Surrey Ethics 
Committee (Project Number: ACE/2001/09/SBLS). Human liver tissue was thawed 
and scissor minced. After homogenisation the total volume was adjusted to give a 
25% w/v homogenate (1 g of liver in 4 ml) using 1.15% (w/v) KC1. The 
homogenate was centrifuged at 10,000 x g, at a temperature of 4°C, for 20 minutes.
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Aliquots of the post-mitochondrial supernatant (S9) were withdrawn, avoiding the 
upper lipid layer and were stored at -80°C until required.
2.2,4 Protein determination
The Lowry procedure was used for determining protein levels in the hepatic 
preparations (Lowry et al., 1951).
2.2.4.1 Reagents
0.5 M NaOH, 2% (w/v) NaiCOg, 1% (w/v) copper sulphate, 2% (w/v) potassium 
sodium tartrate, 500 jig/ ml bovine serum albumin in 0.5 M NaOH, Folin 
Ciocalteu’s phenol reagent. The copper reagent was prepared by freshly mixing 
NazCOg : copper sulphate : potassium sodium tartrate at a ratio of 50:1:1.
2.2.4.2 Procedure
All test samples, blanks and standards were assayed in triplicate. A suitable dilution 
of the samples in 0.5 M NaOH was prepared. To 1 ml of diluted sample, 5 ml of 
freshly prepared copper reagent was added and the tubes were mixed immediately 
with a vortex mixer. After at least 10 minutes, 0.5 ml of fleshly prepared Folin 
Ciocalteu’s phenol reagent diluted 1:1 with distilled water was added to each tube 
and mixed immediately. After at least 30 minutes, the absorbance was measured at 
720 nm using a Kontron 932 spectophotometer. The colour was stable for at least 24 
hours.
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2.2.5 Determination of 6-sulphatoxymelatonin by radioimmunoassay
2.2.5.1 The principle o f radioimmunoassay
The basic principle of a radioimmunoassay (RIA) is the use of a radiolabelled 
antibody to detect antigen:antibody interactions. 6-Sulphatoxymelatonin (aMT6s)
125standard is labelled with the I isotope. The amount of 6-sulphatoxymelatonin 
(aMT6s) generated in the samples is measured by a radioimmunoassay procedure that 
has been modified by Aldhous and Arendt (1988) to use iodinated 125I 6- 
sulphatoxymelatonin. This technique is a very sensitive, rapid and economical.
Varying amounts of cold aMT6s (antigen) contained in the sample were incubated 
with known amounts of radiolabelled aMT6s and an antibody, raised in sheep and 
specific for the antigen to be measured. The unlabelled (cold) and the labelled 
antigen compete for the limited number of antibody binding sites. The free, unbound 
to the antibody, antigen was separated using dextran-coated charcoal. The 
concentration of antigen present in the sample was determined by comparing the 
amount of radioactivity present in the samples to the amounts found in the standards, 
of known concentration, of antigen used to construct a standard curve. The 
radioactivity present in each tube was counted in a y-counter. The concentration of 
antigen contained in each sample was calculated by interpolation using the RIAcalc 
program (Wallac EG & G). The RIAcalc program automatically calculates the 
percentage of total counts in the free fraction being measured. These values were 
then plotted as a function of the known concentration of 6-sulphatoxymelatonin 
standards. A continuous curve was fitted to each pair of standard points, and the 
concentration of antigen in the unknown samples was calculated against this curve. 
Standard curves were performed for each assay, together with low, medium and high
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quality control samples of known concentration to check the assay reproducibility 
and to calculate the inter-assay % coefficient of variation.
Diluted samples of the incubation mixture were incubated with a specific antiserum 
to aMT6s raised in sheep and specific amounts of 125I-aMT6s (10,000 cpm/tube) 
were then added. The free and antibody-bound fractions of aMT6s were separated 
by incubation with dextran-coated charcoal followed by centrifugation (3500rpm at 
4°C for 15min), and the radioactivity counted in a y-counter. A standard curve was 
constructed at the same time from aMT6s standards made up in tricine buffer.
2.2.52 Reagents
Assay buffer: 0.1 M Tricine pH 5.5 containing 0.9% NaCl and 0.1% gelatin. In 
order to achieve dissolution it was necessary to heat the mixture at 50° C for 30 
minutes. Buffer was prepared weekly, in double glass distilled water (DGDW), by 
adding 17.9 g tricine, 9.0 g NaCl and 1.0 g gelatin to a litre of DGDW.
Antiserum: Sheep anti-aMT6s antiserum (Batch No. G/S 1118-23884) was stored 
freeze-dried (1 ml of a 1/10 dilution in tricine buffer). The contents of the vial were 
dissolved in 1 ml DGDW and 9 ml assay buffer to give a final dilution of 1:100. 
Aliquots (100 pi) were stored at -20° C for up to 6 months. Each aliquot was 
sufficient for one assay containing 100 tubes. The working dilution of 1:20,000 was 
made as required by diluting an aliquot up to 20 ml with assay buffer. The working 
solution was prepared on the day of the assay and was not stored.
Radiolabel: 125I-aMT6s was used as the radiolabel for the assay. Each radiolabel 
was kindly provided by Miss Judie English (Stockgrand Ltd). A working solution
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was prepared by diluting the stock solution with assay buffer to a final volume of 
10ml, containing approximately 8,000-10,000 cpm/0.1 ml. This solution was 
prepared fresh before each assay.
Dextran-coated charcoal: Activated charcoal (Sigma Ltd. product number C-5260) 
was suspended at 2% w/v in assay buffer. It was stirred for 5 minutes and then 
centrifuged at 4°C for 5min at lOOOrpm. The supernatant and any fines around the 
sides of the vessel were discarded and the charcoal was resuspended in the original 
volume of assay buffer with 0.02% w/v dextran T-70 (Sigma Ltd. product number 
D-1390). It was stirred for at least Ihour at 4°C. It was stored at 4°C and it was 
prepared weekly.
Standards: Aliquots (2.5 ml) of aMT6s (200 pg/ml), sufficient for one standard 
curve, were prepared by diluting the ethanolic stock aMT6s solution (1 mg/ml) to 
1:250, and stored at 4 °C. Further dilution with assay buffer provided standards (0, 
1, 2, 4, 8,14, 20,40, 100 pg) for the standard curve (Table 2.1). The standards were 
treated in exactly the same way as the rest of the samples.
Table 2.1 Preparation of 6-sulphatoxymelatonin standards
aMT6s standard (pi) Tricine buffer aMT6s concentration
(200 pg/ml)_________________(pi)__________________(pg/tube)
0 500 0
5 495 1
10 490 2
20 480 4
40 460 8
70 430 14
100 400 20
200 300 40
500 - 100
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2.2.S.3 aMT6s assay procedure
Duplicate tubes were set up for all samples, standards, total counts and non-specific 
binding tubes (NSB), except for the aMT6s standard at 0 pg/tube, which was set up 
in quadruplicate. Each tube contained sample or standards in buffer (500 pi), 
antiserum (200 pi), 125I-aMT6s radiolabel (100 pi), dextran-coated charcoal (100 
pi). The total volume was 0.9 ml.
2.2.6 Determination of cytochrome P450 enzyme activities
2.2.6.1 Ethoxyresorufin O-deethylase
The ethoxyresorufin O-deethylase (EROD) assay was based on the method by Burke 
and Mayer (1974). Tris-HCl buffer 0.1 M, pH 7.8 (2 ml), maintained at 37°C, 
ethoxyresorufin 0.5 mM (3 pi) and a 25% microsomal suspension (50 pi) were mixed 
in a fluorimeter cuvette. After establishing a baseline, the reaction was initiated by 
the addition of NADPH 50 mM (10 pi) in 1% (w/v) NaHCOg and the initial rate of 
the reaction was recorded. Assays were carried out in duplicate. Fluorescence was 
measured in a Pelkin-Elmer LS-5 luminescence spectrophotometer, with an 
excitation wavelength of 510 nm and an emission wavelength of 586 nm. A standard 
curve was recorded using resorufin as standard (0-20nmol).
2.2.6.2 Methoxyresorufin O-demethylase
The methoxyresorufin O-demethylase (MROD) assay was carried out as for EROD 
(section 2.2.6.1) with the exception that methoxyresorufin 0.5 mM (10 pi) replaced 
ethoxyresorufin, and 100 pi of 25% microsomal suspension was used. A standard 
curve was recorded using resorufin, as described for EROD.
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2.2.6.3 Pentoxyresorufin O-dealkylase
The pentoxyresorufin 0-depentylase (PROD) assay was based on the method of 
Lubet et al (1985). Tris-HCl buffer 0.1 M, pH 7.8 (2 ml), maintained at 37°C, 
pentoxyresorufin 1 mM (5 pi) and a 25% microsomal suspension (100 pi) were 
mixed in a fluorimeter cuvette. A standard curve was recorded using resorufin as 
described for EROD (section 2.2.6.1).
2.2.6.4 Testosterone hydroxylase assay
Testosterone hydroxylase assays have been widely used to monitor the levels of 
expression of hepatic cytochrome P450 enzymes. This technique is based upon the 
fact that individual cytochrome P450 enzymes form characteristic and unique 
patterns of hydroxylated metabolites when incubated with steroids such as 
testosterone (Waxman et al, 1988). Certain hydroxylation reactions are catalysed 
by a single CYP form, and consequently have been used as a diagnostic probes to 
monitor the levels of expression of that enzyme in rat liver microsomes (e.g. 2a- 
hydroxylation catalysed by CYP2C11) (Morgan et a l, 1985; Waxman et a l, 1984; 
Waxman et a l, 1987). Other hydroxylation reactions are catalysed by multiple CYP 
forms (e.g. 16a-hydroxylation catalysed by CYP2B1/2 and CYP2C11) (Wood et a l, 
1983; Waxman et a l, 1987). These properties enable the simultaneous analysis of 
the levels of expression of multiple cytochrome P450 enzymes by measuring 
changes in the rate of testosterone hydroxylation.
For the current project, an HPLC-based testosterone hydroxylase assay was employed 
to measure CYP-dependent testosterone metabolism in the liver. This assay involved 
incubation of microsomal liver samples with radiolabelled 14C testosterone, followed
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by separation and quantification of metabolites using a reversed-phase HPLC system. 
Metabolites were quantified by radiochemical detection and the identity of each peak 
was confirmed by co-chromatography with hydroxytestosterone standards injected on 
to the column with each sample, and detected by UV absorption.
The following HPLC method (Michelle Coulson, School of Biomedical and 
Molecular Sciences, personal communication) was used to separate and quantify 
testosterone and individual metabolites present in the incubation extracts.
2.2.6.4.1 High Pressure Liquid Chromatography (HPLC)
All analyses were performed using a Hewlett Packard HP1090 Series HPLC system 
controlled by ChemStation software (Hewlett Packard) linked to a Berthold LB 506 
C-l radioactivity monitor (YG-150 solid detector cell) and a SpectroMonitor 3000 
variable wavelength detector (LDC/Milton Roy). Analytes were detected at 240nm 
and by radiochemical detection. Chromatography was performed on a Supelcosil 
LC-18 reverse-phase silica column (150 x 4.6mm, 3pm particle size) preceded by a 
Supelguard LC-18 guard column (2 cm, 5 pm particle size). Berthold HPLC 
software (version 1.51) was used for data acquisition and analysis.
2.2.6.4.2 Preparation o f HPLC Standards
6a-, 6(3-, 15a-, 7a-, 16a-, 16(3-, lip -, 2a- and 2p-hydroxytestosterone standards 
(>98% purity) were initially diluted to 2 pmole/ml in HPLC-grade methanol. 
Standards were then diluted in initial HPLC solvent to give stock solutions of 1 
pmole/ml (lnmole/pl injected). For testosterone and androstenedione, 100 nmol/ml 
solutions were prepared in initial HPLC solvent (0.1 nmole/pl injected).
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2.2.6.43 HPLC Solvents
Mobile Phase A: 90:10 (v/v) methanol:acetonitrile
HPLC-grade methanol (900 ml) and 100 ml HPLC-grade acetonitrile were mixed by 
shaking in a closed container and 0.5% (v/v) glacial acetic acid was added.
The solvent was stored at room temperature for up to 1 month.
Mobile Phase B: 30:70 (v/v) Methanol:IQOmM Ammonium Acetate. vH 4.5 
HPLC-grade methanol (300 ml) and 700 ml 10 mM ammonium acetate (1:10 (v/v)
100 mM ammonium acetate in HPLC-grade water) were mixed together and stored at
room temperature for up to 1 month with continuous stirring.
Stored at room temperature for up to 1 month with continuous stirring.
100 mM Ammonium Acetate, pH  4.5
7.708 g ammonium acetate was made up to 1L with MilliQ water. This was adjusted 
to pH 4.5 with glacial acetic acid and stored at room temperature for up to 3 months.
2.2.6.4.4 Chromatographic Conditions
Testosterone and individual metabolites were separated using the two step linear 
solvent gradient described in Table 2.2. Mobile phase A consisted of 
methanohacetonitrile (90:10 v/v) containing 0.5% (v/v) glacial acetic acid and mobile 
phase B consisted of methanol: lOmM ammonium acetate pH 4.5, (30:70 v / v). The 
mobile phases were degassed for 30 minutes using a gentle stream of helium, and 
then the column was equilibrated with initial solvent conditions for 30 minutes prior 
to injection of the first sample. All chromatographic separations were performed at 
room temperature using a flow rate of 0.8 ml/minute. Testosterone and individual 
metabolites present in test samples were identified by co-chromatography with 
authentic standards injected on to the column with each sample.
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Table 2.2 The solvent gradient used to separate testosterone and its metabolites
Time
(minutes)
Mobile Phase A 
(%)
Mobile Phase B 
(%)
0 10 90
15 10 90
32.5 20 80
55 60 40
60 60 40
65 10 90
2.2.6.4.S Preparation o f the Substrate
Microsomes were incubated with a mixture of 4-14C-testosterone and cold 
testosterone substrate that was prepared as follows. The required volume of 14C- 
testosterone (50 (xCi/ml in toluene, 57 mCi/mmol) was dispensed into a glass vial, 
reduced to dryness under a gentle stream of nitrogen and reconstituted in methanol to 
give a final concentration of 200 pCi/ml. A 1.215 mM solution of cold testosterone 
was prepared by weighing 8.76 mg testosterone in to a 25 ml volumetric flask. This 
was dissolved in 7.5 ml methanol and then slowly made up to volume with 50mM 
potassium phosphate buffer (pH 7.4), and sonicated for approximately 10 minutes to 
aid dissolution. Finally, the 14C-testosterone and cold testosterone solutions were 
mixed to give a solution containing 1.65:98.35 (v/v) 14C-testosterone:cold 
testosterone. 200 jil of this mixture, containing 239 nmoles cold testosterone and
11.6 nmoles ^-testosterone (0.66 jLiCi), was added to each incubation.
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2.2.6.4.6 Extraction o f Testosterone and Metabolites
Testosterone and metabolites were extracted by the addition of 3ml ice-cold ethyl 
acetate followed by vortexing for one minute. Samples were then centrifuged at 2000 
x g for 10 minutes at room temperature. The lower aqueous phase was frozen using 
an acetone/dry ice bath and the upper organic phase transferred to a clean test tube. 
This extraction procedure was repeated once, the two organic phases were combined 
and then reduced to dryness under a gentle stream of nitrogen. Extracts were 
reconstituted in lOOjLil HPLC-grade methanol and made up to a final volume of 200pl 
with HPLC-grade water. Testosterone and metabolites present in extracts were 
separated and quantified using the HPLC method (section 2.2.6.4). BOjul of each 
extract was injected on to the column along with 20pl of a mixture of authentic 
testosterone standards (section 2.2.6.4.2).
2.2.6.4.6.1 Calculation o f the Extraction Efficiency
Aliquots of the 14C-testosterone substrate (200 pi) and reconstituted incubation 
extracts (20 pi) were added to scintillation vials containing 3.5 ml scintillation fluid 
and counted for one minute on a Wallac 1410 liquid scintillation counter. Triplicate 
or duplicate samples were counted for the substrate and extracts respectively. The 
extraction efficiency was calculated as follows:
% Extraction efficiency = extract------  x 100
dpm /  incubation
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2.2.6.4.6.2 Calculation o f Enzyme Activity
The specific activity for the formation of each metabolite was calculated in picomoles 
per minute per milligram of microsomal protein (pmol/min/mg protein) as follows. 
The use of radiolabelled substrate enabled quantification of individual testosterone 
metabolites injected on to the HPLC column in incubation extracts. The Berthold 
HPLC software calculates a percentage Region of Interest (% ROI) value for each 
peak, which corresponds to the percentage of total radioactive counts measured 
during a chromatographic run that were attributable a particular peak.
The % ROI value for a particular metabolite peak was converted to a specific activity 
using the following calculation:
Specific % ROI nmoles / 5 minute
activity = _________ x amount of substrate added (nmoles) = incubation / 0.5 mg
microsomal protein
The product of this calculation was converted to the specific activity in pmol/min/mg 
microsomal protein.
2.2.6.4J Separation o f testosterone metabolites
The HPLC system was capable of resolving at least eleven potential metabolites of 
testosterone, which are expected to include all of the major metabolites generated by 
rat liver microsomes. Figure 2.1 shows a typical separation of a mixture of authentic 
testosterone standards. The retention times of the various testosterone metabolites are 
summarised in Table 2.3. The retention times of hydroxytestosterone standards were 
found to vary over repeated chromatographic runs but crucially the position of each 
metabolite on the chromatogram relative to the other metabolites remained constant. 
Such shifts in retention times were not entirely unexpected and are probably due to
Chapter 2 - Materials and Methods 46
variations in the ambient temperature, as a column oven was not used. This assay 
variation was of little consequence because identification of metabolites was based on 
co-chromatography with authentic standards injected on to the column 
simultaneously with each sample.
uni i s
2a
Testas.
16a
Absorbance 
(240 nm)
And.
15a
7a
6a
20 30
Retention time (mins)
Figure 2.1 A representative chromatogram showing the separation of a mixture of authentic 
testosterone metabolites by HPLC. Approximately 1.8 nmoles of each hydroxylated metabolite and 
0.18 nmoles of testosterone (Testos.) and androstenedione (And.) were injected on to the column. 
Elution of analytes was monitored by optical absorbance at 240nm.
Another characteristic of the chromatogram shown in Figure 2.1 is the gradual rise in 
baseline absorbance during the chromatographic run. This is due to the increasing 
proportion of organic solvent (mainly acetonitrile), which also absorbs at 240 nm. 
This does not interfere with peak integration and quantification as this is based upon 
measurement of radiolabelled metabolites, whilst the optical absorbance trace is used 
solely as a means of peak identification.
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Table 2.3 Chromatographic retention times for testosterone and its metabolites.
Approximately 1.8 nmoles of each hydroxylated metabolite and 0.18 nmoles of testosterone and 
androstenedione were injected onto the column. Elution of analytes was monitored by UV absorbance 
at 240 nm.
Retention time 
(mins)
Standard compound Chemical name
20.06 6a-OHT 4-Androsten-6oc, 17p-diol-3-dione
22.30 15P-OHT 4-Androsten-15p, 17P-diol-3-dione
28.54 6p-OHT 4-Androsten-6p, 17P-diol-3-dione
30.18 15a-OHT 4-Androsten-15a, 17p-diol-3-dione
31.42 7a-OHT 4-Androsten-7a, 17p-diol-3-dione
38.54 16a-OHT 4-Androsten-16a, 17P-diol-3-dione
40.48 16P-OHT 4-Androsten-16p, 17P-diol-3-dione
44.42 llp-OHT 4-Androsten-llp, 17p-diol-3-dione
45.18 2cc-OHT 4-Androsten-2a, 17p-diol-3-dione
46.12 2p-OHT 4-Androsten-2p, 17P-diol-3-dione
50.42 Androstenedione 4-Androsten-3, 17-dione
53.12 Testosterone 4-Androsten-17 P-ol-3-one
2.2.6.S p-Nitrophenol hydroxylase
The hydroxylation of p-nitrophenol to nitrocatechol assay was based on the method 
by Reinke and Moyer (1985) as modified by McCoy and Koop (1988). A time 
dependency study was carried out to determine that the rate was in the linear range. 
The incubation mixture comprised 0.2 M potassium phosphate buffer, pH 6.8 (0.5 
ml), 10 mM ascorbate (0.1 ml), 1 mM p-nitrophenol (0.1 ml) and 25% microsomal 
suspension (0.2 ml). The reactants were pre-incubated for 5 minutes at 37°C in a 
shaking water bath. The reaction was initiated by the addition of 10 mM NADPH 
(0.1 ml). After 20 minutes incubation, the reaction was terminated by the addition of 
ice-cold 0.6 M perchloric acid (0.5 ml). The protein was precipitated by 
centrifugation at 3,000xg for 10 minutes. An aliquot of the supernatant (1 ml) was
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transferred into clean LP3 tubes. Sodium hydroxide 10 M (0.1 ml) was then added 
and the mixtures vortex mixed. The absorbance was read at 536 nm using a Kontron 
Unikon 932 spectrophotometer. The p-nitrophenol hydroxylase activity was 
calculated from a standard curve (0-100 nmol 4-nitrocatechol). Samples were 
assayed in triplicate.
2.2.7 Expression of cytochrome P450 apoprotein levels: Western 
blotting
The expression of apoprotein levels was determined by Western blotting in the case 
where no chemical probe could be used, and in some cases to support the findings 
from the biochemical assays. The cytochrome P450 apoprotein levels were 
determined using antibodies against CYP1A, CYP2A1, CYP2B1/2, CYP2C11, 
CYP2D1, CYP2E1 and CYP4A.
2.2.7.1 Principle o f the immunodetection system
Western blotting is the process of immobilising proteins on a solid membrane 
support, following a gel electrophoresis protein separation stage, and analysing them 
using immunodetection. The blotting procedure reproduces and immortalises the 
relative spatial arrangement of the proteins in the initial electrophoretogram. The 
immunodetection technique offers specificity through the use of an antibody specific 
for the blotting proteins (Towbin et al,, 1979). Following blotting, the membrane is 
treated with a blocking reagent to prevent non-specific binding of the 
immunodetection reagents to the blotting membrane. The immunodetection 
procedure utilises an anti-rat cytochrome P450 (primary) antibody that binds 
specifically to the immobilized cytochrome P450 protein. The membrane is then
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detected with an IgG species-specific (secondary) peroxidase-linked antibody, which 
binds to the primary antibody. After each incubation stage, the unbound antibody is 
removed by washing with Tris buffered saline - Tween™-20 solution. Detection 
using ECL detection reagents utilises the bound horseradish peroxidase to catalyse 
the oxidation of luminol, in the presence of hydrogen peroxide and an enchancer. 
Following oxidation, the luminol is in an excited state, which decays emitting light 
that is captured on film enabling quantification of the bands.
2.2.7.2 SDS-PAGE (polyacrylamide gel electrophoresis)
The separation of microsomal proteins was achieved by the SDS-PAGE, based on 
the method described by Laemmli (1970). A vertical slab gel apparatus (Mini- 
Protean H, Bio-Rad) was used for electrophoresis. Gels were cast between plates 
clamped in place, separated by plastic spacers. The dimensions of the gels were 73 
mm x 80 mm x 1 mm. Prior to use, the glass plates were washed with detergent, 
thoroughly rinsed with RO water, cleaned with 70% ethanol and left to dry. The 
cassettes were assembled and clamped vertically.
The resolving (lower) gel (12%, w/v) was prepared by mixing the following:
Milli-Q water ( 3.55 ml
Resolving gel buffer 4.5 ml
Acrylamide (30%) 7.5 ml
Bis-acrylamide (2%) 2.95 ml
TEMED* 18 pi
*TEMED, MMA^A^-tetramethylethylenediamine
Resolving gel buffer comprised Tris-HCl (1.5 M, pH 8.8) containing SDS (0.4%, 
w/v). Polymerisation was initiated by the addition of freshly prepared ammonium 
persulphate solution (180pl, 10% w/v). After mixing, the gel was pipetted into the
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apparatus up to the indicator line and a layer of water (1 ml) added to ensure a flat 
interface between the upper and the lower gels. After the gel had set, the water was 
removed with filter paper, taking care not to touch the surface of the gel.
The stacking (upper) gel (4%, w/v) was prepared by mixing the following:
A Teflon™ comb was inserted into the upper gel in order to form the sample wells. 
Stacking gel buffer comprised Tris-HCl (0.5 M, pH 6.8) containing SDS (0.4%, 
w/v). Again, polymerisation was initiated by the addition of ammonium persulphate 
(50 pi) and after mixing, pipetted onto the lower gel. After the gel had set, the 
apparatus was placed into the tank full of electrode buffer and the comb removed. 
Electrode buffer comprised Tris-HCl (25 mM, pH 8.3) containing glycine (192 mM) 
and SDS (0.1% w/v).
2.2.7.3 Preparation o f microsomal samples and gel sample loading 
Loading buffer was consisted of 0.5 M Tris-HCl, pH 6.8, (1.2 ml), glycerol (960 pi), 
SDS 10% w/v (1.92 ml), P-mercaptoethanol (480 pi) and 0.05% (w/v) pyronin Y 
(600 pi) in Milli-Q water (4.8 ml). Samples (lmg/ml protein) were diluted with an 
equal volume of loading buffer and heated for 5 minutes at 95-100° C in a water 
bath, briefly centrifuged at 8,000xg in a benchtop centrifuge, then loaded (lOpl) into 
the wells using long-ended pipette tips. Electrophoresis was carried out immediately 
after loading the samples using a Bio-Rad Power Pac 300 power pack, at a constant 
current of 40 mA and a voltage of 120 V. When the pink band of the loading buffer
Milli-Q water 
Stacking gel buffer 
Acrylamide (30%) 
Bis-acrylamide (2%) 
TEMED
6.9 ml 
2.5 ml 
1.0 ml 
0.4 ml
10 pi
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had nearly reached the bottom of the gel, the power was switched off. The cassette 
was removed from the electrophoresis tank, the glass plate separated and the 
stacking gel discarded.
Proteins were transferred electrophoretically to nitrocellulose paper according to the 
method of Towbin et al. (1979). The resolving gel was transferred to the blotting 
apparatus and soaked in transfer buffer for at least 10 minutes to allow equilibration. 
The gel was then placed in the transfer cassette facing a nitrocellulose sheet 
(Hybond ECL), and sandwiched between sheets of filter paper and Scotchbrite™, all 
of which had also been pre-soaked in transfer buffer. Assembly of the cassette was 
perfomed in transfer buffer, ensuring air bubbles were excluded from the assembly. 
Transfer buffer comprised Tris-HCl (16 mM, pH 8.3) containing glycine (120 mM) 
and methanol (20%, w/v).
The cassette was placed into transfer buffer in the electrophoresis tank. Transfer 
was carried out at a constant current of 100 mA and a voltage of 120 V for 16 hours. 
Following transfer, the cassette was dismantled and excess buffer removed from the 
nitrocellulose membrane. The membrane was either wrapped in cling-film and 
stored at 4°C until detection (for up to two weeks), or used immediately for 
detection.
2.2.7.4 Immunodetection and visualisation
Non-specific binding sites were blocked by immersing the membrane in 5% 
blocking reagent comprising non-fat dried milk powder in Tris-buffered saline 
(TBS), (20 mM Tris pH 7.6, 137 mM NaCl) for one hour at room temperature on a
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roller shaker. Subsequently, the membrane was washed with Tris buffered saline 
Tween (TBS-T) (TBS in 0.1% w/v Tween 20), once for 10 minutes and twice for 5 
minutes, with fresh changes of the washing buffer kept at room temperature. The 
membrane was incubated with the appropriately diluted primary antibody for one 
hour at room temperature. Primary and secondary antibodies were diluted in 10 ml 
diluent made up with 1% (w/v) non-fat dried milk powder in TBS-Tween (0.8 g 
non-fat dried milk powder in 80 ml TBS-Tween). The membrane was again washed 
with TBS-Tween once for 10 minutes and twice for 5 minutes with fresh changes of 
the washing buffer kept at room temperature. After the washing, the membrane was 
incubated with the diluted secondary antibody for one hour at room temperature in 
10 ml diluent. Excess antibody was removed by further washing once for 10 
minutes and twice for 5 minutes, before incubation with the detection reagents. An 
equal amount (1 ml) of ECL Western blotting detection solution 1 was mixed with 
the detection solution 2, sufficient to cover the membrane. The excess buffer from 
the washed membrane was drained off and placed in a plastic dish, protein side up. 
The detection reagent was added carefully to the protein side of the membrane and 
incubated for precisely one minute at room temperature without agitation. The 
excess detection reagent was drained off. The blots were placed, protein side down, 
in the film cassette as quickly as possible, to minimise the delay between incubating 
the membrane in the detection reagent and exposing to the film. The membrane was 
then exposed to Polaroid film to visualise the protein bands (ECL mini-camera). 
Membranes were re-exposed for various time periods as required to improve the 
band intensity. Images were captured and quantitated using GeneSnap® image 
capture utility software.
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2.2.8 Determination of conjugation enzymes
2.2.8.1 Glutathione S-transferase
Glutathione S-transferase activity was determined essentially as described by Habig 
et al. (1974). The assay uses the substrates 1,2-dichlo-4-nitrobenzene (DCNB) or 1- 
chloro-2,4-dinitrobenzene (CDNB), which are good substrates for a number of the 
glutathione S-transferase enzymes and result in the formation of S-(2-chloro,4- 
nitrophenyl) and S-(2,4-dinitrophenyl) glutathione respectively. The reaction was 
measured spectrophotometrically as an increase in absorbance at 340nm (CDNB) or 
345nm (DCNB) with time, which was proportional to the enzyme activity. The 
reaction was perfomed using a Kontron Uvikon 932 spectophotometer.
2.2.8.1.1 Using DCNB as substrate
The cytosolic fraction, from a 25% w/v homogenate, was diluted four-fold with 
1.15% w/v KC1 and kept on ice.
The following were added to spectrophotometer cuvettes in duplicate:
Reference Sample
Potassium phosphate buffer (0.1 M, pH 7.5) 0.90 ml 0.80 ml
DCNB (25 mM in absolute ethanol) 0.05 ml 0.05 ml
Reduced glutathione (25 mM in 1.15% w/v KC1) 0.25 ml 0.25 ml
The reaction for was initiated by adding 0.01 ml of the diluted cytosol to the sample 
cuvette. The sample was mixed by inversion and the change in absorbance followed 
at 345 nm. The specific activity of glutathione S-transferase was calculated from the 
initial rate of reaction using a molar extinction coefficent of 8.5 mM'1 cm"1.
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2.2.8.1.2 Using CDNB as substrate
The cytosolic fraction, from a 25% w/v homogenate, was diluted 1 in 100 with 1.15% 
w/v KC1 and kept on ice.
The following were added in spectrophotometer cuvettes in duplicate:
Reference Sample
Potassium phosphate buffer (0.1 M, pH 7.5) 0.90 ml 0.80 ml
CDNB (25 mM in absolute ethanol) 0.05 ml 0.05 ml
Reduced glutathione (5 mM in 1.15% w/v KC) 0.25 ml 0.25 ml
The reaction was initiated by adding 0.01 ml of the diluted cytosol to the sample 
cuvette. The sample was mixed by inversion and the change in absorbance followed 
at 340 nm. The specific activity of glutathione S-transferase was calculated from the 
initial rate of reaction using a molar extinction coefficent of 9.6 mM"1 cm'1 for CDNB.
2.2.8.2 UDP Glucuronosyl transferase
The glucuronosyl transferase activity, responsible for the glucuronidation of 1- 
naphthol was measured by incubating the microsomal fraction in the presence of the 
substrate and UDP-glucuronic acid. The unused substrate is extracted from the 
incubation system, and the product 1-naphthyl glucuronide was measured by its 
fluorescence at alkaline pH. This assay was adapted by the method devised by Bock 
and White (1974).
Standards were prepared from a stock solution of 1-naphthyl glucuronide (2 mM), 
which was diluted 1 in 100 with 0.2 M trichloroacetic acid (TCA)/0.3 M glycine pH
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2.2, to give a working solution of 20 \iM. From this working solution a standard 
curve was constructed.
Standard
(nmol)
1-Naphthyl glucuronide 
stock solution (ml)
0.2 M TCA / glycine 
(ml)
0 0.0 8.0
1 0.4 7.6
2 0.8 7.2
3 1.2 6.8
4 1.6 6.4
5 2.0 6.0
10 4.0 4.0
20 8.0 0.0
The following reagents were added to chloroform-resistant tubes:
Blank Sample
(ml) (ml)
Potassium phosphate buffer
(0.4 M, pH 7.4 containing 5 mM EDTA) 0.85 0.75
Magnesium chloride (100 mM) 0.05 0.05
1-Naphthol (0.5 mM) - 0.10
Microsomal suspension (25% w/v) 0.05 0.05
Tubes in triplicate were pre-incubated for 5 minutes at 37°C in a shaking waterbath. 
The reaction was initiated by the addition of 0.05 ml UDP-glucuronide (20 mM) that 
had also been pre-incubated at 37°C. Incubation was carried out for further 15 
minutes after which time the reaction was terminated by the addition of 1 ml TCA 
(0.4 M containing 0.6 M glycine, pH 2.2) to the tubes. Each tube was vortex-mixed 
and then placed on ice for 5 minutes before the addition of chloroform (10 ml). The 
tubes were capped and placed on a rotary mixer for 10 minutes. They were then 
centrifuged at 3,000xg at 4°C for 5 minutes to separate the two phases. An aliquot of 
1 ml of the aqueous phase was added to 2 ml of sodium hydroxide (0.45 M) in a
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quartz fluorimetric cuvette and mixed by inversion before measuring the fluorescence 
at excitation and emission wavelengths of 293nm and 335nm, respectively (Varian 
Cary Eclipse Fluorescence Spectrophotometer).
2.2.83 Epoxide hydrolase
The fluorimetric determination of the hydrolysis of benzo[a]pyrene-4,5-epoxide to 
benzo[a]pyrene-4,5-dihydrodiol, mediated by microsomal epoxide hydrolase activity, 
was based on the procedure described by Dansette et al. (1979).
The following reaction mixture was prepared in a quartz fluorimetric cuvette in 
duplicates:
The contents were mixed by inversion, and the increase in fluorescence with time 
was monitored at an excitation wavelength of 310nm and an emission wavelength of 
385nm (Varian Cary Eclipse Fluorescence Spectrophotometer). A calibration curve 
was constructed by serial additions (5 pi) of 2 mM benzo[a]pyrene-4,5-dihydrodiol, 
dissolved in acetronile, to 15 mM, pH 8.7 Tris-HCl buffer (2 ml). The reaction was 
initiated by the addition of the microsomes.
Tris-HCl buffer (15 mM, pH 8.7) at 37°C 
Benzo[a]pyrene-4,5-epoxide (2 mM in acetronile) 
Microsomal suspension (25%, w/v) 0.05 ml
0.01ml
2.00 ml
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2.2.9 Procedure of SCN lesioning
The following procedure was conducted at the Netherlands Institute for Brain 
Research (Netherlands). For SCN lesions 16 male Wistar rats obtained from a 
commercial supplier (Harlan, Horst, The Netherlands), 180 - 200 g, anesthetized with 
Hypnorm (Duphar, The Netherlands; 0.6 ml/kg, im), were mounted with their heads 
in a David Kopf Stereotact (Tujunga, CA) with the toothbar set at +5.0 mm, and 
sustained a bilateral lesion of the SCN (coordinates: 1.4 mm rostral to bregma; 1.1 
lateral to the midline; 8.3 mm below the brain surface) using bilateral lesion 
electrodes, 0.2 mm in diameter, with temperature set at 85° C for 1 min (lesion 
generator, Radionics, Burlington, MA). This temperature was found empirically to 
result in lesions large enough to eliminate the SCN bilaterally, but small enough to 
leave surrounding hypothalamic brain structures, such as the paraventricular (PVN) 
and supraoptic (SON) nuclei intact. A drawback of this restricted lesion size is the 
limited yield of completely lesioned animals (i.e. -30%). To restrict the number of 
(false positive) animals to be operated upon, initially the effectiveness of the lesions 
was checked by measuring daily water intake. After a rest period of 2 weeks to 
recover from the trauma of anesthesia and brain trauma, the daily water intake of the 
animals was measured during the middle 8 h of the light period. Only animals 
showing a daytime water intake of more than 30% of the total daily intake (in intact 
control animals this value is typically <10%) were assumed to have complete lesions 
of the SCN until the final immunocytochemical analysis and were allowed to enter 
the experiment. After the experiments, SCN lesions were checked histologically by 
immunocytochemical staining of hypothalamic sections for the presence of 
vasopressin (VP) and/or vasoactive intestinal polypeptide-containing cell bodies or
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fibers in the SCN area. Animals were killed in the middle of the light period at ZT 6 
(13:00 h) and at ZT 18 (21:00 h) of the dark period of the 12:12 LD cycle.
2.3 Data analysis
Specific data analysis is described in more detail within each Chapter.
Unpaired Student’s t-test was performed to compare results between two groups. A 
normality test was performed to test the assumption that the data come from Gaussian 
distributions. The assumption that the two populations have the same SD was tested 
using the F test (equality of variance). One-way ANOVA was used to compare more 
than two groups followed by a Tukey post hoc test to reveal where the significant 
differences exist. Correlation analysis (R) was used to examine the relationship 
between two variables. All these statistical analysis were performed using the 
software GraphPad Instat version 3.
The assessment of light dark rhythms in drug-metabolising enzymes were analysed 
using single cosinor analysis. Also, urinary endogenous 6-sulphatoxymelatonin 
rhythms in animals were analysed using single cosinor analysis (software provided by 
Dr D. Minors, University of Manchester, UK).
CHAPTER THREE
MELATONIN 6-HYDROXYLATION BY 
CYTOCHROME P450 ENZYMES
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3.1 Introduction
Melatonin is a hormone of the pineal gland, is secreted at night and is thus associated 
with night-time events such as sleep, reduced alertness and body temperature (Arendt, 
1988; Arendt and Skene, 2005). The ability of exogenous melatonin to phase-shift 
circadian rhythms has led to its pharmacological use as a “chronobiotic” in a number 
of conditions resulting from disturbed circadian rhythms, such as jet lag following 
rapid time-zone changes, shift work and non-24 h sleep wake disorder in blindness 
(Skene et al, 1996; Arendt et al, 1997; Arendt and Skene, 2005).
The increasing popularity of melatonin for the self-treatment of sleep disorders and 
for a number of other health benefits attributed to its antioxidant properties (Tan et al, 
1993; Reiter, 1995), has led to its increased use (Bonn, 1996). It is important to point 
out that because melatonin occurs naturally in some foods it can be sold in some 
countries such as the USA as a dietary supplement without requiring approval from 
the Food and Drug Administration. This has led to uncontrolled self-medication 
(Bonn, 1996) with the increased possibility of drug interactions in cases where it is 
co-administered with other drugs. Consequently, to be able to predict potential drug 
interactions with melatonin, it is essential to define the enzymic system as well as the 
specific enzymes responsible for the 6-hydroxylation of melatonin, the principal 
metabolic pathway of melatonin (section 1.1.2).
Many different strategies are currently employed in the identification of the enzymic 
system responsible for the biotransformation of a therapeutic agent. A possible 
candidate for the catalysis of melatonin 6-hydroxylation is the cytochrome P450 
system. The cytochrome P450 families that are mainly involved in the
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biotransformation of xenobiotics in both humans and rodents are CYP1, CYP2 and, 
CYP3 (Gonzalez, 1988). By proving that this reaction is localised in microsomes, 
requiring NADPH as well as oxygen will be evidence that the cytochrome P450 is 
involved in the 6-hydroxylation of melatonin. After having established that the 
cytochrome P450 enzymic system is involved, other strategies will be employed to 
identify the major CYP1, CYP2 and CYP3 families involved by using selective 
inducers that help to identify the role of the major subfamilies. After identifying the 
major subfamilies involved in the 6-hydroxylation of melatonin, selective chemical 
inhibitors will be used since these are a useful tool to screen and identify the 
individual enzymes that hydroxylate melatonin at the 6-position (Tassaneeyakul et al., 
1993; Wrighton et al., 1993). Chemical inhibitors of enzymes are usually used to 
identify the individual cytochrome P450 enzymes involved in the metabolism of a 
substrate.
Melatonin in both humans and rodents is metabolised via 6-hydroxylation (Kopin et 
al., 1960) but exogenous melatonin is also O-demethylated to A-acetylserotonin 
(Young et al, 1985; Leone et al., 1987) (section 1.1.2). The general pattern of 
metabolism of exogenous melatonin in humans is very similar to that in rats (Jones et 
al, 1969). The lack of readily available human liver samples for inhibition studies 
means that rat hepatic microsomal preparations can be used as an alternative, and the 
results will be extrapolated to humans. The present study investigates the enzymes 
responsible for the hepatic 6-hydroxylation of melatonin since this is the main 
metabolic pathway of melatonin (Kopin et a l, 1960).
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3.2 Objectives
The objective of these studies is to identify the cytochrome P450 enzymes that act as 
principal catalysts of the hydroxylation of melatonin, at melatonin concentrations that 
may be achieved in plasma following exogenous intake. Both cytochrome P450 
induction and inhibition studies were performed using selective inducers and 
inhibitors.
3.3 Materials and Methods
3.3.1 Methods
3.3.1.1 Incubation system
In these studies 25% (w/v) postmitochondrial fractions (S9),comprising both 
microsomal and cytosolic fractions, from the livers of male Wistar albino rats, 
prepared as previously described (section 2.2.2) were utilised. The microsomal 
fraction contains a full complement of cytochrome P450 enzymes while the cytosolic 
fraction contains the sulphotransferase, the enzyme that adds the sulphate to 6- 
hydroxymelatonin to form the conjugate, 6-sulphatoxymelatonin, detected by the 
radioimmunoassay technique (section 2.2.5). Postmitochondrial fractions are 
relatively easy to prepare and enzymatic activities are stable during prolonged storage 
(Beaune et al., 1986; Yamazaki et al, 1997), if the original tissue is correctly handled 
and frozen immediately after excision.
A limitation of this method is that by measuring the sulphate conjugate instead of 6- 
hydroxymelatonin, it is essential to distinguish between changes in the initial 
oxidation and the subsequent sulphate conjugation. Consequently, 6-
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hydroxymelatonin was also employed as a substrate to exclude the possibility that 
changes in 6-sulphatoxymelatonin production reflect changes in sulphotransferase 
activity and not in 6-hydroxylase activity. Therefore, all incubations were performed 
with melatonin or 6-hydroxymelatonin (50 juM). The incubation mixture, having a 
total volume of 0.5 ml, comprised 0.1 M potassium phosphate buffer pH 7.4 (250 pi), 
15 juM glucose 6-phosphate (50 pi), 1 pM NADP (50 pi), 100 nM adenosine 3’- 
phosphate 5’-phosphosulphate (50 pi), and 50 pi hepatic postmitochondrial fraction. 
After an initial pre-incubation of 10 minutes at 37°C, the reaction was initiated by the 
addition of 50 pM melatonin (50 pi) or 50 pM 6-hydroxymelatonin (50 pi). The 
mixture containing melatonin or 6-hydroxymelatonin was incubated in a shaking 
water-bath at 37°C for 20 or 10 minutes, respectively. The reaction was terminated 
by the addition of 0.2 M perchloric acid (250 pi), and protein was precipitated by 
centrifugation at 3,000 x g for 15 minutes. Supernatant (0.5 ml) was removed 
carefully, and 4 M NaOH (15 pi) was added. Samples were stored in the freezer at — 
20°C until assayed by radioimmunoassy. These samples were further diluted with 0.1 
M potassium phosphate buffer as required to fit the standard curve.
3.3.L2 Sulphate conjugate determination
The 6-sulphatoxymelatonin generated from the incubations using melatonin or 6- 
hydroxymelatonin as substrates was measured in the diluted supernatant (0.5 ml) by 
radioimmunoassay as previously described (section 2.2.5.1). Intra-assay coefficients 
of variation (CVs) were 24.9%, 12.8% and 12.8% at 2.2 ng/ml (n=14), at 14.5 ng/ml 
(n=14) and 27.9 ng/ml (n=14), respectively.
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3.3.2 Preliminary studies
3.3.2.1 NADPH and O2 requirement for the 6-hydroxylation o f melatonin 
Preliminary work in our laboratory (J. Snelling, personal communication) established 
that the reaction was localised in microsomes and that NADPH was essential for the 
conversion of melatonin to its metabolite 6-sulphatoxymelatonin, giving evidence that 
the cytochrome P450 system is involved. To further support this finding, a study to 
show the necessity of aerobic conditions for the 6-hydroxylation of melatonin was 
performed by bubbling nitrogen for 10 minutes prior to the addition of melatonin into 
the tubes and throughout the incubation, to remove the oxygen from the reaction.
3.3.2.2 Time-linearity o f 6-sulphatoxymelatonin generation
Melatonin or 6-hydroxymelatonin (50 pM) was incubated with postmitochondrial 
preparations for different time periods (0, 10, 15, 20, 25, 30 minutes with melatonin 
and 0, 10, 20 and 30 minutes with 6-hydroxymelatonin) to establish the linearity of 
the sulphate conjugate formation with respect to time.
3.3.2.3 Protein-linearity o f 6-sulphatoxymelatonin generation
Melatonin or 6-hydroxymelatonin (50 pM) was incubated with different amounts of 
hepatic postmitochondrial fractions (0, 50, 100, 150, 200, 250, 300 pi) to establish 
that 6-sulphatoxymelatonin formation is linear with respect to protein.
3.3.3 Cytochrome P450 induction studies
Preliminary work in our laboratory (J. Snelling, personal communication) in which a 
range of inducers of cytochrome P450 were employed, revealed that, p- 
naphthoflavone treatment of rats led to a significant increase in the formation of 6-
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sulphatoxymelatonin when melatonin was used as substrate. Moreover, studies 
employing precision-cut liver slices indicated that, in addition to p-naphthoflavone, an 
increase in 6-sulphatoxymelatonin generation from melatonin was also observed 
following the treatment of rats with phenobarbitone. Since both studies did not also 
use 6-hydroxymelatonin as substrate, another study was undertaken, using both 
melatonin and 6-hydroxymelatonin as substrates to exclude the possibility that 
changes in sulphotransferase activity are responsible for the observed increase in 6- 
sulphatoxymelatonin formation.
3.3.3.1 /3-Naphthoflavone induction
Four male Wistar albino rats (200 -  250 g), synchronised in a 12:12 hr lightrdark 
cycle (LD; lights on at 06.00 h), were given an intraperitoneal injection of 25 mg kg'1 
p-naphthoflavone (Table 3.1) dissolved in com oil, once daily for three days. Four 
control animals were given the equivalent volume of com oil. All animals were killed 
24 hours after the last administration, livers were immediately removed on ice, and 
postmintochondrial fractions were prepared as previously described (section 2.2.4) 
and stored at -20° C until use.
3.3.3.2 Phenobarbitone induction
Four male Wistar albino rats (200 - 250 g), synchronised in a 12:12 hr lightdark cycle 
(LD; lights on at 06.00 h), were given an intraperitoneal injection of 80 mg kg'1 
phenobarbitone (Table 3.1) dissolved in water once daily for three days. Four animals 
were given the equivalent volume of saline and served as vehicle. All animals were 
sacrificed on the fourth day, 24 h after the last injection of the inducer or the vehicle.
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The livers were immediately removed on ice, and postmitochondrial fractions were 
prepared as previously described (section 2.2.2) and stored at -20° C until use.
Table 3.1 Treatment with cytochrome P450 inducers.
Treatment Subfamily induced Dose
p-Naphthoflavone (BNF) CYP1 25 mg/kg in com oil
Phenobarbitone (PB) CYP2B/3A 80 mg/kg in water
3.3.4 Cytochrome P450 inhibition studies
Numerous compounds have been characterised for their inhibitory potency against 
different cytochrome P450 enzymes (Halpert et al., 1994). Many of these inhibitors 
are selective for only one enzyme, at particular concentrations, and can facilitate 
characterisation of the specific P450 enzymes that catalyse a reaction. To define the 
individual cytochrome P450 enzymes involved in the 6-hydroxylation of melatonin, a 
number of selective chemical cytochrome P450 inhibitors were employed. These 
studies were conducted by incubating melatonin or 6-hydroxymelatonin with 
untreated pooled rat hepatic postmitochondrial fractions in the presence of inhibitors 
and substrates of CYP1A2, CYP2A1, CYP2B1, CYP2C11, CYP2D1, CYP2E1, and 
CYP3A1. The degree of inhibition of each selective cytochrome P450 inhibitor on 
melatonin 6-hydroxylase was determined by measuring the amount of 6- 
sulphatoxymelatonin generated from melatonin or 6-hydroxymelatonin. Table 3.2 
outlines the inhibitors investigated and the cytochrome P450 enzyme for which they 
display selectivity. In the case of the mechanism-based inactivators of cytochrome 
P450 enzymes, namely furafylline and diethyldithiocarbamate, these compounds were
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pre-incubated with postmitochondrial fractions and cofactors for 15 minutes prior to 
the addition of melatonin or 6-hydroxymelatonin.
The substrate/inhibitors used in the present studies are shown in Table 3.2. Furafylline 
was selected since it is a potent and selective mechanism-based inactivator of 
CYP1A2 (Sesardic et al., 1990). Caffeine was used as a CYP1A2 substrate (Roberts 
et al., 1994) even though other enzymes may be also involved in its biotrasformation 
(Tassaneeyakul et ah, 1994). oc-Naphthoflavone was also used as a CYP1A1/2 
inhibitor (Halpert et al, 1994), coumarin was selected as a CYP2A1 inhibitor (Halpert 
et al, 1994) and orphenadrine was chosen as CYP2B1 inhibitor, although its 
selectivity towards this enzyme has been questioned (Murray and Reidy 1990; Chang 
et al., 1993; Ekins et al., 1997; Guo et al., 1997). A selective inhibitor for CYP2B1 
was not available at the time when the present studies were conducted. Tolbutamide, 
(S)-(+)mephenytoin (Heyn et al., 1996), and sulphaphenazole (Baldwin et al., 1995) 
were selected as CYP2C11 substrate/inhibitors. Quinidine is an established CYP2D1 
inhibitor since it specifically and potently inhibits CYP2D1 at concentrations as low 
as 0.06 juM (Broly et al., 1989; Bourrie et al., 1996) while debrisoquine is a CYP2D1 
substrate (Halpert et al., 1994). Chlorzoxazone (Peter et ah, 1990; Carrière et al., 
1993) and diethyldithiocarbamate, the metabolite of disulfiram (Guengerich et al. 
1991; Brady et al. 1991) were selected as CYP2E1 substrate/inhibitors. Finally, 
ketoconazole and erythromycin were selected as CYP3A1 substrate/inhibitors 
(Baldwin et al., 1995; Murray and Zaluzny, 1988).
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Table 3.2 Cytochrome P450 substrate/inhibitors employed
Inhibitor/Substrates Selectivity Concentration
(pM)
Vehicle* Reference
Furafylline 1A2 10, 25,100 DMSO Sesardic et al., 1990
Caffeine 1A2 10, 25,100 Distilled water Roberts et al., 1994
oc-Naphthoflavone 1A2 1,10, 25 DMSO Halpert et al., 1994
Coumarin 2A1 10, 25 ,100 Distilled water Halpert et al., 1994
Orphenadrine 2B1 10, 25,100 Distilled water Murray and Reidy 
1990
Tolbutamide 2C11 10, 25,100 Ethanol Halpert et al., 1994
(S)-(+)Mephenytoin 2C11 100,250,500 DMSO Heyn et al., 1996
Sulphaphenazole 2C11 10, 25,100 Ethanol Baldwin et al., 1995
Quinidine 2D1 10, 25,100 DMSO Broly et al., 1989; 
Bourrie et al., 1996
Debrisoquine 2D1 10, 25 ,100 Distilled water Halpert et al., 1994
Chlorzoxazone 2E1 10,25,100 DMSO Peter et al., 1990; 
Tajjasi et a l ,  1992
Diethyldithiocarbamate
(DDC)
2E1 10,25 ,100 Distilled water Guengerich et al. 
1991
Ketoconazole 3A1 0.1 ,1 ,10 Ethanol Baldwin et a l,  1995
Erythromycin 3A1 10,25,100 Distilled water Murray and Zaluzny, 
1988
* When DMSO or ethanol was used, the final concentration in the incubation never exceeded 2% v/v.
3.3.5 Statistical Analysis
All results are expressed as mean ± SEM. Unpaired Student’s t-test was used to 
compare 6-sulphatoxymelatonin concentrations between two groups (GraphPad Instat 
3). One-way ANOVA (GraphPad Instat 3) was performed to test whether the 
differences between three or more groups were statistically significant, followed by 
Tukey post-hoc test.
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3.4 Results
3.4.1 Optimisation of incubation conditions
To establish that the generation of 6-sulphatoxymelatonin was linear with time, 
melatonin (50 pM) was incubated with the rat liver postmitochondrial preparations for 
different time periods (0 -  30 minutes). As shown in Figure 3.1, the generation of 6- 
sulphatoxymelatonin was linear for at least 30 minutes. A 20-minute incubation time 
was thus chosen for all subsequent studies.
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Figure 3.1 Effect of incubation time on melatonin 6-hydroxylation.
Rat liver postmitochondrial preparations were incubated with melatonin (50 pM) for various time 
periods, and aMT6s was determined. Results are presented as mean ±  SEM of triplicate determinations.
The same procedure was repeated using 6-hydroxymelatonin (50 pM). The 
generation of 6-sulphatoxymelatonin from 6-hydroxymelatonin was faster in 
comparison with melatonin and was linear at least for 20 minutes (Figure 3.2). 
Therefore a 10-minute incubation time was chosen for the studies using 6- 
hydroxymelatonin as substrate.
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Figure 3.2 Effect of incubation time on 6-hydroxymelatonin sulphation.
Rat liver postmitochondrial preparations were incubated with 6-hydroxymelatonin (50gM) for various 
time points, and aMT6s was determined. Results are presented as mean ±  SEM of triplicate 
determinations.
A further study was performed to define the linear range of metabolite formation with 
respect to S9 protein concentration. Melatonin (50 juM) was incubated with a range 
of hepatic postmitochondrial concentrations. As shown in Figure 3.3, the generation 
of 6-sulphatoxymelatonin was linear up to at least 300 gl S9 and the amount of 50 pi 
was chosen for all subsequent studies. The same procedure was repeated using 6- 
hydroxymelatonin and linearity was observed up to at least 200 pi of S9, and the
amount of 50 pi was also chosen for all subsequent studies using 6-hydroxymelatonin 
(Figure 3.4).
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Figure 3.3 Effect of protein concentration on the formation of 6-sulphatoxymelatonin from 
melatonin.
Rat liver postmitochondrial preparations were incubated with melatonin (50 pM) for various protein 
amounts, and aMT6s was determined. Results are presented as mean ±  SEM of triplicate 
determinations.
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Figure 3.4 Effect of protein concentration on the generation of 6-sulphatoxymelatonin from 6- 
hydroxymelatonin.
Rat liver postmitochondrial preparations were incubated with 6-hydroxymelatonin (50 pM) for various 
protein amounts, and aMT6s was determined. Results are presented as mean ±  SEM of triplicate 
determinations.
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3.4.2 Cytochrome P450- mediated melatonin 6-hydroxylation
When oxygen was replaced in the incubation system by bubbling nitrogen (for 10 
minutes) prior to the addition of melatonin into the tubes and throughout the 
incubation, the generation of 6-sulpatoxymelatonin from melatonin was significantly 
decreased as shown in Table 3.3. In addition, previous studies conducted in our 
laboratory have shown that the postmitochondrial metabolism of melatonin was 
supported by NADPH but not by NADH (J. Snelling, personal communication) and is 
localised in microsomes.
Table 3.3 Requirement of O2 for the 6-hydroxylation of melatonin.
Incubation conditions 6-Sulphatoxymelatonin generation
(ng/min/mg protein)
Nitrogen 2.4 ±0.5***
Oxygen 5.6 ±0.4
Melatonin (50 pM) was incubated with bubbling nitrogen to establish anaerobic conditions. Results are 
presented as mean ±  SEM of triplicate determinations. ***p < 0.001 unpaired Student’s t-test 
compared to aerobic conditions.
3.4.3 Effect of cytochrome P450 inducers
Previous findings in our laboratory (J. Snelling, personal communication) 
demonstrated that incubation of melatonin with postmitochondrial preparations from 
rats treated with cytochrome inducers such as p-naphthoflavone (CYP1), 
phenobarbitone (CYP2B/3A), acetone (CYP2E), dexamethasone, (CYP3A), and 
clofibrate (CYP4A) resulted in a significant increase of 6-sulpatoxymelatonin only in 
the P-naphthoflavone-treated animals and a significant decrease in the clofibrate 
treated animals. In these studies, however, no attempt was made to establish whether 
the changes were exclusively due to increased 6-hydroxylation (i.e. 6-
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hydroxymelatonin was not investigated at the same time). In studies employing 
precision-cut liver slices it was also shown that phenobarbitone increased the 
formation of 6-sulphatoxymelatonin from melatonin, but this was without also using 
6-hydroxymelatonin as substrate to ensure that increased 6-sulphatoxymelatonin 
formation is due to elevated 6-hydroxylation. Consequently, to support the above 
findings the effect of |3-naphthoflavone and phenobarbitone treatment was evaluated 
using both melatonin and 6-hydroxymelatonin as substrates to exclude that the 
observed change occurs at the sulphate conjugation pathway.
When melatonin was utilised as substrate, treatment of animals with p- 
naphthoflavone led to a significant increase in the production of 6- 
sulphatoxymelatonin compared with the untreated animals (Figure 3.5). However, 
when 6-hydroxymelatonin was the substrate no significant increase in the generation 
of 6-sulphatoxymelatonin was observed as shown in Figure 3.6.
Ç
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Figure 3.5 Effect of phenobarbitone and P-naphthoflavone on the 6-hydroxylation of melatonin
Results are presented as mean ± SEM for four animals. Each analysis was carried out in triplicate. 
**/7<0.01 compared with the control.
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Figure 3.6 Effect of phenobarbitone and P-naphthoflavone on the sulphate conjugation of 6- 
hydroxymelatonin. Results are presented as mean ± SEM for four animals. Each analysis was carried 
out in triplicate.
Treatment of animals with phenobarbitone had no effect on the generation of 6- 
sulphatoxymelatonin using either melatonin (Figure 3.5) or 6-hydroxymelatonin 
(Figure 3.6) as substrate.
3.4.4 Effect of selective cytochrome P450 inhibitors and substrates
In order to clarify the specific cytochrome P450 enzymes involved in the 6- 
hydroxylation of melatonin, a wide variety of selective inhibitors were subsequently 
employed to evaluate the potential inhibition of melatonin 6-hydroxylase activity in 
rat liver postmitochondrial preparations. To define the role of the individual CYP 
enzymes in the 6-hydroxylation of exogenous melatonin 14 different selective 
inhibitors or substrates were employed (Table 3.2).
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The effect of inhibition of 6-sulphatoxymelatonin production by specific CYP 
inhibitors and expressed as % of control activity is shown in Figure 3.7.
Caffeine, a CYP1A2 substrate, even at the highest concentration (100 pM) failed to 
inhibit melatonin hydroxylation. oc-Naphthoflavone, an inhibitor of CYP1A1/2, 
significantly (p < 0.001) inhibited 6-sulphatoxymelatonin production at all 
concentrations (1, 10, 25 pM). Furafylline, a CYP1A2 selective mechanism-based 
inhibitor, significantly inhibited (p < 0.001) the formation of 6-sulphatoxymelatonin 
from melatonin even at the lowest concentration employed (10 pM). Coumarin, a 
CYP2A1 did not affect the 6-hydroxylation of melatonin. Orphenadrine, a CYP2B1 
inhibitor had no effect on melatonin 6-hydroxylase. Tolbutamide, sulphaphenazole, 
and (S)-(+)mephenytoin CYP2C11 substrates/inhibitors did not impair the 6- 
hydroxylation of melatonin. Debrisoquine and quinidine, CYP2D1 
substrate/inhibitors had no inhibitory effect on melatonin 6-hydroxylase activity. 
Chlorzoxazone inhibited melatonin hydroxylase but only at the highest concentration 
(100 pM). However, diethydithiocarbamate, a CYP2E1 inhibitor, showed no effect 
on the 6-hydroxylation of melatonin. Ketoconazole and erythromycin, CYP3A1 
substrate/inhibitors, also failed to affect the generation of 6-sulphatoxymelatonin from 
melatonin and 6-hydroxymelatonin.
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Figure 3.7 Effect of cytochrome P450 inhibitor/substrates on the 6-hydroxylation of melatonin.
Results are presented as a percentage of the amount of 6-sulphatoxymelatonin produced compared with 
the corresponding vehicle control. Melatonin 6-hydroxylase activity in the control was 10.1 ±  0.6 
(n=15) ng/min/mg protein but decreased to 7.4 ±  0.4 ng/min/mg protein (n=15) and 7.8 ±  0.6 
ng/min/mg protein (n=9) in the presence of 10 pL of DMSO and ethanol, respectively.
*** p  < 0.001 when compared with the appropriate control.
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As illustrated in Figure 3.8, caffeine, furafylline, and chlorzoxazone had no effect on 
the sulphate conjugation since they did not impair the formation of 6- 
sulphatoxymelatonin when 6-hydroxymelatonin was used as substrate. On the other 
hand, oc-naphthoflavone significantly decreased the amount of 6-sulphatoxymelatonin 
produced from 6-hydroxymelatonin at the same concentrations as it impaired the 
conversion of melatonin to 6-sulphatoxymelatonin.
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Figure 3.8 Effect of cytochrome P450 inhibitors on the sulphation of 6-hydroxymelatonin.
Results are presented as percentage of the amount of 6-sulphatoxymelatonin produced compared with 
its vehicle control. The 100% activity was 202 ± 1 3  ng/min/mg protein (n=6) but decreased to 160 ±  28 
ng/min/mg protein (n=9) in the presence of 10 pL o f DMSO.
*** p  < 0.001 when compared to the appropriate control.
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To support the finding that furafylline and a-naphthoflavone strongly inhibit 
melatonin 6-hydroxylation, the same inhibitors were also incubated with 
postmitochondrial preparations from rats pre-treated with (3-naphthoflavone, a CYP1 
inducer. As shown in Figure 3.9 furafylline caused a marked and concentration 
dependent decrease in the generation of 6-sulphatoxymelatonin from melatonin, while 
it had no effect on the sulphate conjugation of 6-hydroxymelatonin.
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Figure 3.9 Effect of furafylline on the generation of 6-sulphatoxymelatonin from melatonin and 
6-hydroxymelatonin. Rats were pretreated with (3-naphthoflavone. Results are presented as a 
percentage of the amount of 6-sulphatoxymelatonin produced from melatonin and 6-hydroxymelatonin 
compared to the appropriate control. The 100% activities, in the presence of DMSO, for the formation 
of 6-sulphatoxymelatonin from melatonin and 6-hydroxymelatonin were 37.7 ±  2.2 ng/min/mg protein 
(n=6) and 210 ± 2 0  ng/min/mg protein (n=6), respectively.
*** p  < 0.01 compared with the control.
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oc-Naphthoflavone, at the concentrations of 10 jiM and 25 \xM, caused a significant 
decrease in the production of 6-sulphatoxymelatonin from melatonin (Figure 3.10). A 
less pronounced decrease was observed when 6-hydroxymelatonin was used as 
substrate (Figure 3.10).
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Figure 3.10 Effect of a-naphthoflavone on 6-sulphatoxymelatonin formation from melatonin and 
6-hydroxymelatonin. Rats were pre-treated with P-naphthoflavone. Results are presented as a 
percentage of the amount of 6-sulphatoxymelatonin produced from melatonin and 6-hydroxymelatonin 
compared to the appropriate control. The 100% activities, in the presence of DMSO, for the formation 
of 6-sulphatoxymelatonin from melatonin and 6-hydroxymelatonin were 37.7 ±  2.2 ng/min/mg protein 
(n=6) and 210 ±  20 ng/min/mg protein (n=6), respectively.
* p <  0.05; **p < 0.01; *** p  < 0.001 compared with the appropriate control.
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3.5 Discussion
The objectives of this study were initially to establish that the cytochrome P450 
system is involved in the hepatic 6-hydroxylation of melatonin at pharmacological 
concentrations, and subsequently to identify the specific CYP enzymes that catalyse 
this reaction. Melatonin is metabolised to 6-hydroxymelatonin, which is further 
converted to the sulphate (70%) or glucuronide (30%) conjugate, in a classic phase 1 
and phase 2 reaction sequence (section 1.1.2). The sulphate conjugate predominates 
in both rodents and humans (Kopin et al, 1961; Kveder and Mclsaac, 1961; Leone et 
al, 1987).
Previous findings in our laboratory (J. Snelling, personal communication) established 
that melatonin 6-hydroxylase was localized in the microsomes and being NADPH 
dependent. In the present studies, the requirement for oxygen was shown 
experimentally. In the presence of NADPH, one of the oxygen atoms is incorporated 
into the target substrate molecule while the other is released as water. Elimination of 
the oxygen supply from the incubation system by bubbling nitrogen resulted in a 
significant decrease of melatonin 6-hydroxylase activity.
It had already been demonstrated using precision-cut liver slices, that p- 
naphthoflavone treatment of animals, a CYP1 family inducer (loannides and Parke, 
1990), stimulates the production of 6-sulphatoxymelatonin from melatonin implying a 
role for the CYP1 family in melatonin 6-hydroxylation. Similarly, treatment with 
phenobarbitone, an inducer of CYP2B and CYP3A families, caused an increase in the 
generation of 6-sulphatoxymelatonin from melatonin, which was, however, much less 
pronounced compared to the induction effect of p-naphthoflavone. In contrast, no
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increase in the levels of this metabolite was observed following treatment of animals 
with isoniazid, a CYP2E1 inducer, dexamethasone, a CYP3A inducer, or clofibrate, a 
CYP4A inducer. Previous studies from our laboratory employing postmitochondrial 
preparations from rats pre-treated with various cytochrome P450 inducers 
demonstrated that p-naphthoflavone treatment significantly increased the generation 
of 6-sulphatoxymelatonin from melatonin, while treatment with acetone, 
phenobarbitone or dexamethasone had no effect. Pre-treatment of rats with clofibrate 
caused a decrease in the amount of 6-sulphatoxymelatonin produced by melatonin 
possibly due to the fact that a rise in CYP4 levels occurs at the expense of other 
cytochrome P450 enzymes that metabolise melatonin (Lewis and Lake, 1996). Since 
both of these earlier studies did not investigate 6-hydroxymelatonin as substrate, to 
exclude the possibility that these changes occurred at the level of sulphate 
conjugation, the present study with the inducers p-naphthoflavone and 
phenobarbitone was undertaken using melatonin as well as 6-hydroxymelatonin as 
substrates. The results from this induction study revealed that melatonin 6- 
hydroxylase activity was increased in postmitochondrial fractions prepared from p- 
naphthoflavone treated animals while no such increase was observed following 
animal treatment with phenobarbitone clearly indicating the involvement of the 
CYP1A subfamily. This finding is in agreement with previous studies that have 
shown that the aromatic hydrocarbon, 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD), a 
potent CYP1A inducer, decreased serum melatonin levels in rats suggesting that 
TCDD increases the levels of the enzyme that 6-hydroxylates melatonin (Pohjanvirta 
et al, 1996). In addition, a subsequent study by Yeleswaram et a l  (1999) suggested 
that the cytochrome P450 enzyme system, and more specifically the CYP1A family, 
is involved in the metabolism of exogenous melatonin. This study measured
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melatonin (50 jiM ) disappearance by specific cytochrome P450 enzymes in P- 
lymphoblastoid cell lines that had been engineered to express cDNAs of specific 
cytochrome P450 enzymes. However, this study measured the disappearance of 
melatonin and not specifically its 6-hydroxylation. A further disadvantage of the 
method used in this study is that it does not take into account the fact that each 
cytochrome P450 enzyme is not equally distributed in the liver (Lindros, 1997; 
Oinonem and Lindros, 1998).
Taking into consideration that the two members of the CYP1A family display a very 
different pattern of tissue distribution, and more specifically that CYP1A1 is mainly 
expressed in extrahepatic tissues such as the lungs (Takano et al., 2002) the blood 
leucocytes (Dey et al., 2001) and the placenta (Whyatt et al., 1995),) and that 
CYP1A2 is almost exclusively expressed in the liver (Landi et al., 1999), and that 
extrahepatic tissues are unlikely to contribute to melatonin metabolism through 6- 
hydroxylation, CYP1A2 is likely to be the enzyme that catalyses this reaction. Indeed, 
in recent studies (C. loannides, personal communication) precision-cut rat lung and 
kidney slices had less than 1% of the liver melatonin 6-hydroxylation activity, 
indicating that the contribution of extrahepatic 6-hydroxylation of melatonin is 
minimal.
To establish that CYP1A2 plays a major role in the 6-hydroxylation of exogenous 
melatonin, and to further evaluate the degree that each cytochrome P450 enzyme may 
contribute a study employing a wide variety of selective chemical cytochrome P450 
inhibitors and substrates was undertaken. The results from this study demonstrated 
that CYP1A2 plays a major role in melatonin 6-hydroxylation, since furafylline, a
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potent CYP1A2 inhibitor (Sesardic et al, 1990) caused a marked and concentration- 
dependent reduction in melatonin 6-hydroxylase activity. Additionally, oc- 
naphthoflavone, which is also a CYP1A1, as well as a CYP1A2 inhibitor (Murray and 
Reidy, 1990), decreased the amount of 6-sulphatoxymelatonin produced from 
melatonin. However, a similar effect was observed using 6-hydroxymelatonin as 
substrate implying that this effect was due to a decrease in the sulphate conjugation 
rather than at the 6-hydroxylation of melatonin. Of all the other inhibitors and 
substrates tested, chlorzoxazone, a CYP2E1 substrate (Jayyosi et a l, 1995), also 
inhibited the 6-hydroxylation of melatonin. However, this occurred only at a very 
high concentration, and chlorzoxazone at high concentrations is also a substrate of 
CYP1A2 (Berthou et al, 1995; Carrière et al, 1993). Surprisingly, caffeine, a well- 
known substrate and probe for CYP1A2 (Ou-Yang et a l, 1998; Carrillo et a l, 2000) 
displayed no effect on the 6-hydroxylation of melatonin. Caffeine is transformed via 
three Af-demethylation reactions (1-, 3-N-demethylation or 7-N-demethylation) 
producing theobromine, paraxanthine or theophylline, which are further metabolised 
via N-demethylation or C-8 oxidation and excreted in the urine (Tang-Liu et ah, 
1983). CYP1A2 catalyses the N-demethylation reactions with high affinity, but 
CYP2E1 catalyses the 1- and 7- N-demethylations with low affinity (Gu et al, 1992; 
Chung and Cha, 1997). Caffeine is also metabolised by xanthine oxidase, an enzyme 
existing in the cytosolic fraction, to a number of uric acid derivatives (Reinke et a l, 
1987; Kalow and Tang 1991). It is therefore conceivable that, since in the incubation 
system postmitochondrial preparations were used that contain both microsomal as 
well as cytosolic fractions, caffeine could be rapidly metabolised by this pathway and, 
so levels would be too low to influence the 6-hydroxylation of melatonin. This 
finding was confirmed by a study (Faciolla et al, 2001) that also demonstrated that
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caffeine had a negligible effect on the 6-hydroxylation of exogenous melatonin by 
human liver microsomes.
Moreover, when postmitochondrial preparations from p-naphthoflavone-treated rats 
were used, causing an increase in CYP1 family levels, furafylline caused a similar 
pronounced inhibition of the 6-hydroxylation of melatonin, confirming that CYP1A2 
is the most important enzyme involved in the reaction. On the other hand, the 
inhibitory effect of a-naphthoflavone appears to be largely due to impairment of the 
sulphate conjugation of 6-hydroxymelatonin. Collectively, all these findings together, 
provide strong evidence that CYP1A2 is the major catalyst of the hepatic 6- 
hydroxylation of exogenous melatonin in rats. Since, it is well established that the 
CYP1A family is the most conserved family within the phylogenetic tree and that the 
human CYP1A2 displays extensive structural similarity, as well as similar specificity 
to the orthologous rodent proteins (Kawajiri and Hayashi, 1996), it is reasonable to 
suggest that the CYP1A2 is a strong candidate for the hydroxylation of exogenous 
melatonin in the human liver. Indeed a subsequent study by Facciola et ah (2001) 
confirmed that exogenous melatonin is almost exclusively metabolised by human 
CYP1A2 to 6-hydroxymelatonin. This study used microsomes from six human livers 
in the incubation system together with nine different selective cytochrome P450 
inhibitors or substrates. It was noted that of all the inhibitors used, furafylline and 
fluvoxamine, both CYP1A2 inhibitors (Sesardic et al, 1990; Prosen et al, 1993), 
strongly inhibited the 6-hydroxylation of melatonin. The same authors showed that 
when melatonin was incubated with yeast-expressed CYP1A2, CYP2C9 and 
CYP2C19, that CYP1A2 and CYP2C19 were the main enzymes involved in the 6- 
hydroxylation and O-demethylation of melatonin, respectively (Facciola et ah 2001).
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The report concluded that 6-hydroxylation is the principal metabolic pathway of 
melatonin, and is mainly mediated by CYP1A2 in the human liver.
hi concordance with our findings, fluvoxamine, a selective serotonin reuptake 
inhibitor and a CYP1A2 inhibitor (Brosen et al, 1993; Rasmussen et al., 1995) 
inhibited the 6-hydroxylation of exogenous melatonin in vitro by human liver 
microsomes (Facciola et al, 2001). Interestingly, fluvoxamine administered without 
concomitant administration of melatonin, increased the endogenous nocturnal plasma 
melatonin concentrations (Skene et al, 1994). This increase in melatonin was 
extended into the morning hours, affecting the amplitude of the melatonin rhythm, 
implying that fluvoxamine also inhibits endogenous melatonin 6-hydroxylation. 
Similarly, in a subsequent study (von Bahr et al, 2000), fluvoxamine was shown to 
increase the endogenous levels of serum melatonin. Taken together the results from 
these two studies give an indication that CYP1A2 may also hydroxylate endogenous 
melatonin at physiological concentrations, which are far lower than pharmacological 
concentrations. The maximum endogenous melatonin plasma levels in normal adults 
range between 50 to 150 pg/ml during the night, between 02:00 and 04:00 h with 
minimum levels (below 10 pg/ml) during the day (Arendt, 1995). As far as 
exogenous plasma concentrations in healthy adults are concerned, the intake of 
melatonin at doses of 0.05 mg, 0.5 mg and 5 mg, achieved plasma melatonin 
concentrations ranging between 13 to 274 pg/ml, 454 to 3700 pg/ml and 7830 to 
31,450 pg/ml, respectively (Deacon and Arendt, 1995), which are orders of magnitude 
higher than physiological levels.
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The finding that CYP1A2 is the predominant cytochrome P450 enzyme catalysing the 
metabolism of melatonin at pharmacological concentrations may have implications 
from a drug interaction point of view. A number of drugs are metabolised by 
CYP1A2, such as methylxanthines, paracetamol (acetaminophen), theophylline, 
imipramine and propranolol (Guengerich and Shimada, 1991), so that concomitant 
intake of melatonin may influence their pharmacological effect. However, such 
interactions will depend on the tissue concentration of the two compounds.
Intake of cruciferous vegetables, presumably as a result of their indole content, as 
well as numerous other dietary anutrients, including compounds formed by the 
cooking process, such as polycyclic aromatic hydrocarbons and heterocyclic amines, 
have been shown to upregulate CYP1A2 activity in the liver (loannides, 1999). It is 
well established that cigarette smoke exposure induces hepatic CYP enzymes, 
especially CYP1A2 in rat (Nishikawa et al, 2004). In this case it would be expected 
that these individuals would hydroxylate exogenous melatonin more rapidly so that 
the desired plasma levels are not achieved and the pharmacological effect is not 
manifested. Certainly an inter-individual variation in the response to melatonin has 
been reported (Zhdanova and Wurtman, 1997), as well as a large inter-individual 
difference in melatonin pharmacokinetics (Grof et al, 1985). These variations may 
reflect inter-individual differences in CYP1A2 activity. However, since the half-life 
of melatonin in humans is already short, less than an hour (Waldhauser et al, 1984), it 
is unlikely that an increase in CYP1A2 activity will have a major impact on melatonin 
metabolism. After a single 5 mg dose of melatonin, the increase of melatonin in the 
plasma is above endogenous levels and can last up to 16 hours, while by giving daily
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5 mg melatonin, melatonin levels in the body never decline to non-pharmacological 
so maybe CYP1A2 activity does matter.
The present findings were supported by computer modelling studies (DFV Lewis, 
personal communication) of melatonin structure build using the Sybyl fragment 
library, and modelled on the basis of the indole fragment. Like other CYP1A2 
substrates (Lewis et al, 1987), melatonin is characterised by a large area/depth2 ratio. 
The molecular dimensions of melatonin were calculated using the Sybyl molecular 
modelling software (Tripos Associates, St Louis, MO, USA) and found to be: length 
12.8074 Â, width 10,20052 Â and depth 5.73678 Â, giving an area/depth2 ratio of 
3.97. According to this 3.97 area/depth2 ratio melatonin was readily accommodated 
within the human CYP1A2 substrate-binding site in a position favouring 6- 
hydroxylation, the 6-position of melatonin being nearest to the haem. Thus, it would 
also be anticipated that human CYP1A2 will also catalyse the 6-hydroxylation of 
exogenous melatonin.
In conclusion, this study has demonstrated that in the rat liver CYP1A2 is the major 
catalyst of the 6-hydroxylation of melatonin, at pharmacological concentrations.
CHAPTER FOUR
INHIBITION OF MELATONIN 6-HYDROXYLASE
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4.1 Introduction
Melatonin is being prescribed or self administered by a large number of people in the 
USA and Europe. It is thus of importance to know how concomitant administration of 
other drugs may influence the 6-hydroxylation of exogenous melatonin. The 
cytochrome P450 enzyme that primarily catalyses the 6-hydroxylation of exogenous 
melatonin, both in rats (see Chapter 3) and humans (Facciola et al, 2001) was found 
to be CYP1A2. Information on potential drug interactions with concomitant use of 
melatonin, and involving the cytochrome P450 enzyme system, still remains scarce. 
Consequently, the possibility of drugs co-administered with melatonin, to modulate its 
hepatic 6-hydroxylation and alter plasma concentrations needs to be further 
investigated.
4.1.1 Rationale for the selection of drugs
The selection of drugs to be studied that could potentially interact with melatonin was 
based on the knowledge that the 6-hydroxylation of exogenous melatonin is mainly 
mediated by CYP1A2 as previously observed in our studies (see Chapter 3), but also 
on the likelihood of this drug to be co-administrated with melatonin. Thus, 
fluvoxamine, 5-methoxypsoralen, diazepam, tamoxifen, acetaminophen 
(paracetamol), and 17cc-ethinyloestradiol were selected to be tested for their effect on 
melatonin 6-hydroxylase activity.
Fluvoxamine is a well-known potent inhibitor of CYP1A2 (Brosen et al, 1993), the 
enzyme that is responsible for melatonin 6-hydroxylation (Chapter 3). Early work 
showed that a single dose of fluvoxamine increased the nocturnal production of 
endogenous melatonin suggesting for the first time that fluvoxamine and melatonin
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may interact (Skene et al, 1994). Moreover, there is experimental evidence that its 
co-administration with melatonin increases plasma melatonin levels, possibly due to 
inhibition of its metabolism (Hartter et ah, 2000). Based on these studies 
fluvoxamine was selected to assess its effect on the 6-hydroxylation of melatonin.
Figure 4.1 Chemical structure of fluvoxamine.
5-Methoxypsoralen, a drug used in the treatment of psoriasis (Parrish et al, 1974; 
Honigsmann et al, 1979), inhibits caffeine metabolism (Bendriss et al, 1996), which 
is mainly catalysed by CYP1A2 (Gu et ah, 1992). It has been reported that it inhibits 
the hepatic metabolism of exogenous melatonin in the rats (Mauviard et al., 1995) and 
the humans (Souetre et al, 1987).
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Figure 4.2 Chemical structure of 5-methoxypsoralen.
The benzodiazepine diazepam is widely used as a muscle relaxant, anxiolytic, and 
sedative. Diazepam is metabolised in the liver by P450-mediated reactions (Figure
4.3). About 60% of a diazepam is A-demethylated mainly by human CYP3A4 to
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yield nordiazepam (Ono et al, 1996), the major metabolite found in plasma (Jack and 
Colburn, 1983); it is also Cg-hydroxylated to yield temazepam. Both metabolites can 
be further converted to oxazepam. Diazepam was selected because of the likelihood 
of it being taken together with melatonin by individuals suffering with sleep 
problems, for example, the elderly.
ci
Figure 4.3 Chemical structure of diazepam. From Jung et al  (1997).
The nonsteroidal antioestrogen tamoxifen is currently the most widely used 
chemotherapeutic agent in the treatment of breast cancer. It has been shown to halve 
the risk of breast cancer in women with high susceptibility to the disease (Fisher et al., 
1998). Tamoxifen is hydroxylated to its active metabolite, frarcs-4-hydroxytamoxifen 
primarily by CYP2D6 and CYP2B6 with contributions from CYP2C9 and CY3A4 
(Crewe et al., 1997). Af-demethylation of tamoxifen is mainly catalysed by CYP3A4 
(Jacolot et ah, 1991; Crewe et a l, 1997), CYP2D6, with contributions by CYP1A2 
(Simon et al, 1993), CYP2C9, CYP2C19, and CYP3A5 (Crewe et a l, 2002) (Figure
4.4). Tamoxifen has been used in combination with melatonin to increases the
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effectiveness of the former (Lissoni et al., 1996; Kothari et ah, 1997; Garcia et al., 
1998).
Figure 4.4 Metabolic pathways of tamoxifen examined. TMX: Tamoxifen. From Crewe et al (2002).
Acetaminophen (paracetamol) is one of the most widely used analgesic and 
antipyretic agents in the world. It is well established that cytochrome P450 is 
responsible for the bioactivation of acetaminophen in the liver (Mitchell et al., 1973; 
Potter et al., 1973) where it oxidises acetaminophen by two pathways (Figure 4.5) to 
form N-acetyl-p-benzoquinone imine (NAPQI) (Dahlin et al., 1984) and 3-hydroxy- 
acetaminophen (3-OH-APAP) (Harvison et a l, 1988). It is generally accepted that 
NAPQI is the toxic reactive intermediate that causes severe hepatocellular damage 
(Nelson, 1995; Cohen and Khairallah, 1997). CYP2E1 has been considered to be a 
major isoform responsible for the bioactivation of acetaminophen in humans (Raucy 
et al., 1989; Patten et al, 1993). Human CYP1A2 (Raucy et al., 1989), CYP2A6
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(Chen et al., 1998), and CYP3A4 (Thummel et a l, 1993) have also been shown to 
catalyse the oxidation of acetaminophen to NAPQI.
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Figure 4.5 Acetaminophen oxidation pathways. APAP: Acetaminophen; NAPQI: A-acetyl-/?- 
benzoquinone imine. From Dong et al (2000).
Finally, 17oc-ethinyloestradiol, a steroid present in the oral contraceptive pill, is 
extensively sulphated and the sulphate is primarily a storage form of this oestrogen. 
2-Hydroxylation is clearly the major oxidative reaction, and the 2-hydroxy derivative 
is further transformed by méthylation and glucuronidation prior to urinary and faecal 
excretion. The major human catalyst of the 2-hydroxylation reaction in the liver is 
CYP3A4 (Guengerich, 1990), CYP2C9 (Wang et a l, 2004), and CYP2E1 (Ball et al, 
1990). It appears that use of oral contraceptive increases endogenous plasma 
melatonin concentrations (Thapan and Skene, unpublished results), which raises the 
question whether this is due to inhibition of the 6-hydroxylation of melatonin. 17a- 
Ethinyloestradiol was selected to evaluate whether it interferes with the metabolism of 
melatonin.
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Figure 4.6 Chemical structure of 17a-ethinyloestradiol.
4.2 Objectives
The objective of this study is to assess whether, and to what extent, the selected drugs 
(fluvoxamine, 5-methoxypsoralen, diazepam, tamoxifen, acetaminophen and 17a- 
ethinyloestradiol) at pharmacological concentration inhibit the 6-hydroxylation of 
melatonin in vitro in human liver. Because of the scarcity of human liver tissue, 
studies were initially conducted using rat liver preparations before human studies 
were undertaken. The use of rat liver was considered appropriate as CYP1A2 is one 
of the most conserved cytochrome P450 proteins (Kawajiri and Hayashi, 1996) and 
humans and rats display similar substrate specificity (Kawajiri and Hayashi, 1996).
4.3 Materials and Methods
4.3.1 Liver samples
4.3.1.1 Rat liver
Livers from three male Wistar albino rats (200-250 g) synchronised to a 12:12 hr 
lightrdark cycle (LD; lights on at 06.00 h) were used in this study. Animals were 
killed by cervical dislocation, livers were removed and postmitochondrial supernatant 
(S9) was prepared as previously described {section 2.2.2), and stored in 1 ml aliquots
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at -20°C until use. The protein concentration was determined by the method of 
Lowry ef al. (1951).
4.3.L2 Human liver
Human liver (31g) was obtained from Peterborough Hospital Human Research Tissue 
Bank, and information about the donor is outlined in Table 4.1. A Tissue Transfer 
Agreement was completed that included details of the proposed study (Appendix I). 
This Tissue Transfer Agreement received approval from the University of Surrey 
Ethics Committee (ACE/2001/09/SBLS). The tissue arrived at the University snap- 
frozen in ice, and was stored at -80°C. Postmitochondrial supernatant (S9) was 
prepared as described previously {section 2.2.2) and stored at -80°C until use. The 
protein concentration was determined using the method of Lowry et al. (1951).
Table 4.1 Information about the donor of the liver tissue
Age 47 years
Sex Male
Race Caucasian
Medical History Smoker / Drank Alcohol
Date / Time of death 07/03/01 / 21:34
Cause of death__________________  Sub Arachnoid Haemorrhage
4.3.2 Experimental procedure
Two incubation systems were set up; the first containing postmitochondrial fractions 
from rat liver and the second from human liver. Each drug was incubated with either 
melatonin or 6-hydroxymelatonin and the generation of 6-sulphatoxymelatonin was 
determined. The drug concentrations ranged from 1 pM to 1000 pM using rat liver, 
and 1 pM to 500 pM using human liver. A preliminary study was performed to 
examine the effect of the drug solvents on the generation of 6-sulphatoxymelatonin
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from melatonin and 6-hydroxymelatonin, to ensure that the solvents did not interfere 
with the assay, at the concentrations used.
4.3.2.1 Optimisation o f the incubation systems
The incubation system utilising rat postmitochondrial fractions had already been 
optimised {section 3.3.1.1). The incubation system utilising human postmitochondrial 
fractions was optimised with respect to time and protein concentration.
4.3.2.2 6-Sulphatoxymelatonin radioimmunoassay (RIA)
Generation of 6-sulphatoxymelatonin was determined in the supernatant by RIA 
{section 2.2.5). The inter-assay coefficients of variation (CVs) for the study using rat 
hepatic postmitochondrial fractions were 37.5%, 22.6% and 38.2% at 1.6 ng/ml 
(n=24), 13.3 ng/ml (n=24) and 25.9 ng/ml (n=24), respectively. The inter-assay 
coefficients of variation (CVs) for the study using human hepatic post-mitochondrial 
fractions were 18.5%, 19.1% and 13.4% at 1.9 ng/ml (n=14), 10.8 ng/ml (n=14) and 
22.4 ng/ml (n=14), respectively.
4.3.3 Statistical analysis
Results are expressed as mean ± SEM. Values presenting the percent of 6- 
sulphatoxymelatonin produced are expressed as mean ± SD. One-way ANOVA 
(SPSS, version 10) was performed to test whether there were any statistically 
significant differences between the groups, followed by Tukey post-hoc when it was 
found to be significant.
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4.4 Results
4,4.1 Optimisation of human liver incubation
To establish that the generation of 6-sulphatoxymelatonin was linear with time, 
melatonin (50 pM) was incubated with human liver postmitochondrial (S9) for 
different time periods (0 -  60 minutes). As shown in Figure 4.7, the generation of 6- 
sulphatoxymelatonin was linear for at least 60 minutes. A 40-minute incubation time 
was chosen for all subsequent studies.
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Figure 4.7 Effect of incubation time on the generation of 6-sulpahtoxymeIatonin from melatonin 
by human liver S9. Melatonin [50pM] was incubated for different time points with 50pl of S9. 
Results are presented as mean ± SEM for triplicates.
The same procedure was repeated using 6-hydroxymelatonin (50 pM) as substrate. 
The generation of 6-sulphatoxymelatonin from 6-hydroxymelatonin was linear for at 
least for 40 minutes, and a 10-minute incubation time was chosen for all the 
subsequent studies using 6-hydroxymelatonin as substrate (Figure 4.8).
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Figure 4.8 Effect o f time on 6-sulphatoxymelatonin production from 6-hydroxymelatonin by 
human liver S9. 6-Hydroxymelatonin (50jiM) was incubated for different time points with 50pl of 
S9. Results are presented as mean ± SEM for triplicates.
A further study was performed to define the linear range of 6-sulphatoxymelatonin 
with respect to S9 protein concentration. Melatonin (50 juM) was incubated with a 
range of protein concentrations. As shown in Figure 4.9, the generation of 6- 
sulphatoxymelatonin was linear up to at least 200 jil S9, and 50 pi was the chosen 
concentration for use in all subsequent studies. The same procedure was repeated 
using 6-hydroxymelatonin as substrate and it was observed that it was linear up to at 
least 150 pi S9 (Figure 4.10), 50 pi of S9 was used in all subsequent studies.
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Figure 4.9 Effect o f protein concentration on 6-sulphatoxymelatonin production from melatonin 
by human liver 89. Melatonin [50pM] was incubated with different concentrations of S9 for 40 
minutes. Results are presented as mean ± SEM for triplicates.
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Figure 4.10 Effect of protein concentration on 6-sulphatoxymelatonin production from 6- 
hydroxymelatonin by human liver 89. 6-Hydroxymelatonin [50pM] was incubated with different 
concentrations of 89 for 10 minutes. Results are presented as mean ± SEM for triplicates.
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4,4,2 Effect of solvents on the 6-hydroxylation of melatonin
When ethanol or dimethylsulphoxide (2% v/v final volume) was added to the liver 
incubation, a decrease in the production of 6-sulphatoxymelatonin from melatonin 
was observed (Figure 4.11). The same solvents (2% v/v final volume) did not impair 
the 6-sulphatoxymelatonin from 6-hydroxymelatonin (Figure 4.12). Although the 
decrease was not statistically significant, a lower concentration (1% v/v) was chosen 
because it had a less of an effect on the generation of 6-sulphatoxymelatonin from 
melatonin (Figure 4.11).
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Figure 4.11 Effect of solvents on 6-sulphatoxymelatonin production from melatonin by human 
liver S9. Melatonin [50pM] was incubated with different amounts of ethanol or dimethylsulphoxide 
(DMSO). Results are presented as mean ± SEM for triplicates.
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Figure 4.12 Effect of solvents on 6-sulphatoxymelatonin production from 6-hydroxymelatonin by 
human liver S9. 6-Hydroxymelatonin [50pM] was incubated with ethanol or dimethylsulphoxide 
(DMSO). Results are presented as mean ± SEM for triplicates.
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4,4,3 Effect of drugs on the 6-hydroxylation of melatonin
4.4,3,1 Effect o f fluvoxamine
As shown in Figure 4.13, fluvoxamine at concentrations of 50 pM and higher 
significantly inhibited the generation of 6-sulphatoxymelatonin in rat liver S9 when 
melatonin was utilised as substrate. In contrast when 6-hydroxymelatonin was used 
as substrate, fluvoxamine did not impair the conversion to 6-sulphatoxymelatonin 
(Figure 4.14). It thus appears that fluvoxamine is a potent inhibitor of 6- 
hydroxylation of melatonin in rat liver.
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Figure 4.13 Effect o f fluvoxamine on the generation of 6-sulphatoxymelatonin from melatonin by 
rat liver postmitochondrial supernatant. Results are presented as mean ± SEM for triplicate 
determinations. *** p  < 0.001 compared with vehicle control.
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Figure 4.14 Effect of fluvoxamine on the generation of 6- sulphatoxymelatonin from 6- 
hydroxymelatonin by rat liver postmitochondrial supernatant. Results are presented as mean ±  
SEM for triplicate determinations.
4.4.3.2 Effect o f 5-methoxypsoralen
5-Methoxypsoralen at a concentration as low as 5 pM, significantly suppressed the 
conversion of melatonin to 6-sulphatoxymelatonin (Figure 4.15). At the highest 
concentrations (> 500 pM), 5-methoxypsoralen also caused a significant inhibition in 
the generation of 6-sulphatoxymelatonin from 6-hydroxymelatonin (Figure 4.16). 
Clearly, 5-methoxypsoralen can impair the oxidation of melatonin at the 6-position in 
the rat.
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Figure 4.15 Effect of 5-methoxypsoralen on the generation of 6-sulphatoxymelatonin from  
melatonin by rat liver postmitochondrial supernatant. Results are presented as mean ± SEM for 
triplicate determinations. ** P  <0.01; *** p<  0.001 compared with vehicle control
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Figure 4.16 Effect of 5-methoxypsoralen on the generation of 6-sulphatoxymelatonin from 6- 
hydroxymelatonin by rat liver postmitochondrial supernatant. Results are presented as mean ± 
SEM for triplicate determinations. ** p  <0.01 ; *** p<  0.001 compared with vehicle control
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When human liver postmitochondrial fractions were used, 5-methoxypsoralen at the 
lowest concentration tested (1 pM), completely impaired the production of 6- 
sulphatoxymelatonin from melatonin (Figure 4.17). Subsequently, a further study 
was performed using a lower range of concentrations of concentrations (0.01 -  0.5 
pM). It was observed that 5-methoxypsoralen, at concentrations as low as 0.01 pM, 
decreased significantly the production of 6-sulphatoxymelatonin from melatonin 
(Figure 4.18). On the other hand, the inhibitory effect on the formation of 6- 
sulphatoxymelatonin from 6-hydroxymelatonin was evident only at 50 pM 
concentration, it was relatively modest (Figure 4.19). Clearly, in the human liver, 5- 
methoxypsoralen was a more potent inhibitor of melatonin 6-hydroxylase compared 
with the rat liver.
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Figure 4.17 Effect of 5-methoxypsoralen on the generation of 6-sulphatoxymelatonin from
melatonin by human liver postmitochondrial supernatant. Results are presented as mean ± SEM
for triplicate determinations. ***/?< 0.001 compared with vehicle control.
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Figure 4.18 Effect of 5-methoxypsoralen on the generation of 6-sulphatoxymelatonin from 
melatonin by human liver postmitochondrial supernatant. Results are presented as mean ± SEM 
for triplicate determinations. ** p <  0.01; ***p<0.001 compared with vehicle control.
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Figure 4.19 Effect of 5-methoxypsoralen on the generation of 6-sulphatoxymelatonin from 6-
hydroxymelatonin by human liver postmitochondrial supernatant. Results are presented as mean
± SEM for triplicate determinations. * p <  0.05 compared with vehicle control.
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4.43.3 Effect o f diazepam
Diazepam at concentrations of 50 pM and higher caused a significant dose-dependent 
inhibition of the production of 6-sulphatoxymelatonin from melatonin in rat liver 
postmitochondrial fractions (Figure 4.20). In contrast, when 6-hydroxymelatonin was 
used as substrate, diazepam only inhibited the generation of 6-sulphatoxymelatonin at 
the 500 pM concentration (Figure 4.21). These observations thus show that 
diazepam impairs melatonin oxidation in the rat.
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Figure 4.20 Effect of diazepam on the generation of 6-sulphatoxymelatonin from melatonin by 
rat liver postmitochondrial supernatant. Results are presented as mean ± SEM for triplicate 
determinations. ***p < 0.001 compared with vehicle control.
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Figure 4.21 Effect of diazepam on the generation of 6-sulphatoxymelatonin from 6- 
hydroxymelatonin by rat liver postmitochondrial supernatant. Results are presented as mean ± 
SEM for triplicate determinations. < 0.05 compared with vehicle control.
When human liver postmitochondrial fractions replaced the rat fractions, diazepam at 
the lowest concentrations used, namely 100 pM and 500 pM, inhibited the formation 
of 6-sulphatoxymelatonin from melatonin (Figure 4.22). Similarly, when 6- 
hydroxymelatonin was used as substrate in the incubation, the production of 6- 
sulphatoxymelatonin was also significantly decreased, but only at the highest 
concentration (500pM) of diazepam used (Figure 4.23), but the effect appeared less 
pronounced than when melatonin was used as substrate. From these findings it may 
be cautiously inferred that high concentrations of diazepam decrease the 6- 
hydroxylation of melatonin.
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Figure 4.22 Effect of diazepam on the generation of 6-sulphatoxymelatonin from melatonin by 
human liver postmitochondrial supernatant Results are presented as mean ± SEM for triplicate 
determinations. * p < 0.05; *** p  < 0.001 compared with vehicle control.
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Figure 4.23 Effect of diazepam on the generation o f 6-sulphatoxymelatonin from 6- 
hydroxymelatonin by human liver postmitochondrial supernatant. Results are presented as mean 
± SEM for triplicate determinations. *** p  < 0.001 compared with vehicle control.
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4.4.3.4 Effect o f tamoxifen
Tamoxifen at the two highest concentrations tested (500 jiM and 1000 pM) 
significantly suppressed the generation of 6-sulpatoxymelatonin from melatonin when 
rat postmitochondrial fractions were utilised (Figure 4.24). In contrast when 6- 
hydroxymelatonin was used as substrate tamoxifen did not impair the sulphation of 6- 
hydroxymelatonin (Figure 4.25). These observations demonstrate that tamoxifen 
does not impair the metabolism of melatonin in the rat, but only at the very high 
concentrations.
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Figure 4.24 Effect o f tamoxifen on the generation of 6-suIphatoxymelatonin from melatonin by 
rat liver postmitochondrial supernatant. Results are presented as mean ± SEM for triplicate 
determinations. < 0.05 compared with vehicle control.
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Figure 4.25 Effect o f tamoxifen on the generation o f 6-sulphatoxymelatonin from 6- 
hydroxymelatonin by rat liver postmitochondrial supernatant. Results are presented as mean ± 
SEM for triplicate determinations.
Following incubation with human hepatic postmitochondrial preparations, tamoxifen 
had no effect on the amount of 6-sulphatoxymelatonin produced from melatonin 
(Figure 4.26) or 6-hydroxymelatonin (Figure 4.27). These results show that in human 
liver tamoxifen does not appear to interact with the oxidation and sulphation of 
melatonin.
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Figure 4.26 Effect of tamoxifen on the generation of 6-sulphatoxymelatonin from melatonin by 
human liver postmitochondrial supernatant. Results are presented as mean ± SEM for triplicate 
determinations.
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Figure 4.27 Effect of tamoxifen on the generation of 6-sulphatoxymelatonin from 6- 
hydroxymelatonin by human liver postmitochondrial supernatant. Results are presented as mean 
± SEM for triplicate determinations.
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4.4.3.S Effect o f acetaminophen
Acetaminophen, at high concentrations (500 juM), decreased the amount of 6- 
sulphatoxymelatonin generated from melatonin in rat liver (Figure 4.28). Similarly, at 
the same concentrations acetaminophen inhibited the conversion of 6- 
hydroxymelatonin to 6-sulpatoxymetonin in the rat (Figure 4.29).
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Figure 4.28 Effect of acetaminophen on the generation of 6-sulphatoxymelatonin from melatonin 
by rat liver postmitochondrial supernatant. Results are presented as mean ± SEM for triplicate 
determinations. * p  < 0.05; ** p  < 0.01; ***/? < 0.001 compared with vehicle control.
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Figure 4.29 Effect of acetaminophen on the generation of 6-sulphatoxymelatonin from 6-
hydroxymelatonin by rat liver postmitochondrial supernatant. Results are presented as mean ±
SEM for triplicate determinations. * p <  0.05; * * * p <  0.001 compared with vehicle control.
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In contrast, in human liver acetaminophen failed to show any significant inhibitory 
effect on the generation of 6-sulphatoxymelatonin from either melatonin or 6- 
hydroxymelatonin (Figures 4.30 and 4.31, respectively).
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Figure 4.30 Effect o f acetaminophen on the generation of 6-sulphatoxymelatonin from melatonin 
by human liver postmitochondrial supernatant Results are presented as mean ± SEM for triplicate 
determinations.
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Figure 4.31 Effect of acetaminophen on the generation of 6-sulphatoxymelatonin from 6-
hydroxymelatonin by human liver postmitochondrial supernatant. Results are presented as mean
± SEM for triplicate determinations.
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4.4.3.6 Effect o f 17a-ethinyloestradiol
17a-Ethinyloestradiol was a very potent inhibitor of the metabolism of melatonin to
6-sulphatoxymelatonin, significant inhibition being evident at concentrations as low 
as 1 pM (Figure 4.32). The effect of 17oc-ethinyloestradiol was concentration 
dependent. In contrast, no inhibitory effect was observed when 6-hydroxymelatonin 
was used as substrate (Figure 4.33). It may be concluded from these results that this 
steroid is a potent inhibitor of melatonin 6-hydroxylase in the rat.
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Figure 4.32 Effect of 17a-ethinyIoestradiol on the generation of 6-sulphatoxymelatonin from  
melatonin by rat liver postmitochondrial supernatant. Results are presented as mean ± SEM for 
triplicate determinations. ** p  < 0.01; ***/>< 0.001 compared with vehicle control.
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Figure 4.33 Effect of 17a-ethinyloestradiol on the generation of 6-sulphatoxymelatonin from 6-
hydroxymelatonin by rat liver postmitochondrial supernatant. Results are presented as mean ±
SEM for triplicate determinations.
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In human liver, 17oc-ethinyloestradiol at concentrations of 50 pM and higher gave rise 
to a marked and dose-dependent inhibition of the generation of 6- 
sulphatoxymelatonin from melatonin (Figure 4.34). In contrast to the rat, 17a- 
ethinyloestradiol also impaired the sulphation of 6-hydroxymelatonin (Figure 4.35).
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Figure 4.34 Effect of 17(X-ethinyloestradioI on the generation of 6-sulphatoxymelatonin from 
melatonin by human liver postmitochondrial supernatant. Results are presented as mean ± SEM 
for triplicate determinations. ***/> < 0.001 compared with vehicle control.
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Figure 4.35 Effect of 17a-ethinyloestradiol on the generation of 6-sulphatoxymelatonin from 6- 
hydroxymelatonin by human liver postmitochondrial supernatant. Results are presented as mean 
± SEM for triplicate determinations. * p  < 0.05; ** p  < 0.01; *** p  < 0.001 compared with vehicle 
control.
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4,4.4 Drug interactions with melatonin: A comparison between rat and 
human liver.
With the exception of fluvoxamine all the other drugs studied were incubated using 
both rat and human liver postmitochondrial fractions. Some rat-human differences 
with respect to the amount of 6-sulphatoxymelatonin produced were noted.
5-Methoxypsoralen was a far more potent inhibitor of the metabolism of melatonin to
6-sulphatoxymelatonin in the human liver compared to the rat, but no such difference 
was noted when 6-sulphatoxymelatonin was the substrate (Figure 4.36).
In the case of diazepam, however, the degree of inhibition, for both substrates, was 
the same whether rat or human liver was used (Figure 4.37).
Tamoxifen reduced the production of 6-sulphatoxymelatonin from melatonin in the 
rat liver, but no such effect was evident in human liver. When 6-hydroxymelatonin 
was used as substrate, the formation of 6-sulphatoxymelatonin was not altered by 
tamoxifen in both the rat and human liver (Figure 4.38).
A difference between human and rat liver in the generation of 6-sulphatoxymelatonin 
from melatonin in the presence of acetaminophen was observed; this pathway was 
inhibited in rat liver, at concentrations > 50 jliM, but no effect was seen in human 
liver. Similarly, when 6-sulphatoxymelatonin was utilised as the substrate, sulphation 
was impaired in the rat, but not human liver (Figure 4.39).
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The inhibitory effect of 17oc-ethinyloestradiol on the production of 6- 
sulphatoxymelatonin from melatonin was similar in the rat and human liver. 
However, 6-sulphatoxymelatonin generation from 6-hydroxymelatonin was 
suppressed by 17oc-ethinyloestradiol more effectively in human (Figure 4.40).
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Figure 4.36 Effect of 5-methoxypsoralen on the rate of melatonin metabolism using as substrate 
(a) melatonin and (b) 6-hydroxymelatonin by rat and human liver. Values are expressed as mean 
± SEM. The 100% activities, in the presence of DMSO, for the formation of 6-sulphatoxymelatonin 
from melatonin and 6-hydroxymelatonin by rat were (mean ±  SEM) 3.5 ±  0.4 (n=3) and 52.8 ± 1 . 3  
(n=3), respectively and by human were (mean ±  SEM) 2.0 ±  0.3 (n=3) and 22.8 ±  2.5 (n=3).
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Figure 4.37 Effect of diazepam on the rate of melatonin metabolism using as substrate (a) 
melatonin and (b) 6-hydroxymelatonin by rat and human liver. Values are expressed as mean ±  
SEM. The 100% activities, in the presence of DMSO, for the formation of 6-sulphatoxymelatonin from 
melatonin and 6-hydroxymelatonin by rat were (mean ±  SEM) 3.5 ±  0.3 (n=3) and 45.53.8 ±  (n=3), 
respectively and by human were (mean ±  SEM) 2.1 ±0 .1 (n=3) and 24.7 ±  0.5 (n=3).
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Figure 4.38 Effect of tamoxifen on the rate of melatonin metabolism using as substrate (a) 
melatonin and (b) 6-hydroxymelatonin by rat and human liver. Values are expressed as mean ±  
SEM. The 100% activities, in the presence of DMSO, for the formation of 6-sulphatoxymelatonin from 
melatonin and 6-hydroxymelatonin by rat were (mean ±  SEM) 2.5 ±  0.3 (n=3) and 29.0 ±  4.6 (n=3), 
respectively and by human were (mean ±  SEM) 2.0 ±  0.02 (n=3) and 26.4 ±1 .5 (n=3).
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Figure 4.39 Effect of acetaminophen on the rate of melatonin metabolism using as substrate (a) 
melatonin and (b) 6-hydroxymelatonin by rat and human liver. Values are expressed as mean ±  
SEM. The 100% activities, in the presence of DMSO, for the formation of 6-sulphatoxymelatonin from 
melatonin and 6-hydroxymelatonin by rat were (mean ±  SEM) 2.6 ±  0.3 (n=3) and 82.1 ±  7.4 (n=3), 
respectively and by human were (mean ±  SEM) 2.4 ±  0.05 (n=3) and 22.3 ±1 .8  (n=3).
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Figure 4.40 Effect of 17a-ethinyloestradiol on the rate of melatonin metabolism using as 
substrate (a) melatonin and (b) 6-hydroxymelatonin by rat and human liver. Values are expressed 
as mean ±  SEM. The 100% activities, in the presence of DMSO, for the formation of 6- 
sulphatoxymelatonin from melatonin and 6-hydroxymelatonin by rat were (mean ±  SEM) 7.2 ±  0.5 
(n=3) and 61.4 ±  2.3 (n=3), respectively and by human were (mean ±  SEM) 2.6 ±  0.2 (n=3) and 60.2 ±  
12.0 (n=3).
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4.5 Discussion
Data acquired in the current study may be used to predict whether the tested drugs are 
likely to inhibit melatonin 6-hydroxylation, under clinically relevant dosing 
conditions in humans. Hence, plasma concentrations of each drug and melatonin 
under clinically relevant conditions must be taken into account.
The present findings demonstrate that fluvoxamine strongly inhibits rat liver 
melatonin 6-hydroxylase activity. This is not surprising bearing in mind that 
fluvoxamine is a potent CYP1A2 inhibitor (Brosen et al, 1993). These observation 
concords with previous published work showing that co-administration of 
fluvoxamine with melatonin significantly increased serum melatonin concentrations 
in humans (Hartter et al., 2000), and findings that fluvoxamine potently inhibited the
6-hydroxylation of exogenous melatonin in vitro (Hartter et al., 2001). Moreover, it 
was proposed that fluvoxamine administration impairs also the metabolism of 
endogenous melatonin (Skene et al., 1994), implying that CYP1A2 may be a catalyst 
of melatonin oxidation at both the exogenous and the far lower physiological 
concentrations of melatonin. However, this remains to be established in appropriate 
studies. In support of this view, fluvoxamine administration significantly raised 
endogenous melatonin plasma levels and stimulated the excretion of 6- 
sulphatoxymelatonin in the urine, indicating that fluvoxamine more likely acts by 
inhibiting the hepatic 6-hydroxylation of melatonin (von Bahr et ah, 2000). A 
possible explanation of the mechanism by which fluvoxamine impaired melatonin 6- 
hydroxylation in the current study is the competitive irreversible inhibition between 
the two substrates for CYP1A2 (Levy et a l, 2003). This suggests that the degree of 
inhibition in clinical situation is dose-dependent of plasma concentrations of
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fluvoxamine. Steady state fluvoxamine plasma concentrations associated with a 
beneficial clinical response are between 160-200 ng/ml (Nathan et al., 1990), which is 
equivalent to a concentration less than 0.1 juM. In the current study fluvoxamine at 
concentration > 50 pM inhibited melatonin at a concentration 50jliM. However, in 
vivo plasma concentrations of both drugs will be less than 0.1 pM. On the basis of the 
current observations and taking into consideration that plasma concentrations of 
fluvoxamine and melatonin are at < 0.1 pM, concomitant use of fluvoxamine with 
melatonin may result in increased plasma melatonin levels.
5-Methoxypsoralen was a strong inhibitor of rat and human 6-hydroxylation of 
exogenous melatonin. This observation is consistent with previous studies 
demonstrating that 5-methoxypsoralen prolongs the half-life of exogenous melatonin 
in the rat (Mauviard et al., 1995). It appears that routine use of 5-methoxypsoralen 
plus UVA treatment in humans significantly increased not only the exogenous but 
also the endogenous plasma melatonin concentrations an hour after the administration 
of 8-methoxypsoralen (Garde et al., 1994), indicating that it may also interfere with 
the 6-hydroxylation of endogenous melatonin. These findings raise the possibility 
that CYP1A2 may catalyse the 6-hydroxylation of both endogenous and exogenous 
melatonin. The fact that 5-methoxypsoralen is a CYP1A2 mechanism-based inhibitor 
(Fouin-Fortunet et al, 1986; Mays et al., 1987; Tinel et al., 1987) may explain its 
potent inhibitory effect on the 6-hydroxylation of melatonin. The possible mechanism 
by which 5-methoxysporalen inhibits melatonin 6-hydroxylation is by suicide 
inactivation, related to the covalent binding of its intermediate metabolite to the 
protein moiety of several cytochrome P450 enzymes, including CYP1A2 (Fouin- 
Fortunet et al, 1986; Tinel et al, 1987; Labbe et al, 1989). hi other words, 5-
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methoxysporalen because it is converted to an intermediate metabolite prior to 
inactivation, destroys the cytochrome P450 enzymes (Koenigs and Trager, 1998). 
This mechanism-based inhibition causes irreversible loss of function of several P450 
enzymes. Since 5-methoxypsoralen at the therapeutic dose (1.2 mg / kg) is able to 
inhibit the CYPlA2-mediated caffeine metabolism in humans (Bendriss et a l, 1996), 
it may also inhibit the 6-hydroxylation of exogenous melatonin in humans. Mean 5- 
methoxypsoralen plasma concentration after a standard oral dose (1.2 mg / kg) 
reaches 378 ± 161 ng/ml (Stolk et al, 1981; Treffel et al, 1992; Tanew et al, 1988; 
Shephard et al, 1999), which is equivalent to a concentration of 1.75 pM in vitro. 
This concentration appears to be higher than the concentration of 0.01 pM that 
inhibited the melatonin 6-hydroxylase activity in the current study, but since the 
mechanism by which it inhibits the enzyme is not dose-dependent, it would expected 
to cause inhibition. Consequently, patients treated with 5-methoxypsoralen should be 
informed that concomitant use of melatonin may significantly increase their plasma 
melatonin concentrations. It has been reported that 5-methoxypsoralen administration 
increased daytime sleepiness and this correlated with high plasma melatonin levels 
(Souetre et al, 1989). The consequences of such effect, for example on daytime 
alertness requires more study.
The present results demonstrate that diazepam at a concentrations > 50 pM 
significantly inhibited the 6-hydroxylation of melatonin in the rat liver, whereas in the 
human liver inhibition occurred at a concentrations > 100 pM. However, in both rat 
and human liver, high concentrations of diazepam impaired the sulphation of 6- 
hydroxymelatonin. It is therefore, conceivable that the decrease in the conversion of 
melatonin to 6-sulphatoxymelatonin reflects largely a less efficient sulphate
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conjugation, since diazepam is metabolised by CYP3A4 in humans (Ono et al, 1996). 
Mean steady-state plasma concentrations of diazepam are 329 ng/ml (Greenblatt et 
ah, 1981), equivalent to a concentration of 1.2 pM, which is much lower than the 
concentration that impaired the sulphate conjugation of melatonin in the current study. 
Hence, it could be predicted that concomitant use of diazepam with melatonin will not 
impair the metabolism of melatonin.
According to the present findings, tamoxifen impaired rat, but not human, melatonin
6-hydroxylase activity. This difference between the rat and human liver could 
possibly be attributed to the minor contribution of CYP1A2 in human hepatic 
tamoxifen metabolism compared with the rat. A possible mechanism of melatonin 6- 
hydroxylase inhibition by tamoxifen in the rat is competition for the CYP1A2 binding 
site. On the basis that the inhibition occurred only in the rat liver and at a very high 
concentration (> 500 jiM), it can be predicted that administration of tamoxifen would 
be unlikely to impair the metabolism of melatonin if administered concomitantly in 
humans.
The present results demonstrate that acetaminophen (paracetamol) inhibited only in 
the rat, the conversion of melatonin to 6-sulphatoxymelatonin, whereas it did not 
impair it in the human liver. It is possible that acetaminophen impairs melatonin 
metabolism in the rat due to the formation of the reactive metabolite, which 
covalently binds to cytochrome P450 enzymes and thus rendering them inactive. This 
is possibly the reason why inhibition was observed at both the oxidation and 
sulphation pathways of melatonin metabolism, and only at high concentrations, as at 
low concentrations the reactive intermediate is probably detoxicated by glutathione
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(Allameh et al, 1997). However, this does not explain the lack of inhibition in 
human liver. Possible reasons are that the human liver used could not form readily 
the reactive intermediate of acetaminophen and/ or that the detoxication of the 
reactive metabolite by glutathione may be more efficient in human liver compared 
with rat.
Women taking oral contraceptives appear to have higher plasma melatonin levels 
during the active part of their treatment compared to their washout period (Thapan 
and Skene, unpublished results). The present findings demonstrate that in the rat liver 
17a-ethinyloestradiol, even at low concentrations of 1 juM, significantly decreased the
6-hydroxylation of melatonin in a dose-dependent manner but did not impair the 
sulphation of 6-hydroxymelatonin. Similarly, in the human liver 17a- 
ethinyloestradiol was a potent inhibitor of the conversion of melatonin to 6- 
sulphatoxymelatonin but, in contrast to the rat liver, it also impaired sulphation of the 
hydroxylated melatonin. Mean serum ethinyloestradiol levels following 30 mg 
administration was found to be 153 pg / ml (Baisini et al, 2004). This is equivalent to 
a concentration of 0.5 nM, which is much lower than the concentration that caused 
impairment in the metabolism of melatonin (1 pM) in the current study. Bearing in 
mind that sulphation of 17a-ethinyloestradiol is a major pathway of metabolism in 
liver (Schrag et al, 2004) at clinically relevant concentrations (< 10 nM), it is 
possible to predict that it will not impair the sulphate conjugation of exogenous 
melatonin.
Exogenous melatonin is a potential treatment for circadian disruption and insomnia 
(section 1.1.4.2), and induces sleepiness (Arendt, 2000). Melatonin has been shown
Chapter 4 -Inhibition of melatonin 6-hydroxylase 125
to induce a small deficit in performance on a range of neurobehavioural tasks such as 
unpredictable tracking, memory, alertness and logical reasoning (Rogers et al., 2003). 
In general, exogenous melatonin has few immediate side effects except drowsiness 
(Arendt, 1997; Avery et a l, 1998). Inhibition of the hepatic 6-hydroxylation of 
melatonin may cause decrease in alertness.
4.5,1 Conclusions
On the basis of the present findings, the plasma concentrations of the drugs based on 
the literature and the mechanism of interaction, it is possible to conclude that of all the 
drugs screened for their potential to inhibit melatonin 6-hydroxylation, fluvoxamine 
and 5-methoxypsoralen are the more likely to impair this metabolic pathway in vivo in 
humans. It can also be postulated that in humans, diazepam, tamoxifen, and 
acetaminophen are unlikely to impair melatonin 6-hydroxylation and hence unlikely 
to cause a drug interaction. 17oc-Ethinyloestradiol appeared not to impair the 6- 
hydroxylation but to inhibit the sulphation of exogenous melatonin in human liver" 
although the concentration in plasma is not high enough to cause an impairment in the 
sulphation of melatonin. Collectively, the above findings demonstrate that drugs 
acting as CYP1A2 inhibitors, such as fluvoxamine and 5-methoxypsoralen can 
potentially inhibit the hepatic 6-hydroxylation of exogenous melatonin in humans, 
since this enzyme primarily is involved in this metabolic pathway. In some cases, this 
inhibitory effect could be beneficial, especially in individuals with extremely low 
plasma melatonin levels and could act as enhancer of melatonin to increase its plasma 
levels and hence to prolong its effectiveness.
CHAPTER FIVE
EFFECT OF CAFFEINE ON URINARY 6- 
SULPHATOXYMELATONIN EXCRETION
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5.1 Introduction
CYP1A2 is a liver-specific enzyme that plays a major role in drug and, especially, 
carcinogen metabolism. It catalyses the iV-oxidation of carcinogenic aromatic and 
several heterocyclic amines, the latter being found in food such as meat cooked under 
domestic conditions and, to a lesser extent, in cigarette smoke (MacLeod et al, 1997). 
There has been a major interest in exposure to heterocyclic amines as a possible risk 
factor for cancer, since they induce tumours in the colon and breast, two most 
common sites of human cancer (Zheng et a l, 1998; Marie et al., 2000; Felton et al., 
2002). Consequently, methods for measuring CYP1A2 activity in vivo in humans are 
important tools to establish the relationship between exposure to chemicals and cancer 
incidence.
Caffeine (1,3,7-trimethylxanthine) is a well-established probe drug for assessing 
CYP1A2 activity (Tassaneeyakul et al, 1994). About 80% of caffeine is N3- 
demethylated to paraxanthine and the major enzyme catalyzing this reaction is 
CYP1A2 (Campbell et al, 1987; Berthou ef al, 1991; Gu et al, 1992). Several 
different caffeine metabolite ratios have been used to define CYP1A2 activity 
(Rostami-Hodjegan et al, 1996). Exogenous melatonin is primarily metabolised in 
the liver to 6-hydroxymelatonin by CYP1A2 in rats (see Chapter 3) and humans 
(Facciola et a l, 2001), and the major urinary metabolite is 6-sulphatoxymelatonin 
(section 1.1.2). Based on this finding, it may be hypothesised that the main urinary 
metabolite of melatonin, 6-sulphatoxymelatonin, could reflect CYP1A2 activity in 
humans.
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In order to test this hypothesis, the effect of chronic intake of oral caffeine on the 
metabolism of melatonin to 6-sulphatoxymelatonin was investigated. Long-term 
intake of caffeine in the diet has been found to increase CYP1A2 activity in the liver 
of rats (Ayalogu et al, 1995). Moreover, caffeine has been shown to be responsible 
for the rise in CYP1A2 activity in the liver of rats exposed to green or black tea (Bu- 
Abbas et al, 1994).
5.2 Objectives
The objectives of this study were to assess the effect of caffeine-mediated CYP1A2 
induction in the metabolism of both endogenous and exogenous melatonin to 6- 
sulphatoxymelatonin. It would be anticipated that caffeine, being an inducer of 
CYP1A2 (Ayalogu et al, 1995), would enhance the metabolism of exogenous 
melatonin through 6-hydroxylation. Moreover, an increase in the 6-hydroxylation of 
endogenous melatonin would imply that CYP1A2 contributes to its metabolism 
through this pathway. Whether the urinary excretion of 6-sulphatoxymelatonin 
correlates with in vitro hepatic CYP1A2 activity was also investigated.
5.3 Materials and Methods
53.1 Animals
Twelve male Wistar albino rats (200-250 g), kept in a 12:12 h light:dark cycle (LD; 
lights on at 06.00 h), were used in this study. The darkness period was from 18:00 to 
06:00 h. The animals were fed standard food and water ad libitum.
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5.3.2 Study design
Animals were randomly divided into two groups, control and caffeine-treated, each 
comprising six rats. The animals were housed in separate metabolic cages that 
allowed the collection of timed urine samples. A drinking bottle and food inlet were 
connected to each cage. The control group received water and the caffeine-treated 
group was provided with a caffeine solution (0.1% w/v) as the sole drink for nine days 
prior to initiation of the study, and for the study period (4 days). Urine was collected 
into tubes arranged in a fraction collector and samples were stored at -20 °C until 
assayed for 6-sulphatoxymelatonin (section 2.2.4).
5.3.2.1 Endogenous melatonin
At the commencement of the study period, urine samples were collected for 48 hours 
(days 1 and 2), at four-hourly intervals, starting at 11:00 h clock time (ZT 5). 
Measurement of 6-sulphatoxymelatonin in the urine was performed to provide an 
assessment of the animals’ endogenous melatonin rhythms in the presence or absence 
of caffeine.
53.2.2 Exogenous melatonin
On day 3, melatonin (1 mg/kg) was injected intraperitoneally to both the control and 
caffeine-treated groups at 11:00 h. Urine samples were collected for another 48 h 
(days 3 and 4) at four-hourly intervals, starting at 11:00 h. Measurement of 6- 
sulphatoxymelatonin in the urine was performed to assess the elimination pattern of 
exogenous melatonin in control and caffeine-treated animals.
Chapter 5 -  Effect of caffeine on urinary 6-sulphatoxymelatonin excretion 129
53.2.3 Determination ofCYP!A2 activity
At the end of the study, 12 days in total, animals from both groups were sacrificed by 
cervical dislocation, livers were removed on ice and postmitochondrial fractions (S9) 
were prepared (section 2.2.2) and stored at -20° C until use. CYP1A2 activity was 
determined in hepatic microsomes using methoxyresorufin O-demethylase as 
previously described (sections 2.2.2 and 2.2.6.2).
53.2.4 Determination o f urinary 6-sulphatoxymelatonin
Urine samples were defrosted and centrifuged at 2,500 x g for 10 minutes to remove 
any solid material. All urine samples were assayed in duplicate by 
radioimmunoassay, using 125I-labeled aMT6s tracer (Aidons and Arendt, 1988) 
(section 2.2.5). Urine samples were diluted with assay buffer 1:250 and 1:2500 for the 
control and the caffeine-treated groups, respectively, directly into the assay tubes 
using an automatic pipette and diluter. The limit of detection for the assay was 
approximately 1.8 ng/ml. Maximum binding was around 88% and the non specific 
binding was 5%. The inter-assay coefficients of variation (CVs) were 16.6, 8.6 and 
4.8% (n=12 each) for mean 6-sulphatoxymelatonin values of 3.8, 9.3 and 33.4 ng/ml, 
respectively.
5.3.3 Statistical Analysis
The results are expressed as mean ± SEM. Unpaired Student’s t-test was performed to 
test whether there were statistically significant differences between the control and 
caffeine-treated groups. The Spearman Rank Correlation coefficient (Rs) was 
calculated to determine the relationship between the endogenous urinary 6-
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sulphatoxymelatonin rhythms and hepatic methoxyresorufin O-demethylase activity 
(GraphPad InStat Software version 3).
5.4 Results
5.4.1 Effect of caffeine treatment on hepatic CYP1A2 activity
Hepatic CYP1A2 activity, as exemplified by the O-demethylation of 
methoxyresorufin, determined after the completion of the study (12 days) was found 
to be significantly higher in the caffeine-treated group compared with the control 
group (Figure 5.1). The administration of caffeine solution (0.1 % w/v), as the sole 
source of drinking fluid for twelve days, gave rise to a 9-fold increase in hepatic 
CYP1A2 activity.
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Figure 5.1 CYP1A2 activity measured by methoxyresorufin O-demethylase. Caffeine was 
administered to the animals in their drinking water (0.1% w/v) for 12 days. Values are presented as 
mean ± SEM (n=6).
*** p < 0.001
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5.4.2 Effect of caffeine treatment on endogenous melatonin metabolism
Of the six control animals in this study, only four were included in the analysis since 
the other two animals had incomplete urine samples (samples were lost due to 
blockage of the urine collecting tubes). The control animals exhibited a 24-hour 
rhythm in their excretion of urinary 6-sulphatoxymelatonin with high values occurring 
during the dark phase and low values during the day (Figure 5.2). For all the control 
animals, the urinary 6-sulphatoxymelatonin peak occurred during the same time 
period i.e. 23:00 to 03:00 h (ZT 17-21), during the dark period that was from 18.00 to 
06.00 h. The lowest amount of urinary 6-sulphatoxymelatonin excreted was between 
11:00 and 19:00 h (Figure 5.2).
Of the six caffeine-treated animals, only three were included in the analysis since 
there was a high number of missing urine samples for the other three animals due to 
the blockage of their urine collecting tubes. Similar to the controls, the caffeine- 
treated animals also exhibited a 24 h rhythm in their urinary 6-sulphatoxymelatonin 
excretion (Figure 5.3). The peak urinary excretion of 6-sulphatoxymelatonin was also 
observed between 23.00 and 03.00 h during the dark period of the light-dark cycle, as 
it occurred in the controls. Their lowest urinary excretion of 6-sulphatoxymelatonin 
was observed between 11:00 to 15:00 h, during the light period of the light-dark cycle 
(Figure 5.3).
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Figure 5.2 Urinary excretion of endogenous 6-sulphatoxymelatonin in each of the control rats (n
= 4). Lights were off between 18:00 and 06:00 h. Urine samples were collected at 4h intervals from 
11:00 h for 48 h. The 6-sulphatoxymelatonin concentrations for similar time periods on days 1 and 2 
were averaged.
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Figure 5.3 Urinary excretion of endogenous 6-sulphatoxymelatonin in each of the caffeine-treated 
rats (n= 3). Caffeine was administered to the animals in their drinking water (0.1% w/v) for 7 days. 
Lights were off between 18:00 and 06:00 h. Urine samples were collected at 4 h intervals from 11:00 h 
for 48 h. The 6-sulphatoxymelatonin concentrations for similar time periods on days 1 and 2 were 
averaged.
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Comparing the mean amount of urinary 6-sulphatoxymelatonin excreted from 
endogenous melatonin from the control group and the caffeine treatment group at the 
different time intervals during the 24 h cycle, it was observed that there is a 
significant difference between the two groups at the time period 23:00 to 03:00 h 
(Figure 5.4), while no significant differences were found between the two groups at 
the other time intervals.
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Figure 5.4 Urinary excretion of endogenous 6-sulphatoxymelatomn in control and caffeine- 
treated animals. Lights were off between 18:00 and 06:00 h. Urine samples were collected at 4-hr 
intervals from 11:00 h for 48 hrs. Values are presented as mean ± SEM. **p<0.01 Unpaired Student’s 
t-test
Cosinor analysis of the endogenous urinary 6-sulphatoxymelatonin rhythms showed 
that the rhythms were significant for all the control animals, and the mean acrophase 
time occured at 3.4 h (Table 5.1). On the other hand, none of the caffeine treated
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animals had a significant rhythm thus the acrophase times calculated by cosinor 
analysis (Table 5.1) are not reliable.
Table 5.1 Cosinor analysis of endogenous urinary 6-sulphatoxymelatonin 
rhythms._____________________________________________________________
Control Animals Caffeine Animals
Acrophase %R Acrophase %R
Time (h) Time (h)
1 3.3 92.6* 2.5 77.7
2 3.5 91.7* 2.5 68.1
3 3.8 86.5* 3.2 78.7
4 3.1 93.1*
Mean ± SEM 3.4 ± 0.1 91.0* 2.7 ± 0.2 74.8
Acrophase time is in decimal hours; %R is percentage rhythm; * p<  0.05
The total amount of endogenous urinary 6-sulphatoxymelatonin excreted over the 24- 
hour period was higher in the caffeine-treated animals compared with controls, but the 
difference was not statistically significant (Table 5.2). The peak of urinary 6- 
sulphatoxymelatonin excretion occurred between 23:00 to 03:00 hours in both control 
and caffeine-treated animals. The peak amount of 6-sulphatoxymelatonin, however, 
was found to be significantly higher in the caffeine-treated animals compared with the 
controls (Table 5.2).
Table 5.2 Effect of caffeine-treatment on the urinary excretion of endogenous 6- 
sulphatoxymelatonin in rats. Values are presented as mean ± SEM.
Control Peak aMT6s (ng/h) Caffeine Peak aMT6s (ng/h)
Total 24-h aMT6s excretion in controls Total 24-h aMT6s excretion in caffeine-
Excretion Excretion treated
(ng/h) (ng/h)
82.3 24.7 126.1 51.9
79.9 24.7 72.3 38.3
72.9 25.0 109.5 41.6
101.2 34.5
84.1 ±6.1 28.1 ±2.4 103 ±15.9 44 ±4.1**
**p<0.01 Unpaired Student’s t-test
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The relationship between the peak endogenous urinary 6-sulphatoxymelatonin 
concentrations and the hepatic methoxyresomfin O-demethylase activity is shown in 
Figure 5.5. Correlation analysis revealed that there was a significant correlation (R = 
0.8108; p < 0.05) between the peak 6-sulphatoxymelatonin levels and the hepatic 
methoxyresomfin O-demethylase activity, which reflects CYP1A2.
25,0 n
£  20,0 - 
i i  i
O bû
1 1  1 0 ,0  -
0,0
20 30 40 50 60100
Peak endogenous urinary aMT6s excretion (ng/h)
Figure 5.5 Relationship between the peak endogenous urinary 6-sulphatoxymelatonin excretion 
and methoxyresorufin O-demethylase activity, determined at the end of the study.
(Spearman Rank Correlation R = 0.8108; p<0.05)
5.4.3 Effect of caffeine treatment on exogenous melatonin metabolism
The amount of 6-sulphatoxymelatonin excreted in the urine during the first 8 hours 
following the injection of exogenous melatonin was found to be higher but not 
significantly in the caffeine-treated animals compared with the controls (Figure 5.6). 
It should be noted that since none of the caffeine-treated animals produced urine 
during the first 4 hours after the injection of melatonin, the comparison between the
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two groups in the amount of urinary 6-sulphatoxymelatonin excreted, was calculated 
for the first 8 hours following the melatonin injection.
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Figure 5.6 Urinary 6-sulphatoxymelatonin excretion over the first 8 hours following melatonin 
administration. Both control (□ )  (n=6) and caffeine-treated (■) animals (n=6) were administered 
intraperitoneally a single dose (1 mg/kg) of melatonin. Results are presented as mean ± SEM.
The amount of 6-sulphatoxymelatonin excreted in the subsequent 4 hours, i.e. from 8 
to 12 hours after melatonin injection, was found to be significantly higher in the 
caffeine-treated animals compared with the control animals (Figure 5.7). Compared 
with the control animals, the caffeine-treated animals excreted similar amounts of 6- 
sulphatoxymelatonin at all the subsequent time points (from 12 hours up to 48 hours) 
following melatonin injection (Figure 5.7).
The relationship between the amount of urinary 6-sulphatoxymelatonin excreted 
between 8 to 12 hours following melatonin injection and the hepatic 
methoxyresorufin O-demethylase activity is shown in Figure 5.8.
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Figure 5.7 Urinary 6-sulphatoxymelatonin excretion following melatonin administration. Both 
control (□ )  and caffeine-treated (■) animals were administered intraperitoneally with a single dose (1 
mg/kg) of melatonin. Results are presented as mean ± SEM. ** p <  0.01
Correlation analysis revealed that there was a significant correlation (R = 0.9145; 
pcO.OOl) between the amount of 6-sulphatoxymelatonin excreted between 8 to 12 
hours after melatonin injection and the hepatic methoxyresorufin O-demethylase 
activity.
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Figure 5.8 Relationship between urinary 6-sulphatoxymelatonin excretion and methoxyresorufin 
O-demethylase activity. Values are presented for each control (n=6) and caffeine-treated animal (n=5) 
(Spearman Rank Correlation Rs = 0.9145; p  < 0.001)
5.5 Discussion
The objectives of this study were to assess the effect of CYP1A2 induction by oral 
caffeine intake on the amount of urinary 6-sulphatoxymelatonin excreted by untreated 
animals (endogenous levels), and rats treated with melatonin (exogenous levels). 
Furthermore, the relationship between the nocturnal peak of urinary 6- 
sulphatoxymelatonin excretion and the in vitro hepatic CYP1A2 activity in all the 
animals was examined.
As expected, caffeine treatment in the drinking water as the sole drink for 12 days, in 
total, caused a significant rise in the hepatic methoxyresorufin O-demethylase, which 
is a probe for CYP1A2 activity in vitro (Ayalogu et al, 1995). This result is 
consistent with the findings from previous studies showing that caffeine given as part
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of the diet to male Fischer-344 rats for 2 weeks increased the expression of CYP1A2 
16-fold (Tureskyef al.y 2003).
The present findings demonstrate that treatment of rats with caffeine appears to 
significantly increase the excretion of urinary endogenous 6-sulphatoxymelatonin at 
night. However, caffeine treatment did not significantly increase the total 24-hour 6- 
sulphatoxymelatonin amount excreted compared with the control animals, hi 
addition, caffeine treatment did not delay or advance the time of the peak of urinary 6- 
sulphatoxymelatonin, since it occurred between 23:00 to 03:00 h for both the control 
and caffeine-treated animals. Cosinor analysis revealed that pre-treatment of animals 
with caffeine resulted in the loss of the endogenous 6-sulphatoxymelatonin rhythm 
compared with the controls. It appears that caffeine had an effect on the urinary 6- 
sulphatoxymetonin profile, which produced a non-cosine pattern. This effect could be 
attributed to the increase of hepatic CYP1A2 activity.
These findings suggest that induction of CYP1A2, through oral caffeine intake for 
one week, significantly increased the hepatic 6-hydroxylation of endogenous 
melatonin at the time when most melatonin production occurs (i.e. at night), but did 
not similarly stimulate melatonin 6-hydroxylation when melatonin production is low 
(i.e. during the day). Based on these findings, it may be cautiously inferred that the 
CYP1A2 enzyme plays a significant role in the 6-hydroxylation of endogenous 
melatonin. In addition, a significant correlation was observed between the peak 
urinary 6-sulphatoxymelatonin concentrations at 23.00 to 03.00 h and hepatic 
CYP1A2 activity. This correlation implies that the nocturnal peak excretion of 
endogenous urinary 6-sulphatoxymelatonin is more appropriate than the total 24-hour
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urinary 6-sulphatoxymelatonin production for assessing CYP1A2 activity using 
melatonin. It would be of interest to investigate in humans with induced CYP1A2 
activity such as smokers (Parsons and Neims, 1978; Kalow and Tang, 1991) whether 
6-sulphatoxymelatonin excretion in the urine is higher compared with non-smokers. If 
this is the case, it could be proposed that the amount of endogenous urinary 6- 
sulphatoxymelatonin in the nocturnal peak might be used as an index of CYP1A2 
activity in humans. The production of 6p-hydroxycortisol excretion in the urine from 
endogenous cortisol is already used as an indicator of CYP3A4 activity (Ged et al, 
1989; Kovacs et al, 1998).
Following melatonin injection, caffeine treatment appeared to increase 6- 
sulphatoxymelatonin excretion, but this increase was not significantly different from 
the control animals during the first 8 hours following melatonin injection. This may 
be attributed, at least partly, to the fact that caffeine-treated animals did not urinate for 
the first 4 hours after melatonin injection. However, caffeine treatment significantly 
increased the urinary excretion of 6-sulphatoxymelatonin between 8 and 12 hours 
following melatonin administration. These findings suggest that CYP1A2 induction 
by oral caffeine intake stimulates the hepatic 6-hydroxylation of exogenous 
melatonin.
Hartter et al. (2001), assessing CYP1A2 activity in individuals using oral caffeine and 
a year later using oral melatonin, noted a significant correlation between caffeine 
clearance and clearance of melatonin. Moreover, serum melatonin concentrations 1.5 
hours after melatonin intake were significantly correlated with caffeine clearance, 
suggesting that the collection of blood at this time point reflects CYP1A2 activity.
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Moreover, in a subsequent study the same authors (Hartter et al, 2003) observed that 
smokers exhibited lower Cmax and AUC serum melatonin compared with 
nonsmokers following oral intake of a 6 mg dose of melatonin. This is not surprising 
since smokers have induced CYP1A2 levels (Parsons and Neims, 1978; Kalow and 
Tang, 1991) compared with nonsmokers. These findings are in agreement with the 
current observation that hepatic 6-hydroxylation of exogenous melatonin was 
enhanced in CYPlA2-induced animals by caffeine treatment.
Based on the findings of the present studies, endogenous peak nocturnal 6- 
sulphatoxymelatonin should be further evaluated as a possible index of CYP1A2 
activity in humans. A study in humans could be undertaken investigating whether 
following a single oral dose of melatonin, smokers (CYPlA2-induced group) display 
lower plasma or saliva melatonin levels, but higher urinary 6-sulphatoxymelatonin 
excretion compared with a group of nonsmokers (control group). Simultaneously 
employing plasma or saliva melatonin as well as the excretion of urinary 6- 
sulphatoxymelatonin will enable us to determine which method is the most sensitive 
and more appropriate to reflect in vivo CYP1A2 activity. Although measurement of 
plasma melatonin is considered the gold standard, other methods like measurement of 
salivary melatonin are easier to perform, are non-invasive for the volunteers and 
correlate well with plasma melatonin levels (Laakso et a l, 1990; Voultsios et al, 
1997).
On the basis of the present findings, it may be concluded that individuals with 
induced CYP1A2 levels will be expected to metabolise exogenous melatonin faster 
and hence excrete more 6-sulphatoxymelatonin in the urine. For the first time, the
Chapter 5 -  Effect of caffeine on urinary 6-sulphatoxymelatonin excretion 143
data in this chapter demonstrate that the 6-hydroxylation pathway of endogenous 
melatonin was also stimulated by caffeine drinking during the night, when most of the 
endogenous melatonin production occurs. Finally, both endogenous and exogenous 
melatonin merits further studies as possible alternatives to caffeine for assessing 
CYP1A2 activity in humans.
CHAPTER SIX
DAILY RHYTHMS IN RAT HEPATIC DRUG 
METABOLISING ENZYMES
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6.1 Introduction
Circadian rhythms exist in most organisms and are essential for their adaptation to the 
periodic changes in the environment. It is well established that in mammals the 
suprachiasmatic nuclei (SON) of the hypothalamus drives the circadian rhythms 
(Klein, et al, 1991). Lesions of the SCN seem to abolish all circadian rhythms in 
rodents (Moore and Eichler, 1972; Stephan and Zucker, 1972).
6.1.1 The suprachiasmatic nuclei -  the endogenous circadian clock
The suprachiasmatic nucleus (SCN) is composed of a pair of bilaterally symmetric 
structures located in the anterior hypothalamus, immediately dorsal to the optic 
chiasm (Weaver, 1998; Moore, 1997). The SCN plays a key role in the generation of 
circadian rhythms in behavioural, metabolic, and endocrine functions, and their 
entrainment to the environmental light-dark cycle (see section 1.3.3.1).
6.1.2 Circadian Rhythm Entrainment - Photic entrainment
Entrainment is the process by which extrinsic stimuli change or reset the phase of the 
circadian clock. Light is one of the most important entrainments. Light information 
from the eye reaches the circadian oscillator, the SCN, via a specific neural pathway, 
the retinohypothalamic tract (Moore and Lenn, 1972) that mediates a close coupling 
with the SCN and the light-dark cycle as perceived by photopigments in the eye 
(Lowrey and Takahashi, 2000). Through this functional connection with the retina, 
the SCN responds rapidly to light, entraining to a shifted light-dark schedule within a 
day (Yamazaki et al, 2000).
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6.1.3 Peripheral Clocks - Liver
The clocks in peripheral tissues such as the liver and the heart are called peripheral 
clocks. Initially these clocks were thought to be dependent on the SCN oscillator for 
their entrainment. However, the finding that peripheral clocks have the capacity to 
continue to generate rhythms on their own in culture (Yamazaki et al., 2000), 
underlines that can also operate independently of the SCN in vivo. The SCN appears 
to coordinate the rhythm in the peripheral clocks mainly though rhythmic feeding 
patterns that are imposed through rest-activity cycles. Under normal conditions these 
peripheral clocks need input from the SCN, but the feeding time can play a dominant 
role in their entrainment. It has been observed that daytime feeding of nocturnal 
animals can completely reverse the circadian clock gene expression in peripheral 
tissues such the liver and the heart without affecting the phase of the SCN (Damiola et 
al., 2000; Stokkan et al., 2001). There is evidence that efferent autonomic pathways 
may also signal time of day to the liver and other tissues (la Fleur et al., 2000).
6.1.4 Daily rhythms in hepatic drug-metabolising enzymes
The first studies concerned with the presence of daily rhythms in drug-metabolising 
enzyme activities of rat liver were undertaken during the 60s and 70s. These studies 
established that light/dark rhythms exist, and that these activities were high during the 
dark period and low during the light period (Radzialowski and Bousqet, 1967; Nair 
and Casper 1969). Since at that time the knowledge that the cytochrome P450 system 
comprises a number of different enzymes was limited, it was not possible to 
determine the light/dark difference in individual cytochrome P450 enzymes. In these 
early studies the oxidation of hexobarbital and the déméthylation of substrates such as 
aminopyrine, p-nitroanisole and imipramine were examined. It was observed that in
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male rats hepatic aminopyrine demethylase, imipramine N-demethylase, hexobarbital 
alklylhydroxylase and p-nitroanisole O-demethylase activities were high during the 
dark period and low during the light period under a 12:12 h light/dark cycle (Jori et 
al, 1971). Similar findings were noted in the liver of male hamster (Burke et al, 
1972). Under a 12:12 h light/dark cycle (lights on at 06.30 h), maximum enzyme 
activities were observed in the middle of the dark period, and minimum in the middle 
of the light period (Lake et a l, 1976). In agreement with these findings, drug efficacy 
and toxicity of some drugs have been shown to undergo a day/night variation, which 
has been attributed to possible day/night fluctuations in liver drug-metabolising 
enzyme activities (Belanger, 1996).
In more recent studies (Furukawa et a l, 1999) hepatic cytochrome P450 activity, 
monitored by 7-alkoxycoumarin O-dealkylase (ACD), was found to be significantly 
higher during the dark period compared with the light period of the light/dark cycle. 
Moreover, this light/dark difference disappeared in SCN-lesioned rats, suggesting a 
role for SCN in the regulation of these rhythms in the liver.
It should be pointed out that these studies do not provide sufficient information about 
the activity of individual cytochrome P450 enzymes under a light/dark cycle.
Daily rhythms are not only confined to cytochrome P450-enzymes, but also affect 
phase II conjugation reactions. Diurnal variation in glutathione ^-transferase (GST) 
activity toward 1 -chloro-2,4-dinitrobenzene (CDNB) in the liver of male mouse under 
a 12:12 h light:dark cycle has been observed, the activity being higher during the light 
period at 13.00 h and lower at the dark period at 01.00 h. Under reversed lighting
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conditions this light/dark difference disappeared, suggesting that it may be controlled 
by the lighting conditions (kioue et al, 1999). This finding is supported by the study 
of Tunon et al. (1992) who showed that hepatic glutathione 5-transferase activity in 
male rats under a 12:12 h light:dark cycle was high during the light period and low 
during the dark period of the LD cycle (Tunon, et al, 1992). In contrast, it has also 
been reported (Davies et a l, 1983) that the higher activities occurred during the dark 
and not the light period of the LD cycle, whereas other workers noted no light/dark 
difference in GST activity in the same animal species (Belanger et al, 1991). In male 
mice, hepatic glutathione-S-transferase activity was significantly higher during the 
dark period as compared with the light period (Davies et a l, 1983). In male mice, 
glutathione peroxidase activity, monitored using two different substrates, was 
biphasic. When cumene hydroperoxide was used, the enzyme activity was maximum 
at 18:00 h and 06:00 h and minimum at 10:00 h, 14:00 h and 22:00 h. (Davies et al, 
1983). When hydrogen peroxide was used as substrate, enzyme activity was 
maximum at 14:00 h and 06:00 h and minimum at 10:00 h and 22:00 h. Similarly, 
glutathione concentration peak levels occurred between 06:00 h and 10:00 h and 
minimum occurred at 18:00 h. These studies established that glutathione levels and 
two enzymes utilising glutathione as a co-substrate follow a similar rhythmic pattern, 
with the highest activity occurring during the dark period (Davies et al, 1983).
6.2 Objectives
The objectives of this study are to investigate whether individual hepatic xenobiotic 
cytochrome P450 enzymes exhibit a daily rhythm namely, CYP1A1, CYP1A2, 
CYP2B1, CYP2E1, CYP2A1/2, CYP2C11, CYP3A1/2, CYP2D1 and CYP4A1 
monitored using chemical probes and Western blotting; the phase II enzymes UDP-
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glucuronyltransferase, epoxide hydrolase and cytosolic glutathione ^-transferases 
were also studied. The role of the SCN and PVN in the regulation of the enzymes that 
exhibit a light/dark difference was also investigated.
6.3 Materials and methods
6.3.1 Animals
Adult male Wistar albino rats (200-300 g) were used in all the experimental studies 
(Netherlands Institute for Brain Research, Amsterdam, The Netherlands). Rats were 
housed in separate cages at a room temperature of 20°C, under a 12:12 h lightrdark 
(LD) schedule. The animals were provided food and water ad libitum. Animals were 
sacrificed by cervical dislocation, livers were rapidly excised and frozen at -80 °C. 
Samples were packed in dry ice and transported to the University of Surrey where 
they were stored at -80°C until preparation of the postmitochondrial fraction (S9) 
(section 2.2.2).
6.3.2 Study design
6.3.2.1 Daily rhythms in P450 and conjugation enzymes in the rat liver 
Six groups of control rats (n = 3-5/group) synchronised to a 12:12 h LD cycle (lights 
on at 07:00 h) were killed at 4-h intervals throughout a 24-h period starting at 
zeitgeber time (ZT) 2 (= 09:00 h) (by convention ZT 0 is the time of lights on). 
Livers were removed, snap-frozen in liquid nitrogen, and stored at -80°C.
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6.3.2.2 Effect o f SCN and PVN lesions on light/dark rhythm o f enzyme activities 
The surgical procedure for this experiment was conducted at the Netherlands Institute 
for Brain Research (section 2.2.9). Four groups of animals were included: (1) 
unoperated control (n = 8), (2) sham-operated (n = 12), (3) SCN-lesioned (n = 16), 
and (4) PVN-lesioned (n = 20). Animals from all groups were killed in the middle of 
the light period at ZT 6 (13:00 h) or the dark period at ZT 18 (21:00 h) period of the 
12:12 LD cycle. The livers from all animals were excised, frozen at -80°C, packed in 
dry ice and transported to the University of Surrey where they were stored at -80°C 
until further analysis.
6.3.3 Tissue preparation
At the University of Surrey, liver samples were removed from -80°C storage and left 
on ice overnight. Once the livers defrosted, they were washed in ice-cold 
homogenising medium (1.15% v/v KC1) and blotted dry. Livers were weighed, 
scissor-minced and then homogenised on ice. The volume of the homogenate was 
adjusted to 25% (w/v) and then centrifuged at 10,000 x g for 20 minutes to remove 
cell debris, nuclei, mitochondria and lysosomes. The S9 supernatant was stored in 0.5 
ml aliquots at -80°C. The microsomal pellet was obtained by centrifuging the thawed 
S9 at 200,000 x g for 45 minutes. The supernatant was discarded and the microsomal 
pellet was kept on ice overnight in homogenising medium (1.15 v/v % KC1). The 
microsomal pellet was resuspended prior to use and kept on ice during the assay.
6.3.4 Analytical methods
The assay of ethoxyresorufin O-deethylase (EROD) was based on the method by 
Burke and Mayer (1974). Methoxyresorufin O-demethylase (MROD) was carried out
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as for EROD with the exception that methoxyresomfin 0.5 mM (10 pi) replaced 
ethoxyresomfin, and 100 pi of 25% microsomal suspension was used instead of 50 pi 
as in the EROD assay. Pentoxyresomfin Odepentylase (PROD) was based on the 
method by Lubet et al. (1985). The hydroxylation of p-nitrophenol to nitrocatechol 
carried out by the method by Reinke and Moyer (1985), as modified by McCoy and 
Koop (1988). An HPLC-based testosterone hydroxylase assay was employed to 
measure CYP-dependent testosterone metabolism in the liver (Tredger et al, 1984 
and M. Coulson personal communication). These methods are described in detail in 
Chapter 2.
Cytochrome P450 apoprotein levels were determined for CYP1A2, CYP2A1, 
CYP2B, CYP2C11, CYP2D1, CYP2E1, CYP3A and CYP4A using Western blotting 
technique. Images were captured and quantitated against the corresponding positive 
controls (induced microsomes) using GeneSnap® image capture utility software 
(Chapter 2).
Glutathione S-transferase activity was determined as described by Habig et al (1974). 
Two substrates were used, 1,2-dichlo-4-nitrobenzene (DCNB) or chloro-2,4- 
dinitrobenzene (CDNB). Glucuronosyl transferase activity was measured in the 
presence of 1-naphthol and UDP-glucuronic acid. This assay was adapted from the 
method devised by Bock and White (1974). Microsomal epoxide hydrolase activity 
was measured by the fluorimetric determination of the hydrolysis of benzo[ot]pyrene- 
4,5-epoxide to benzo[oc]pyrene-4,5-dihydrodiol based on the procedure described by 
Dansette et al. (1979). Detailed methodology is described in Chapter 2.
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6.3.5 Statistical analysis
The mean ± SEM was calculated for each sampling time point. One way ANOVA 
followed by post hoc analysis using the Student Neuman Keuls test established which 
groups and time points were significantly different (p < 0.05). Unpaired Student’s t- 
test was used to compare two groups. The 24 h rhythm of each enzyme activity was 
assessed by single cosinor analysis to provide the time of maximum activity 
(acrophase) and the amplitude (half of total predictable change in a rhythm).
6.4 Results
6.4.1 Daily rhythms in cytochrome P450 expression
A statistically significant light/dark rhythm was observed by single cosinor analysis 
(section 2.3) in the ethoxyresorufin O-deethylase activity, characterised by an 
amplitude of 1.9 pmol/min/mg protein and an acrophase occurring at ZT 19.5 (02:30 
h) (Table 6.1). The enzyme activity was lower during the light or the non-active 
period, with minimum activity occurring at ZT 6 (13:00 h) (Figure 6.1.) The mean 
enzyme activity during the light period was significantly lower compared with the 
mean enzyme activity during the dark period (Table 6.2). Minimum activity 
occurring at ZT 6 was significantly different from the maximum at ZT 22 (Table 6.3).
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Figure 6.1 Rhythmic pattern of CYP1A1 expression. CYPlAl-mediated by ethoxyresorufin O- 
deethylase (EROD). The data have been double plotted over 48-h to better visualise the rhythms. 
Values are presented as means ± SEM, n = 3-5 for each time point. The period o f darkness was from 
ZT 12 until ZT 24 and is indicated by the grey bars.
Table 6.1 Single cosinor analysis of ethoxyresorufin 0-deethylase, 
pentoxyresomfin 0-depentylase and/7-nitrophenol hydroxylase activities.
Chemical probe Amplitude Acrophase 
(clock time; ZT)
%
Rhythm
P
Ethoxyresorufin O-deethylase 
(CYP1A)
(pmol/min/mg protein)
1.9 02:30 h; 19.5 92.9 0.02*
Pentoxyresomfin O-depentylase 
(CYP2B1)
(pmol/min/mg protein)
0.2 03:20 h; 20.3 91.4 0.03*
p-Nitrophenol hydroxylase 
(CYP2E1)
(nmol/min/mg protein)
0.1 04:00 h; 21.0 93.3 0.02*
*p < 0.05
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The light/dark difference in methoxyresorufin O-demethylase activity, a probe for 
CYP1A2 activity, having minimum activity at ZT 10 during the light and maximum at 
ZT 22 during the dark period was not statistically significant (Figure 6.2.a). The 
apoprotein levels of CYP1A, that in the untreated rat reflects CYP1A2 expression, 
were minimum at ZT 10 and maximum at ZT 14, and were found to be higher during 
the dark period (Figure 6.2b). While the minimum levels occurred at the same 
zeitegeber time as the enzyme activity (ZT 10), the maximum apoprotein levels 
occurred earlier than the observed in methoxyresorufin O-demethylase activity (ZT 22 
versus ZT 14).
Table 6.2 Cytochrome P450 enzyme activities during 12:12 h light:dark 
conditions.
Chemical probe
n
Light
(mean ± SEM) n
Dark
(mean ± SEM)
Ethoxyresomfin O-deethylase 
(CYP1A1)
(pmol/min/mg protein)
12 7.7 ± 0.6 14 10.0 ± 0.6*
Methoxyresorufin O-demethylase 
(CYP1A2)
(pmol/min/mg protein)
12 12.6 ±1.1 14 14.4 ±1.0
Pentoxyresomfin O-depentylase 
(CYP2B1)
(pmol/min/mg protein)
12 1.33 ±0.1 13 1.60 ±0.1*
P-Nitrophenol hydroxylase 
(CYP2E1)
(nmol/min/mg protein)
12 0.36 ±0.04 14 0.44 ± 0.03
* light vs dark p  < 0.05
Hepatic CYP2B1, as reflected by pentoxyresomfin O-depentylase, showed a 
statistically significant light/dark rhythm with an amplitude 0.2 pmol/min/mg protein 
and the acrophase occurring at ZT 20.3 (03:00 h) (Table 6.1). The enzyme activity 
was low during the light period, started increasing in the early dark period and peaked
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at the end of the dark period at ZT 22 (Figure 6.3a). The mean enzyme activity during 
the light period was significantly lower compared with the dark period (Table 6.2). 
The minimum enzyme activity at ZT 6 (13:00 h) and ZT 10 (17:00 h) was 
significantly different compared with the maximum at ZT 22 (05:00 h) (Table 6.3). 
The CYP2B apoprotein levels support this finding, with minimum levels occurring at 
ZT 6 and maximum at ZT 22.
Table 6.3 Minimum and maximum of cytochrome P450 enzyme activities.
Chemical probe n ZT Minimum n ZT Maximum
(mean iSE M ) (mean ±SEM)
Ethoxyresorufin O-deethylase
(CYP1A1) 4 6 6.9 ±0.4 4 22 10.9 ±1.2*
(pmol/min/mg protein)
Methoxyresorufin O-demethylase
(CYP1A2) 3 10 10.5 ±0.6 4 22 15.2 ±1.4*
(pmol/min/mg protein)
Pentoxyresomfin O-depentylase
(CYP2B1) 4 6,10 1.27 ±0.05 4 22 0.72 ±0.2*
(pmol/min/mg protein)
P-Nitrophenol hydroxylase
(CYP2E1) 4 6,10 0.32 ±0.04 5 18,22 0.50 ±0.03**
(nmol/min/mg protein)______________________________________________________
*p < 0.05; ** p<  0.005 when minimum and maximum activities are compared
Hepatic CYP2E1, as determined by p-nitrophenol hydroxylase, showed a statistically 
significant light/dark rhythm with an amplitude of 0.1 nmol/min/mg protein and the 
acrophase occurring at ZT 21 (04:00 h) (Table 6.1). However, /7-nitrophenol 
hydroxylase activity did not show a statistically significant difference between the 
light and dark period (Table 6.2). The enzyme activity was lower during ZT 6, 10 and 
14 from the middle of the light period until the beginning of the dark period (Figure 
6.4a). Minimum enzyme activities occurred at ZT 6 and 10 were significantly
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(a)
different when compared with ZT 18 and 22 (Table 6.3). The apoprotein CYP2E1 
levels mirror the rhythmic pattern of p-nitrophenol hydroxylase activity (Figure 6.4b).
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Figure 6.2 Rhythmic pattern of CYP1A2 expression (a) C Y P1 A2-mediated methoxyresorufin O -  
demethylase (MROD) activity. The data have been double plotted over 48-h to better visualise the 
rhythms. Values are presented as means ± SEM, n = 3-5 for each time point. The period of darkness 
was from ZT12 until ZT24 and is indicated by the grey bars, (b) % levels of CYP1A apoprotein levels 
determined by Western blotting against a positive control (PC) comprising microsomes from |3- 
naphthophlavone-treated rats (c) gel showing CYP1A apoprotein levels at ZT2, 6, 10, 14, 18 and 22. 
Solubilised microsomal proteins were resolved by 10% (w/v) SDS-PAGE and transferred 
electrophoretically to nitrocellulose. The immunoblot was carried out with anti-rat CYP1A (diluted 
1:10000) followed by peroxidase-labelled anti-sheep IgG (diluted 1:2000). All lanes were loaded 
with 10 pg of protein.
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Figure 6.3 Rhythmic pattern of CYP2B expression (a) CYP2B-mediated activity measured by 
pentoxyresorufin O-depentylase (PROD). The data have been double plotted over 48-h to better 
visualise the rhythms. Values are presented as means ± SEM, n = 3-5 for each time point. The period of 
darkness was from ZT 12 until ZT 24 and is indicated by the grey bars, (b) % levels of CYP2B1 
apoprotein levels determined by Western blotting against a positive control (PC) comprising 
microsomes from phenobarbital-treated rats (c) gel showing CYP2B apoprotein levels at ZT2, 6, 10, 
14, 18 and 22. Solubilised microsomal proteins were resolved by 10% (w/v) SDS-PAGE and 
transferred electrophoretically to nitrocellulose. The immunoblot was carried out with anti-rat CY P2B1 
(diluted 1:1000) followed with peroxidase-labelled anti-goat IgG (1:10000 dilution). All lanes were 
loaded with 5 pg of protein.
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Figure 6.4 Rhythmic pattern of CYP2E1 expression (a) CYP2E1 activity measured by p-nitrophenol 
hydroxylase (PNPH). The data have been double plotted over 48-h to better visualise the rhythms. 
Values are presented as means ± SEM, n = 3-5 for each time point. The period of darkness was from 
ZT12 until ZT24 and is indicated by the grey bars, (b) % levels of CYP2E1 apoprotein levels 
determined by western blotting against a positive control (PC) comprising microsomes from acetone- 
treated rats (c) gel showing CYP2E1 apoprotein levels at ZT2, 6, 10, 14, 18, 22. Solubilised 
microsomal proteins were resolved by 10% (w/v) SDS-PAGE and transferred electrophoretically to 
nitrocellulose. The immunoblot was carried out with anti-rat CYP2E1 (diluted 1:500) followed by 
peroxidase-labelled anti-goat IgG (diluted 1:1000). All lanes were loaded with 2.5 pg of protein.
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Figure 6.5 Rhythmic pattern of CYP2C11 expression (a) CYP2C11 activity determined using 16a- 
testosterone hydroxylase. The data have been double plotted over 48-h to better visualise the rhythms. 
Values are presented as means ± SEM, n = 3-5 for each time point. The period of darkness was from 
ZT12 until ZT24 and is indicated by the grey bars, (b) % levels of CYP2C11 apoprotein levels 
determined by Western blotting against a positive control (PC) comprising microsome from 
Aroclor 1254-treated rats (c) gel showing CYP2C11 apoprotein levels at ZT2, 6, 10, 14, 18, 22. 
Solubilised microsomal proteins were resolved by 10% (w/v) SDS-PAGE and transferred 
electrophoretically to nitrocellulose. The immunoblot was carried out with anti-rat CYP2C11 (diluted 
1:1,000) followed by peroxidase-labelled IgG donkey (diluted 1:2,000). All lanes were loaded with 5 
pg of protein.
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Figure 6.6 Rhythmic pattern of CYP2A1/2 expression (a) CYP2A1/2 activity determined using 7a- 
testosterone hydroxylase. The data have been double plotted over 48-h to better visualise the rhythms. 
Values are presented as means ± SEM, n = 3-5 for each time point. The period of darkness was from 
ZT12 until ZT24 and is indicated by the grey bars, (b) % levels of CYP2A apoprotein levels 
determined by Western blotting against a control (C) of double amount untreated microsomes (c) gel 
showing CYP2A1/2 apoprotein levels at ZT2, 6, 10, 14, 18, 22. Solubilised microsomal proteins were 
resolved by 10% (w/v) SDS-PAGE and transferred electrophoretically to nitrocellulose. The 
immunoblot was carried out with anti-rat CYP2A1/2 (diluted 1:1,000) followed by peroxidase-labelled 
IgG anti-rabbit (diluted 1:2,000). All lanes were loaded with 10 pg of protein.
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16a-Testosterone hydroxylase, which reflects CYP2C11 activity in rat liver, failed to 
show a light/dark rhythm (Figure 6.5a). Moreover, the CYP2C11 apoprotein levels 
showed no difference between light and dark period (Figure 6.5b and Figure 6.5c).
CYP2A1/2 activity monitored by 7oc-testosterone hydroxylase, showed no difference 
between the light and dark periods (Figure 6.6a). Western blotting identified two 
bands. The apoprotein levels of CYP2A1 were found to be higher at ZT 14 and 22 
and lower at ZT 2, 6 and 18 (Figure 6.6.b).
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Figure 6.7 Rhythmic pattern of CYP2D1 expression (a) % levels of CYP2D1 apoprotein levels 
determined by Western blotting against a control (C) comprising microsomes from control rats (b) gel 
showing CYP2D1 apoprotein levels at ZT2, 6, 10, 14, 18, 22. Solubilised microsomal proteins were 
resolved by 10% (w/v) SDS-PAGE and transferred electrophoretically to nitrocellulose. The 
immunoblot was carried out with anti-rat CYP2D1 (diluted 1:500) followed by peroxidase-labelled IgG 
mouse (diluted 1:250). All lanes were loaded with 10 pg of protein.
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The minimum apoprotein levels of CYP2D1 appear to be at the end of the light period 
(ZT 10) and the end of dark period (ZT 22), while the maximum levels appeared to be 
reached at the dark period (ZT 14) and the light period (ZT 2) (Figure 6.8). The 
difference between the minimum and maximum levels were quite low and appear to 
follow a biphasic pattern.
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Figure 6.8 Rhythmic pattern of CYP4A expression (a) % levels of CYP4A apoprotein levels 
determined by Western blotting against a positive control (PC) comprising microsomes from clofibrate- 
treated rats (b) gel showing CYP4A apoprotein levels at ZT2, 6, 10, 14, 18, 22. Solubilised microsomal 
proteins were resolved by 10% (w/v) SDS-PAGE and transferred electrophoretically to nitrocellulose. 
The immunoblot was carried out with anti-rat CYP4A (diluted 1:1,000) followed by peroxidase- 
labelled IgG anti-sheep (diluted 1:2,000). All lanes were loaded with 2.5 (ig of protein.
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The apoprotein levels of CYP4A were maximal at ZT 20, at the end of the dark period 
and minimal at the beginning of the light period (ZT 2), but it does not appear to 
follow a light/dark rhythm.
No statistical difference was found between the light and dark period in testosterone 
7a-, 2a-, 16a-, 2(3-, 6a- hydroxylases and androstenedione hydroxylase activities 
(Figure 6.4).
Table 6.4 Testosterone metabolites during 12:12 h lightidark conditions.
Chemical probe
(pmol/min/mg protein) n
Light
(mean ±  SEM) n
Dark
(mean ± SEM)
Testosterone 7a-hydroxylase 
(CYP2A1/2)
11 227 ± 33 13 190 ±29
Testosterone 2a-hydroxylase 
(CYP2C11)
11 605 ± 57 13 507 ±74
Testosterone 16a-hydroxylase 
(CYP2C11)
11 653 ± 73 13 578 ± 90
Testosterone 6|3-hydroxylase 
(CYP3A1/2)
11 186 + 22 13 218 ±33
Testosterone 2|3-hydroxylase 
(CYP3A1/2)
11 202 ±37 10 146 ± 19
Testosterone 16|3-hydroxylase 10 172 ±35 10 173 ± 27
Testosterone 6a-hydroxylase 12 165 ±22 14 136 ± 22
Androstenedione hydroxylase 11 653 ±69 13 583 ± 68
Testosterone 7a-hydroxylase activity, which reflects CYP2A1/2, was significantly 
different between the maximum occurring at the beginning of the light period (ZT 2) 
and the minimum that occurred at ZT 14, at the beginning of the dark period (Table 
6.5). Androstenedione hydroxylase activity showed a significant difference, with
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maximum at ZT 2, the beginning of the light period, and minimum at ZT 14, the 
beginning of the dark period (Table 6.5). Testosterone 2a- and 16a-hydroxylase 
activities, which both reflect CYP2C11, showed no statistical difference between the 
light and the dark period (Table 6.5). Testosterone 6p- and 2p-hydroxylase activities, 
which both reflect CYP3A1/2 activity, had a contrasting profile and no significant 
difference between light and dark period was observed (Table 6.5). Testosterone 16p- 
and 6a-hydroxylase activities failed to show a light-dark difference (Table 6.5).
Table 6.5 Minimum and maximum activity of testosterone metabolites.
Chemical probe
(pmol/min/mg protein)
n ZT Minimum
(mean ±SEM)
n ZT Maximum
(mean ±SEM)
Testosterone 7a-hydroxylase 
(CYP2A1/2) 4 14 168 ±27 4 2 292 ±48*
Testosterone 2a-hydroxylase 
(CYP2C11) 5 14 425 ± 126 3 10 721± 153
Testosterone 16a-hydroxylase 
(CYP2C11) 4 22 440± 104 3 10 826 ± 195
Testosterone 6P-hydroxylase 
(CYP3A1/2) 4 6 125 ±24 4 18 248 ± 75
Testosterone 2P-hydroxylase 
(CYP3A1/2) 4 18 139 ±16 3 10 227 ± 55
Testosterone 16p-hydroxylase 4 14 89 ±40 2 22 265 ±46
Testosterone 6a-hydroxylase 5 14 120 ±41 4 6 165 ±44
Androstenedione hydroxylase 5 14 476 ± 82 4 2 804 ± 92*
*p < 0.05 minimum vs maximum activity
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6.4.2 Expression of daily rhythm in conjugation enzymes
In all phase II activities studied no differences were noted between the light and the 
dark periods (Table 6.6). Similarly, the differences between maximal and minimal 
activities were not statistically different (Table 6.7).
Table 6.6 Phase II enzyme activities during 12:12 h lightidark conditions.
Chemical probe n Light
(mean ±SEM)
n Dark
(mean ±SEM)
GST towards CDNB 
(pmol/min/mg protein) 12 0.56 ± 0.02 14 0.58 ±0.02
GST towards DCNB 
(nmol/min/mg protein) 12 22.4 ±1.5 14 25.3 ±1.3
UDP-glucuronyltransferase 
(nmol/min/mg protein) 12 0.71 ±0.04 14 0.63 ± 0.04
Epoxide hydrolase 
(nmol/min/mg protein) 12 0.90 ± 0.03 14 1.0 ±0.06
Table 6.7 Minimum and maximum of phase II enzyme activities.
Chemical probe n ZT Minimum
(mean ±  SEM)
n ZT Maximum
(mean ±  SEM)
GST towards CDNB 
(pmol/min/mg protein) 3 10 0.48± 0.06 5 18 0.62 ± 0.04
GST towards DCNB 
(nmol/min/mg protein) 3 10 18.9 ±4.2 4 6 27.0 ±1.3
UDP-glucuronyltransferase 
(nmol/min/mg protein) 5 14 0.56 ±0.1 3 10 0.77 ±0.1
Epoxide hydrolase 
(nmol/min/mg protein) 3 10 0.88 ± 0.05 5 14 1.08 ±0.15
All phase II enzyme activities measured failed to show a statistically significant 
light/dark rhythm (Figure 6.9; Figure 6.10; Figure 6.11).
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Figure 6.9 Rhythms in glutathione S-transferase (a) Cytosolic GST activity was determined utilising 
chloro-2,4-dinitrobenzene (CDNB) (b) cytosolic GST activity determined using 2-dichloro-4- 
nitrobenzene as substrate (DCNB). The data have been double plotted over 48-h to better visualise the 
rhythms. Values are presented as means ± SEM, n = 3-5 for each time point. The period of darkness 
was from ZT 12 until ZT 24 and is indicated by the grey bars.
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Figure 6.10 Rhythms in UDP-glucuronide transferase. Microsomal UDP-glucuronosyl transferase 
activity using 1-naphthol as substrate. The data have been double plotted over 48-h to better visualise 
the rhythms. Values are presented as means ± SEM, n = 3-5 for each time point. The period o f darkness 
was from ZT 12 until ZT 24 and is indicated by the grey bars.
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Figure 6.11 Rhythms in epoxide hydrolase. Activity was determined using benzo [a]pyrene-4,5- 
dihydrodiol as substrate. The data have been double plotted over 48-h to better visualise the rhythms. 
Values are presented as means ± SEM, n = 3-5 for each time point. The period of darkness was from 
ZT 12 until ZT 24 and is indicated by the grey bars.
Chapter 6 -  Daily rhythms in rat hepatic drug metabolising enzymes 167
6.4.3 Effect of SCN and PVN lesions on daily rhythms
Animals were surgically lesioned according to the procedure already described 
(section 2.2.9). After the lesion procedure the animals had a rest period of 2 weeks to 
recover from the trauma of anesthesia and brain trauma. Complete lesions of the SCN 
were assumed to have the animals showing a daytime water intake of more than 30% 
of the total daily intake. Age-matched intact and sham operated controls as well as 
the lesioned animals were killed at ZT 6 in the light period and ZT 18 in the dark 
period. These time points were chosen on the basis of the daily rhythms already 
described earlier (section 6.4.1). The two groups, intact and sham operated controls 
were compared with the complete SCN- and PVN- lesioned animals, also with intact 
and sham operated groups being combined to form a single control group.
The daily rhythm in ethoxyresorufin O-deethylase (EROD) activity remained, with 
significantly higher activity occurring at the middle (ZT 18) of the dark period in the 
intact animals and in the group of intact and sham-operated grouped together (Figures 
6.12) as it was observed in the previous experiment (section 6.4.1). In the complete 
SCN-lesioned animals the EROD activity increased at the light period and decreased 
at the dark period and subsequently the rhythm disappeared (Figure 6.12). The effect 
of PVN lesions was different to that of SCN-lesions since it decreased significantly 
the EROD activity at both the light and dark period compared with the intact and the 
grouped together intact and sham-operated animals. Also, in the PVN-lesioned there 
was no significant difference between the light and the dark period (Figure 6.12).
In this experiment no significant rhythm was found in the activity of PROD in the 
intact animals as it was observed in the previous experiment (section 6.4.1), possibly
Chapter 6 -  Daily rhythms in rat hepatic drug metabolising enzymes 168
because the significant difference between the light and the dark period occurred 
previously at a different time point during the dark period (ZT 22 instead of ZT 18). 
However, there was a significant daily rhythm when the intact and the sham-operated 
were grouped together (Figure 6.13). The complete SCN-lesioned animals exhibited 
as well, a daily rhythm, with the activity being slightly but not significantly lower at 
the dark period (Figure 6.13), demonstrating that the SCN is not affecting this daily 
rhythm in PROD activity. PVN-lesions increased the activity at light period and 
decreased the activity at dark period resulting to the disappearance of the daily rhythm 
(Figure 6.13).
In contrast, to the previous experiment the p-nitrophenol hydroxylase activity that 
followed a clear light-dark rhythm, in this experiment the difference was not quite 
significant (Figure 6.14). This could be due to the fact that only two time points, one 
in the middle of the light and one in the middle of the dark period, were only chosen 
since the minimum was previously observed at ZT 10 and the maximum at ZT 22 
(Figure 6.4). However, in the experiment the complete SCN-lesioned animals show 
no significant difference between the light and the dark period and the activity seems 
decreased at the dark period (Figure 6.14). The PVN-lesions had no effect on the 
daily rhythm of p-nitrophenol hydroxylase activity (Figure 6.14).
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Figure 6.12 Role o f SCN and PVN in the daily rhythm in the hepatic EROD activity, (a) EROD 
activity was determined in intact, sham-operated, complete-SCN and PVN-lesioned animals at the 
middle of the light (ZT 6) and the dark (ZT 18) period, (b) EROD activity in intact and sham-operated 
animals grouped together. * p  < 0.05, ** p  < 0.01 compared with the corresponding night values; f p < 
0.05; f f p < 0.01 compared with the corresponding intact and sham light and dark values.
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Figure 6.13 Role of SCN and PVN in the daily rhythm in the hepatic PROD activity, (a) PROD 
activity was determined in intact, sham-operated, complete-SCN and PVN-lesioned animals at the 
middle of the light (ZT 6) and the dark (ZT 18) period, (b) PROD in intact and sham-operated animals 
grouped together. ** p  < 0.01 compared with the corresponding night values.
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Figure 6.14 Role of SCN and PVN in the daily rhythm in the hepatic p-nitrophenol hydroxylase 
activity, (a) p-Nitrophenol hydroxylase activity was determined in intact, sham-operated, complete- 
SCN and PVN-lesioned animals at the middle of the light (ZT 6) and the dark (ZT 18) period, (b) p- 
Nitrophenol hydroxylase activity in intact and sham-operated animals grouped together.
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6.5 Discussion
The principal objectives of the present study were to investigate the existence of light- 
dark rhythms in the activity and expression of individual cytochrome P450 enzymes 
(phase I) and conjugation (phase II) systems in the liver of male rats, and to define the 
role of SCN, PVN in such light-dark rhythms.
6.5.1 Daily rhythms in xenobiotic-metabolising enzyme in rat liver
It was observed that ethoxyresorufin O-deethylase (CYP1A1), pentoxyresorufin O- 
depentylase (CYP2B), and p-nitrophenol hydroxylase (CYP2E1) activities showed 
significant day/night rhythms following single cosinor analysis, with peak activities 
(acrophases) occurring during the dark period of the LD cycle. Immunological 
analysis by Western blotting of CYP2B1 and CYP2E1 enzymes showed that the 
apoprotein levels followed a similar pattern, suggesting that the day/night difference 
in activity is a consequence of different enzyme levels. The current findings are in 
agreement with the results from previous studies in that there is a light dark rhythm in 
some cytochrome P450 enzymes (Nair and Casper, 1969; Jori et al 1971; Lake et al 
1976; Furukawa et al, 1999). However, in the previous studies the activities 
measured could not be attributed to specific P450 enzymes, thus the present study, 
using selective chemical probes, investigated for the first time the activities of 
individual P450 enzymes.
However, not all the cytochrome P450 enzymes exhibited a clear daily rhythm. 
C YP1 A2-mediated activity measured by methoxyresorufin Odemethylase, 
CYP2A1/2 determined by 7oc-testosterone hydroxylase, CYP2C11 measured by 16a- 
testosterone hydroxylase, CYP2D1 and CYP4A measured by Western blotting failed
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to show any light/dark difference. In contrast, CYP2A1/2 determined by 7a- 
testosterone hydroxylase activity as well as androstenedione hydroxylase were found 
to be significantly higher at ZT 2 (light period) and lower at ZT 14 (dark period), 
suggesting that not all cytochrome P450 enzyme activities peak during the dark 
period.
Daily rhythms in phase II enzyme activities were also determined. Glutathione S- 
transferase activities did not show a light/dark difference. This finding is not in 
agreement with a previous study demonstrating that in male mouse glutathione S- 
transferase activity toward l-chloro-2,4-dinitrobenzene (CDNB) was higher during 
the light period and lower during the dark period (kioue, et al, 1999). The same 
study showed that glutathione S-transferase activities toward CDNB and 1,2-dichloro- 
4-nitrobenzene (DCNB) were maximal at 13:00 h and minimal at 01:00 h and this 
difference was also observed in the female mouse. According to our study, 
glucuronyl transferase as well as epoxide hydrolase activity appear not to display a 
light/dark difference.
6.5.2 Role of suprachiasmatic nuclei in the rhythmic pattern of 
cytochrome P450
The second study investigated whether the lesioning of the SCN could impair the 
light/dark rhythms of ethoxyresorufin O-deethylase, pentoxyresorufin O-depentylase, 
and p-nitrophenol hydroxylase activities. SCN lesions abolished the light/dark 
rhythm in EROD and p-nitrophenol activities, but had no effect on PROD, suggesting 
that the involvement of the endogenous SCN circadian pacemaker in their regulation 
is probably more indirect than direct. This finding is partly in agreement with a
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pervious study (Furukawa et al, 1999) were it was also observed that the light-dark 
difference in 7-alkoxycoumarin O-dealkylase activities were eliminated in SCN- 
lesioned rats. However, it should be noted that disappearance of a light/dark rhythm 
in EROD and p-nitrophenol activities following SCN lesions, as observed in our 
study, does not prove unequivocally direct SCN clock control, because in SCN- 
lesioned animals other rhythmic signals may also become arrhythmic e.g. the 
endogenous melatonin rhythm.
6.5.3 Role of paraventricular nucleus in the rhythmic patterns of 
cytochrome P450
Lesions of the PVN resulted in disappearance of the light/dark rhythm of 
ethoxyresorufin O-deethylase and pentoxyresorufin O-depentylase activity. In 
addition, a decrease in the overall activity of ethoxyresorufin O-deethylase was 
observed. It is worth noting that PVN lesions significantly increased the body weight 
of the animals. The livers of the PVN lesioned animals were clearly more fatty 
compared with the livers from the intact, sham-operated and SCN-lesioned groups.
6.5.4 Significance of daily rhythms in P450 activity
The synchronisation of behavioural rhythms such as rest-activity cycle, to the 24-hour 
day is by environmental cues, primarily the light-dark cycle (section 1.1.5.1). 
Biotransformation enzymes, such as the cytochrome P450, are essential for initiating 
conversion of lipophilic xenobiotics into more hydrophilic metabolites. They reduce 
the half-life of and duration of exposure to xenobiotics and prevent accumulation of 
the parent compounds. It is important to note that excessive cytochrome P450 activity 
without adequate concomitant conjugating activity may be a risk factor for cancer
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(Vermeulen, 1996). The present studies revealed that the activity of a number of 
cytochrome P450 enzymes in the rat liver are higher during the dark period of the 
12:12 h lightidark cycle i.e. at the period when physical activity and feeding occurs.
CYP1A1 is mostly an extrahepatic enzyme (loannides et al., 1990) and with CYP1A2 
play a dominant role in the bioactivation of planar toxic and carcinogenic chemicals 
(loannides and Parke, 1990; Gonzalez and Gelboin 1994). The CYP1A family 
appears to be the most conserved within the phylogenetic tree, so that the human 
proteins have similar substrate specificity to that of the rodents (Gondalez, 1992). 
The CYP2B family is predominantly involved in the metabolism of exogenous 
chemicals many of which also induce CYP2B. The CYP2E1 enzyme shows restricted 
substrate specificity towards small molecular weight compounds (Bonis et al., 1993), 
and plays an important role in the bioactivation of drugs, such as paracetamol 
(acetaminophen) and chemical carcinogens such as dimethylnitrosamine and carbon 
tetrachloride. The toxicity linked to CYP2E1 is mediated partly by its propensity to 
produce reactive oxygen species that give rise to lipid peroxidation (Bonis et al., 
1993). These three cytochrome P450 enzymes were shown to have higher activity 
during the dark period, which in rodents represents their subjective day, where all the 
physical activity and most of the feeding occurs, and subsequently there is a increased 
need for detoxification. Extrapolating these findings to humans it would be expected 
that, in these cytochrome P450 enzymes, higher activity occurs during the light period 
of the 24-hour day, where most of the physical activity and feeding normally occurs. 
However, this should be demonstrated in in vitro studies, using appropriate probes 
such as caffeine in the case of CYP1A2 (Kalow and Tang, 1991; Butler et al., 1992; 
Basmussen and Brosen, 1996) and chlorzoxazone in the case of CYP2E1 (Lucas et
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al., 1999). At present no validated probe for CYP1A1 activity in the body is 
available. Finally, the present study demonstrated that the biological clock in the 
brain, the suprachiasmatic nuclei, plays a major role in the regulation of the light/dark 
rhythm of these cytochrome P450 enzymes, although the mechanism remains to be 
elucidated.
In conclusion, the present study illustrates that ethoxyresorufin O-deethylase, 
pentoxyresorufin O-depentylase and p-nitrophenol hydroxylase activities in rat liver 
display a daily rhythm. It has also been demonstrated that the rhythm in EROD and p- 
nitrophenol hydroxylase disappeared after lesioning the SCN, suggesting that the SCN 
may indirectly coordinate the expression of some of these light-dark rhythms. 
Bearing in mind that these activities can be modulated more effectively by exposure 
to environmental and dietary chemicals and the presence of disease, and that the 
differences between maximum and minimum are small, these light/dark rhythms 
observed in the current study may have little relevance clinically. It is conceivable 
that with drugs having a narrow therapeutic index (i.e. drugs which have to be 
maintained within a narrow concentration range in the blood), it might be of more 
importance, since drug efficacy may differ, depending whether the drug is taken 
during the light or the dark period.
This study also shows that the major cytochrome P450 subfamilies that are 
responsible for the metabolism of drugs, namely CYP3A, CYP2C and CYP2D do not 
display a daily rhythm. Consequently, it is reasonable to infer that the impact the 
light/dark rhythm of CYP1A1, CYP2B1 and CYP2E1 enzyme activities specifically 
on hepatic drug metabolism will be at best limited.
CHAPTER SEVEN
GENERAL DISCUSSION
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7.1 Introduction
In the UK and most European Countries melatonin is considered to be a drug and is 
only available on prescription from a physician for the alleviation of jet-lag symptoms 
and other circadian related sleep disorders (section 1.1.4.1). In contrast, in the USA, 
melatonin is considered a dietary supplement and is sold by health food stores. It is 
therefore not regulated with regard to effectiveness, purity and adverse effects by the 
U.S. Food and Drug Administration.
Even though melatonin appears to be safe and causes few clinical side effects (Arendt, 
1997), limited data are available about the enzyme system that catalyses its 6- 
hydroxylation, the principal hepatic metabolic pathway, and potential interactions 
when is taken with other medications. Knowledge of the enzymes involved in the 
hepatic 6-hydroxylation of exogenous melatonin would enable the prediction of 
potential metabolic interactions, when it is taken with other therapeutic agents, and 
alert physicians to adverse drug combinations involving melatonin. Hence, a major 
objective of the present project was to identify the specific enzymes that catalyse the 
hepatic 6-hydroxylation of melatonin at pharmacological concentrations using the rat 
liver a model system.
7.2 Chapter 3: Melatonin 6-hydroxylation by 
cytochrome P450 enzymes
Our preliminary findings indicated that the cytochrome P450 enzyme system 
catalyses the 6-hydroxylation of exogenous melatonin, since this reaction was found 
to be NADPH- and O2- dependent, which both characterise cytochrome P450
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enzymes (section 3.3.2.1). In addition, another study supported the involvement of 
cytochrome P450 enzymes in the metabolism of melatonin (Yeleswaram et al, 1999). 
In this study, using CYP enzymes expressed in p-lymphoblastoid cell lines, it was 
found that CYP1A1 and CYP1A2 contributed mostly in the metabolism of melatonin 
(50 pM) in their incubation system. A limitation of this study was that the actual 
generation of 6-hydroxymelatonin, the major metabolite of melatonin was not 
measured. Findings from the current studies (Chapter 3) clearly demonstrated that in 
the rat liver the principal enzyme responsible for the 6-hydroxylation of exogenous 
melatonin is CYP1A2. A limitation of the method used in this project was that it does 
not measure the product of 6-hydroxylation, i.e. 6-hydroxymelatonin, but the final 
metabolite, 6-sulphatoxymelatonin. However, this limitation was partially overcome 
by determining the conversion of melatonin to 6-sulphatoxymelatonin, as well as the 
conversion of 6-hydroxymelatonin to 6-sulphatoxymelatonin. This way it was feasible 
to identify whether the effect was at the 6-hyroxylation or the sulphate conjugation 
metabolic step of melatonin. Our findings in rat liver are in agreement with a study 
published while the current investigations were in progress, showing that exogenous 
melatonin 6-hydroxylation is also almost exclusively mediated by CYP1A2 in human 
liver (Facciola et a l, 2001). This study examined the contribution of CYP enzymes in 
the 6-hydroxylation and the O-demethylation of exogenous melatonin using human 
liver microsomes, as well as cDNA yeast-exressed human enzymes in combination 
with selective CYP inhibitors and substrates. They found that fluvoxamine, similarly 
to our results, potently inhibited the 6-hydroxylation of melatonin. Also, furafylline, 
sulphaphenazole and omeprazole appeared to inhibit both 6-hydroxylation and O- 
demethylation of melatonin. Moreover, according to their finding these researchers 
suggest that the role of CYP2C19 and CYP2C9 appeared to be less important
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compared with CYP1A2 in the 6-hydroxylation of exogenous melatonin. The finding 
of Facciola et al. (2001) that CYP1A2 is the major enzyme involved in the 6- 
hydroxylation in the human liver is in accordance with our findings in the rat liver 
(Chapter 3), which is conceivable since rodent CYP1A2 displays similar substrate 
specificities to the orthologous human protein (Kawajiri and Hayashi, 1996). Our 
findings have been supported from a very recent study demonstrating that melatonin 
(10 jiM), using 11 different human recombinant cDNA-expressed cytochrome P450 
enzymes, is primarily metabolised by CYP1A2, with a contribution from CYP1A1, 
CYP1B1 and CYP2C19 (Ma et al., 2005). Taking into consideration that both 
CYP1A1 and CYP1B1 are mainly extrahepatic enzymes, this recent study confirms 
our results that CYP1A2 is the major cytochrome P450 enzyme involved in the 
hepatic 6-hydroxylation of melatonin. The authors suggest that a minor contribution 
of CYP1B1 in the hepatic 6-hydroxylation of melatonin should not be excluded (Ma 
et al., 2005). In addition, this study found that CYP1B1 is responsible for 
approximately 40% of melatonin 6-hydroxylation in mouse brain homogenate 
melatonin. In our studies the role of CYP1B1 was not specifically assessed due to the 
lack of a selective inhibitor. Since, in our induction studies (section 3.4.3), pre­
treatment of animals with the CYP1 family inducer, p-naphthoflavone, nearly doubled 
the formation of 6-sulphatoxymelatonin, the possibility of a minor contribution from 
CYP1B1 could not be excluded. Unfortunately, due to the lack of a selective 
CYP1B1 inhibitor, at the time when these experiments conducted, there was no 
possibility to examine the role of this enzyme in the 6-hydroxylation of melatonin in 
our inhibition studies. Based on the finding that oc-naphthoflavone, a 
substrate/competitive CYP1B1 inhibitor (Shimada et al., 1997), inhibited the 
metabolism of melatonin may provide some evidence on a role of CYP1B1 in the
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hepatic 6-hydroxylation of exogenous melatonin. Recently, it was reported that the 
compound 2,4,3',5'-tetramethoxystilbene is a selective and potent CYP1B1 inhibitor 
(Kim et al., 2002).
7.3 Chapter 4: Inhibition of melatonin 6-hydroxylase
Based on the finding that exogenous melatonin is primarily 6-hydroxylated by 
CYP1A2 (chapter 3), the subsequent objective was to evaluate whether drugs that are 
likely to be co-administered with melatonin, could interact with melatonin through 
CYP1A2 inhibition, decreasing its metabolism and hence potentially leading to higher 
melatonin plasma concentrations.
In the present study, of all the drugs assessed, fluvoxamine and 5-methoxypsoralen 
were the most potent inhibitors of the 6-hydroxylation of exogenous melatonin in the 
rat liver (section 4.4.3.2). The observed inhibitory effect of fluvoxamine can be 
explained by the fact that it is a well-established CYP1A2 inhibitor (Brosen et al,
1993). In agreement with our observations, administration of fluvoxamine (50 mg) 
three hours before the administration of melatonin (5 mg) to humans significantly 
increased melatonin serum concentrations compared to melatonin alone (Hartter et ah, 
2000). More specifically fluvoxamine caused a nine-fold increase in the area under 
the concentration time-curve (AUC) and a six-fold increase in maximum 
concentration (Cmax) of serum melatonin. However, the elimination half-life appeared 
not be affected. In the Hartter et al. (2000) study, the serum concentration of 
melatonin was 2.5 ng/ml (equivalent to 0.011 pM) and in our in vitro study the 
concentration of melatonin used was much higher at 50 pM. Also, in the same study,
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the serum concentration of fluvoxamine was 10 ng/ml (equivalent to 0.0314 JiM) 
whereas in our study the concentration that was found to significantly decrease the 
metabolism of melatonin was 50 yM. It is difficult to compare the in vivo 
concentrations of melatonin and fluvoxamine with the in vitro concentrations, since it 
is clear that the in vivo concentrations were much lower. The fact that a single dose of 
fluvoxamine led to elevated endogenous melatonin concentrations at night (Skene et 
al., 1994) suggests, but does not prove, that endogenous melatonin could be 
metabolised, at least in part, by CYP1A2.
The inhibitory effect of 5-methoxypsoralen on the 6-hydroxylation of exogenous 
melatonin was more potent in human than in rat liver, suggesting either that 5- 
methoxypsoralen is a more potent CYP1A2 inhibitor in the human liver or that it is 
less specific CYP1A2 inhibitor in the rat. Based on the fact that 5-methoxypsoralen 
has been found to reduce hepatic caffeine metabolism in patients with psoriasis 
(Bendriss et al., 1996), the mechanism by which this inhibition may occur is by a 
decrease in CYP1A2 activity. Our in vitro finding is also supported by an in vivo 
study where administration o f 5-methoxypsoralen together with melatonin (100 or 1 
pg) significantly increased the half-life of melatonin in rats (Mauviard et al., 1995).
Interestingly, caffeine, a CYP1A2 substrate, appears not to affect the in vitro 6- 
hydroxylation of exogenous melatonin, possibly by being metabolised through other 
pathways, and hence not interfering with the CYP1 A2-mediated 6-hydroxylation of 
melatonin. This observation is supported by another study where caffeine failed to 
inhibit the metabolism of melatonin in vitro (Facciola et al., 2001). In contrast, when 
administered in vivo, caffeine appears to decrease the metabolism of exogenous
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melatonin, as indicated in a study when caffeine (200 mg) was administered one hour 
before melatonin (6 mg). This dose of caffeine, which is equivalent to one to two 
cups of coffee, increased the plasma maximum concentrations (Cmax) on average 
137% and the area under the concentration-time curve (AUC) of melatonin by 120%, 
while it decreased its clearance (Hartter et al, 2003), suggesting that caffeine 
competes with melatonin for the CYP1A2 enzyme. Therefore, it appears that our 
finding that caffeine had no inhibitory effect on 6-hydroxylation of melatonin cannot 
be extrapolated to the in vivo situation.
Caffeine could also have an influence on the endogenous melatonin profile according 
to our results (Chapter 5), showing that animals pre-treated with caffeine excreted 
significantly more 6-sulphatoxymelatonin during the night compared with the 
controls. Moreover, cosinor analysis revealed that animals pre-treated with caffeine 
had no significant 6-sulphatoxymelatonin rhythms compared with controls that 
showed a clear rhythm in the 24 h 6-sulphatoxymelatonin profile. A future study 
should investigate the effect of long-term caffeine intake on the 24 h endogenous 6- 
sulphatoxymelatonin rhythm. This study could be designed as a crossover study 
using the same group of non-smoking volunteers. During one study period, 
volunteers would have to abstain from caffeine as well as from other well-known 
CYP1A2 inducers, for a period of a month followed by determination of their 24 h 
urinary 6-sulphatoxymelatonin profile. During the second study period, volunteers 
would have to follow a high in caffeine diet for a month period followed by 
determination of their 24 h urinary 6-sulphatoxymelatonin profile. A possible 
outcome of this study could possibly be that the high in caffeine diet may impair the 
24 h urinary 6-sulphatoxymelatonin rhythm of volunteers. Also, volunteers after the
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period on the high caffeine diet may excrete significantly more 6- 
sulphatoxymelatonin in the urine compared with the amount excreted after the one 
month period of caffeine abstinence.
Investigation of the interaction between 17oc-ethinyloestradiol and melatonin showed 
that 17a-ethinyloestradiol decreased the hepatic metabolism of exogenous melatonin 
not via the 6-hydroxylation pathway but by the sulphate conjugation of 6- 
hydroxymelatonin. Such a mechanism may explain to some extent why melatonin 
levels during the night are higher in females taking oral contraceptives (Brun et al, 
1987; Webley and Leidenberger, 1986; Wright and Badia, 1999). It is conceivable 
that the 17a-ethinyloestradiol competes with 6-hydroxymelatonin for the 
sulphotransferase substrate-binding site since sulphation is an important pathway in 
the metabolism of 17oc-ethinyloestradiol (Pacifici and Back, 1988). Since 17a- 
ethinyloestradiol appeared to decrease the sulphate conjugation of 6- 
hydroxymelatonin, it would be advisable in studies assessing melatonin treatment to 
exclude volunteers that use oral contraceptives because it could influence their 
melatonin profiles.
Finally, the drugs diazepam, tamoxifen and acetaminophen did not influence the 6- 
hydroxylation of melatonin suggesting that these drugs coadministered with melatonin 
will not cause an increase in plasma melatonin levels.
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7.4 Chapter 5: Effect of caffeine on urinary 6- 
sulphatoxymelatonin excretion
It has been proposed that melatonin, being primarily metabolised by the CYP1A2 
enzyme could be used for assessment of hepatic CYP1A2 activity in humans (Hartter 
et dl, 2003), as an alternative method to caffeine (Tassaneeyakul et al., 1994). The 
main advantage of melatonin as a probe drug for CYP1A2 activity over caffeine is 
that it is almost exclusively metabolised by CYP1A2, while caffeine jV-demethylation 
reactions with low affinity are catalysed by CYP2E1 (Gu et al, 1992; Chung and Cha, 
1997) and, moreover, caffeine is metabolised by xanthine oxidase to a number of uric 
acid derivatives (Reinke et a l, 1987; Kalow and Tang, 1991).
The idea to use melatonin as a marker of CYP1A2 activity in vivo was tested in rats 
by measuring the urinary excretion of the main metabolite of melatonin, 6- 
sulphatoxymelatonin, from both endogenous and exogenous melatonin (Chapter 5). 
These studies revealed that the nocturnal peak of urinary 6-sulphatoxymelatonin 
appears to reflect the in vitro rat hepatic CYP1A2 activity (section 5.4.2). In addition, 
the CYP1 A2-induced animals given caffeine pre-treatment, had significantly higher 
endogenous nocturnal peaks of urinary 6-sulphatoxymelatonin compared with 
controls. This finding in animals leads to the speculation that people who drink high 
amounts of coffee on a daily basis may excrete more 6-sulphatoxymelatonin during 
the night. If proven this would provide indirect evidence that CYP1A2 may also be 
involved in the hepatic 6-hydroxylation of endogenous melatonin. If proven, then 
measurement of the endogenous nocturnal peak of urinary aMT6s could be a useful 
non-invasive index of CYP1A2 activity in humans. Measurement of the endogenous
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nocturnal peak of urinary 6-sulphatoxymelatonin could be a useful non-invasive index 
for CYP1A2 activity in humans.
An outstanding question is whether the well-known inter-individual variation in 
endogenous 6-sulphatoxymelatonin levels could be explained by the inter-individual 
variation in CYP1A2 activity. A future study could be done investigating the 
contribution of CYP1A2 to the variability of endogenous melatonin metabolism and 
how this could influence its profile. In this study, the 24 h urinary 6- 
sulphatoxymelatonin profile could be compared between a group of subjects with low 
CYP1A2 activity (non-smokers and no caffeine intake) with subjects with high 
CYP1A2 (smokers and high caffeine intake). The in vivo CYP1A2 activity could also 
be measured using the caffeine to metabolite ratio method (Kalow and Tang, 1991). 
The association between each subject’s CYP1A2 activity and their 24 h 6- 
sulphatoxymelatonin profile may provide evidence of the contribution of CYP1A2 
variation in the interindividual variation of endogenous melatonin in humans.
The urinary excretion of 6-sulphatoxymelatonin between 08 to 12 h after an 
intraperitoneal injection of melatonin reflected the hepatic CYP1A2 activity measured 
in vitro, suggesting that, at least in rats, this time period could be used as a marker of 
CYP1A2 activity. Similar to our study, other researchers have tested this hypothesis 
in humans and found that melatonin and caffeine clearance was significantly 
correlated (Hartter et al, 2001) supporting the idea that exogenous melatonin 
metabolism can reflect CYP1A2 activity in humans. Further studies are needed in 
order to establish whether the measurement of urinary 6-sulphatoxymelatonin
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excretion following melatonin administration can be used as an alternative probe to 
caffeine to asses CYP1A2 activity in humans.
In humans, CYP1A2 activity is considerably induced by cigarette smoking (Sesardic 
et al., 1988), and thus it would be reasonable to expect that exogenous melatonin 
would be more quickly metabolised by 6-hydroxylation, leading to lower plasma 
melatonin levels in smokers than in non-smokers. A study examined the melatonin 
serum concentrations following melatonin administration (25 mg) in habitual smokers 
before and after one week of smoking abstinence (Ursing et al, 2005). This study 
showed that melatonin serum concentrations were significantly lower after one week 
of smoking abstinence, suggesting that smoking can increase the hepatic metabolism 
of exogenous melatonin. These results agree with our findings on the effect of 
caffeine pre-treatment on exogenous melatonin metabolism. However, there is 
another study that found that the endogenous serum melatonin levels during the day 
time (11:00 -  12:00 h) were higher in smokers than in non-smokers (Tarquini et al,
1994). Unfortunately, this study did not measure the nocturnal endogenous melatonin 
profiles in these two groups. In addition, a future study is needed to investigate the 
effect of smoking on the endogenous levels of melatonin. In this study, habitual 
smokers should be assessed as in the Ursing et al. (2005) study with the difference 
that melatonin would not be administered exogenously. The 24h urinary 6- 
sulphatoxymelatonin profiles would be determined on two occasions, before and after 
one week of smoking abstinence.
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7.5 Chapter 6: Daily rhythms in rat hepatic drug 
metabolising enzymes
In the present study, the aim was to examine whether a selection of individual 
cytochrome P450 enzymes and a selection of conjugation drug-metabolising enzymes 
in rat liver exhibit a 24-h daily rhythm in the rat liver (Chapter 6). Data from these in 
vitro studies revealed that not all hepatic drug-metabolising enzymes display a light- 
dark rhythm. Of all the enzymes examined, CYP1A1, CYP2B1 and CYP2E1 
demonstrated a light-dark rhythm, all with minimum activity occurring during the 
light period and maximum activity during the dark period. This finding is in 
agreement with the study of Furukawa et ah (1999) that also found that maximum 
activities of 7-alkoxycoumarin O-dealkylase activities occurred during the dark 
period.
It could be speculated that this increase in enzyme activity during the dark period 
could be attributed, at least partly, to the fact that feeding occurs during the dark 
period in rats. This higher activity of CYP1A1, CYP2B1 and CYP2E1 during the 
dark period could be explained as a protection mechanism against the various 
xenobiotics that enter into the body through feeding.
The light-dark rhythm observed in CYP1A1, CYP2B1 and CYP2E1 activity could be 
exogenously driven by factors such as the light-dark cycle and food or could be 
endogenously driven by the circadian pacemaker or a combination of both exogenous 
and exogenous factors. In order to know whether the daily rhythms in these CYP 
enzymes are circadian in nature, animals should be exposed to constant darkness 
(DD). If these CYP enzyme rhythms persist in constant darkness (DD) this would
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suggest that they are endogenously driven rhythms more likely regulated by the 
endogenous clock located in the SCN. Another way to assess the role of the circadian 
clock in the observed CYP activity rhythms, however, was employed in this study. 
The SCN of rats were lesioned and its effect on the light-dark CYP activity rhythm 
assessed (section 6.4.3). The light-dark difference in CYP1A1 and CYP2E1 activity 
was abolished by SCN lesioning suggesting a role of the circadian pacemaker in these 
rhythms. In contrast, the CYP2B1 activity rhythm was unaffected by SCN lesions. 
These findings suggest that the mechanisms involved in the regulation of hepatic CYP 
enzyme activity are complicated. The role of the SCN may be direct or indirect 
through the control of other circadian rhythms like locomotor activity, hormones and 
feeding.
During these studies the role of endogenous melatonin signal on hepatic CYP enzyme 
rhythms was also examined using PVN-lesioned animals. The finding that PVN 
lesions affected the 24 h rhythm of CYP1A1 and CYP2B1 activity, but not the rhythm 
of CYP2E1 activity, implies that the rhythms of these two CYP metabolising enzymes 
are under a different mechanism of regulation. Since destruction of the PVN evokes 
hyperphagia and abnormal body weight gain accompanied by modifications in 
endocrine and autonomic profiles (Aravich and Sclafani, 1983), it could be postulated 
that the effect of the PVN lesion could, in part, be attributed either to increased body 
weight or the occurrence of fatty liver in these animals.
A future study should be to investigate these CYP rhythms under DD as mentioned 
above. However, a problem for animals are in DD is that their feeding rhythm also 
ffee-runs like activity (similarly for SCN lesions, both the activity rhythm and the
Chapter 7 -  General Discussion 189
feeding rhythm is disrupted) therefore it is difficult to distinguish whether it is the 
feeding per se or the circadian clock that drives these rhythms. It would be of interest 
to investigate the involvement of feeding on the daily rhythms of CYP1A1, CYP2B1, 
and CYP2E1 in the rat liver, since it has been shown that feeding acts as a 
synchroniser (zeitgeber) for the liver (Damiola et al, 2000; Yamazaki et al, 2000; 
Hara et al, 2001). Furthermore, by subjecting animals to constant feeding conditions, 
for example a scheduled feeding regime with six identical meals equally distributed 
over the 24 h light-dark cycle, this would suppress the influence of the rhythmic 
feeding behaviour and investigate its effect on CYP1A1, CYP2B1 and CYP2E1 24 h 
light-dark rhythms.
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